

2024 Sustainability Report

厦门大学附属厦门眼科中心

Stock code 301267

Contents



About This Report	01
Preface	03
About Us	05
2024 Sustainable Development Impact	06
2024 Honors and Awards	07
Management of Material Matters	09
Stakeholder Engagement	19
Sustainability-Related Governance	20

Index

Data Overview	102
Guidelines No. 17 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Sustainability Report (Trial)	110
SASB Index	111
ESRS Index	113
ISDS Index	118
Independent Limited Assurance Report	122



Climate Response	28
Energy Utilization	36
Water Resources Utilization	37
Ecosystem and Biodiversity Protection	38
Environmental Compliance Management	39
Pollutant Discharge	41
Waste Disposal	44
Circular Economy	46



Rural Revitalization and Social Contributions	48
Innovation-driven Development	54
Suppliers and Clients	60
Employees	79



Risk Management and Compliance	94
Business Practices	98

About This Report

This is the 2024 Sustainability Report ("this report") released by Huaxia Eye Hospital Group Co., Ltd. (referred to as "Huaxia Eye Hospital" or "We"). This report aims to provide stakeholders with an overview of the company's sustainability efforts and accomplishments in 2024.

Reference Guidelines



We prepare this report in accordance with the the Sustainability Disclosure Standards for Enterprise - General Requirements (Trial), jointly formulated by the Ministry of Finance of the People's Republic of China, the Ministry of Foreign Affairs, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Ecology and Environment, the Ministry of Commerce, the People's Bank of China, the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), the National Financial Regulatory Administration, and the China Securities Regulatory Commission. We also follow the Guidelines No. 17 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Sustainability Report (Trial) and the Guide No.3 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Preparation of Sustainability Report issued by the Shenzhen Stock Exchange, the Sustainability Accounting Standards Board Standards (SASB Standards), the European Sustainability Reporting Standards (ESRS) released by the European Commission, the two IFRS Sustainability Disclosure Standards (ISDS) issued by the International Sustainability Standards Board (ISSB), and the United Nations Sustainable Development Goals (SDGs).

Reporting Scope



The report is released annually, and the reporting period of this report is from January 1, 2024 to December 31, 2024. Some parts of the report may be beyond the aforementioned scope. Unless otherwise specified, the sustainability data disclosed in this report covers all entities within the company's consolidated scope.

Access to Report and Feedback



This report is published in electronic format in both Simplified Chinese and English. In the event of any inconsistencies between the Chinese and English versions, the Chinese version shall prevail. The electronic version of the report can be accessed and downloaded from our official website (<https://www.huaxiaeye.com/>) and the Shenzhen Stock Exchange website (<http://www.szse.cn/>). If you have any comments or suggestions on our economic, environmental, and social performance, please reach us by 0592-2108975.

External Assurance



RSM China CPA LLP independently guarantees the environmental, social and corporate governance performance key indicators in this report.

Explanatory Note

Abbreviation	Full Name
Huaxia Eye Hospital or We	Huaxia Eye Hospital Group Co., Ltd.
Xiamen Ophthalmology Center	Xiamen Ophthalmology Center Co., Ltd., subsidiary of Huaxia Eye Hospital, with former name as Xiamen University Affiliated Xiamen Ophthalmology Center Co., Ltd.
Chongqing Huaxia Ophthalmology Hospital	Chongqing Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Shenzhen Huaxia Ophthalmology Hospital	Shenzhen Huaxia Ophthalmology Hospital, subsidiary of Huaxia Eye Hospital.
Shanghai Heping Ophthalmic Hospital	Shanghai Heping Ophthalmic Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Bijie Huaxia Yangming Ophthalmology Hospital	Bijie Huaxia Yangming Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Ningbo Yinzhou Ophthalmology Hospital	Ningbo Yinzhou Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Zhangzhou Huaxia Ophthalmology Hospital	Zhangzhou Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Xuchang Huaxia Ophthalmology Hospital	Xuchang Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Santai Huaxia Ophthalmology Hospital	Santai Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Jiangyou Huaxia Ophthalmology Hospital	Jiangyou Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Chengdu Aidi Eye Hospital	Chengdu Aidi Eye Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Dongguan Huaxia Ophthalmology Hospital	Dongguan Huaxia Ophthalmology Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.
Yichang Yangming Ophthalmic Hospital	Yichang Yangming Ophthalmic Hospital Co., Ltd., subsidiary of Huaxia Eye Hospital.



Preface



The meaning of healthcare goes beyond a relentless fight against disease, it is about offering visible hope for life throughout its long journey. With the rapid advancement of technology and the awakening of health awareness, people's expectations of healthcare are shifting from mere healing to a more holistic understanding and protection. As the "windows to the soul," eye health holds a uniquely profound meaning in the pursuit of a fulfilling life. Behind every restoration of sight lies a journey that unites medical expertise with human warmth. "Whether rich or poor, we serve each patient with care, and protect healthy and bright eyes for all" is the unwavering mission of Huaxia Eye Hospital and the belief steadfastly held by every member of the Huaxia family.


In 2024, we continued to hone our medical expertise, driving service precision through the development of specialized disciplines. Focusing on the eight major subfields of ophthalmology—including cataracts, refractive surgery, retinal care, strabismus and amblyopia, pediatric ophthalmology, ocular surface diseases, glaucoma, orbital and ocular tumors, and ocular trauma—we continuously optimized diagnostic and treatment pathways, and enhanced technical collaboration, providing high-quality medical experiences for more patients. Moreover, we further improved our research incentive mechanisms, encouraging frontline doctors to engage in clinical research, results translation, and regional adaptation, advancing from "treatment plans" to an overall leap in "knowledge and capabilities." We understand that true medical innovation is always illuminated by humanistic care, leveraging science and professionalism to help people see a clearer world.

In 2024, we consistently integrated sustainable principles into our hospital operations, exploring the possibilities where "intelligence," "green," and "human-centric" converge. We implemented various energy-saving and emission-reducing measures to lower greenhouse gas emissions and enhance energy efficiency, taking actions to support the green and low-carbon transition. We improved standards in areas such as water conservation, medical waste disposal, and the circular economy, responding to the demands of ecological civilization with meticulous management. We selected environmentally friendly and energy-efficient medical equipment and established a classified recycling system for recyclable medical consumables, effectively reducing waste in medical resources. We firmly believe that by embracing the concept of sustainable development, we can better protect the quality of life and create a cleaner, safer treatment environment for our patients.




In this year, we extended the reach of light to even further places, bringing professional services to more underserved communities. We continued to carry out public welfare projects such as "Care from Bright Journey of Overseas Chinese" and "The Bright Vision Project," providing free clinics, screenings, and surgeries in rural areas, remote mountainous regions, and even overseas, effectively improving the eye health conditions at the grassroots level. We further advanced our education system for eye health covering all age groups, promoting myopia prevention in schools and eye screenings in communities, thereby enhancing the protection, step by step, and on a deeper level. We also continued to implement our international public welfare strategy, carrying out international medical assistance activities to serve more international friends with professional medical resources. On our medical journey, we nurtured every pair of eyes, allowing them to see their unique world, with every professional care bringing a spark of hope to life.

In this year, we also turned our focus inward, strengthening the foundation of our organization and culture. We enhanced the mechanisms for building our healthcare talent pipeline, offering diverse growth pathways for our employees. We paid close attention to the professional well-being, work rhythm, and sense of belonging of our medical personnel, fully embodying the value of "being responsible for patients, employees, and the work itself." We established multiple channels for employee communication, prioritizing their feedback and opinions, ensuring their legal and democratic rights. With solid foundations, we were able to cultivate a humanistic environment for establishment of our healthcare ecosystem, allowing every professional commitment to grow with renewed vitality.



Looking to the future, we will remain dedicated on "Patient Satisfaction, Employee Contentment, Peer Endorsement, Societal Recognition, Government Trust," blending technological innovation seamlessly with humanistic principles. Together with our partners, we will pass on the mission of nurturing the next generation of healthcare professionals, persistently improve healthcare accessibility, and forge ahead in the journey of building a Healthy China. Guided by the principles of sustainable development, we will safeguard every pair of eyes with superior medical expertise, noble medical ethics, and attentive service, while offering fair pricing, convenient access, and a pleasant environment to every patient.



About Us

Huaxia Eye Hospital (Stock Code: 301267), established in 2004, is a large-scale ophthalmology medical chain group specializing in medical services of ophthalmology specialty. We provide comprehensive ophthalmic diagnosis and treatment services for ophthalmic patients domestically and internationally. The services cover eight subspecialties of ophthalmology, including cataracts, refractive error, ocular fundus diseases, strabismus & amblyopia and pediatric ophthalmology, ocular surface diseases, glaucoma, orbit and oculoplastics, ocular tumors, and ocular trauma, as well as optometry specialty.

At present, we have set up 62 ophthalmic hospitals and 66 optometry centers in China, covering 18 provinces and 48 cities, spanning across the East China, Central China, South China, Southwest China, North China and other vast areas. We have established a nationwide diagnosis and treatment service network system through the chain operation model. We own two nationally renowned tertiary grade-A specialized hospital: Xiamen Ophthalmology Center and Chengdu Aidi Eye Hospital. Xiamen Ophthalmology Center is a national clinical key specialty (Ophthalmology) construction unit, a national drug clinical trial institution (GCP), and is equipped with a post-doctoral research station, an academician expert workstation, and the Key Laboratory of Ocular Surface and Corneal Diseases in Fujian Province. Chengdu Aidi Eye Hospital is a key ophthalmology specialty of Chengdu, a managing unit for the Ophthalmology Quality Control Center of Qingyang District in Chengdu, and the leading unit of the Ophthalmology "All-Specialty Alliance".

Corporate Culture



Vision

Build a Renowned Eye Hospital, Cast a Hundred Years of Huaxia



Mission

Whether rich or poor, we serve each patient with care, and protect healthy and bright eyes for all.



Goal

Patient Satisfaction, Employee Contentment, Peer Endorsement, Societal Recognition, Government Trust.



Service Tenet

Patient Always Comes First.




Core Value

Responsibility, Care, Innovation, Win-Win



Business Philosophy

Superior Medical Expertise, Fair Pricing, Noble Medical Ethics, Attentive Service, Convenient Access, Pleasant Environment.



*白色点位区域为上市公司属下医院

2024 Sustainable Development Impact



Economic Impact

Total asset

792,404.32 Ten-thousand RMB

Operating revenue

402,701.08 Ten-thousand RMB

Net profit attributable to shareholders of the parent company

42,864.05 Ten-thousand RMB



Environmental Impact

GHG emission intensity

574.96 tCO₂e / hundred-million RMB of operating revenue

Energy intensity

144.07 Tons of coal equivalent / hundred- million RMB of operating



Social Impact

Total social contributions

177,085.74 Ten-thousand RMB



Including

• Total tax payment
25,836.94 Ten-thousand RMB

• Employee compensation
131,180.35 Ten-thousand RMB

• Dividends paid to shareholders
12,477.05 Ten-thousand RMB

• Interests paid to creditors
40.90 Ten-thousand RMB

• Social donations
7,550.50 Ten-thousand RMB

Total employees

7,883 persons

Total employee training hours

296,760 hours



2024 Honors and Awards



Economic Observer

"Top 100 Most Respected Enterprises 2023-2024"

Securities Times

The "18th China Listed Companies Value Awards - Top 50 Most Valuable GEM-Listed Companies"

Securities Times

The "18th China Listed Companies Value Awards – 2024 Top 100 ESG China Listed Companies"

Cailian Press

"2024 ESG Profound Awards – ESG Pioneer Award"

China.com

"2024 ESG Brand Influence Award"

VALUEONLINE

"2024 Best ESG Practice Award for Listed Companies"

Pointer Finance Institute, China Investment Network, and ZMONEY.com

"7th Jingxi Awards – 2024 Excellent Brand Case"

China Association for Public Companies

"2024 Best Practices of Board Office for Public Companies"

Chinese Securities Journal

"2024 Outstanding Cases of Innovative Development for Listed Companies"

p5w.net

The 5th "Investor Relations Gold Award" including "Outstanding IR Company," "Outstanding IR Team," and "Outstanding Institutional Communication Award"

Fujian Federation of Industry and Commerce

"2024 Top 100 Private Service Enterprises in Fujian Province"

China Times

"2024 Top 10 Innovative Enterprises in Precision Medicine"

Xiamen Federation of Industry and Commerce

"2024 Top 100 Private Enterprises in Xiamen"

Xiamen Ophthalmology Center
7th place among national specialized ophthalmic hospitals on the "National GCP Institution Comprehensive Ranking by Drug Clinical Trial Volume" recognized by CCHRPP

Xiamen Ophthalmology Center
3rd place among national specialized ophthalmic hospitals on the "National GCP Institution Leadership Ranking by Drug Clinical Trial Volume" recognized by CCHRPP



Management of Material Matters



We conducted double materiality assessments in alignment with the methodologies outlined in latest domestic and international disclosure standards, including the Sustainability Disclosure Standards for Enterprise - General Requirements (Trial), jointly formulated by the Ministry of Finance of the People's Republic of China, the Ministry of Foreign Affairs, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Ecology and Environment, the Ministry of Commerce, the People's Bank of China, the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), the National Financial Regulatory Administration, and the China Securities Regulatory Commission. We also referred to the Guidelines No. 17 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Sustainability Report (Trial) and the Guide No.3 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Preparation of Sustainability Report issued by the Shenzhen Stock Exchange, the European Sustainability Reporting Standards (ESRS) released by the European Commission, and the two IFRS Sustainability Disclosure Standards (ISDS) issued by the International Sustainability Standards Board (ISSB), to identify sustainability matters that have a significant impact on the company's long-term value and stakeholders.

In the materiality assessment, we followed the principle of "double materiality" and conducted stakeholder communication and research through a questionnaire survey, collecting feedback from over 200 stakeholders. Based on the results of the stakeholder survey and the financial materiality assessment of relevant matters, we have identified 10 material matters, which are further explained in the corresponding sections of this report.

Double Materiality Assessment Process

Step 1 Understanding the Context and Identifying Sustainability Matters

We conducted a comprehensive context analysis, taking into account five key aspects: the sustainability disclosure standards and guidelines, international initiatives, global economic and macro policy outlook, market trends, and the corporate strategy and development needs. Based on the analysis, we identified 30 sustainability matters relevant to the company.



Sustainability Disclosure Standards and Guidelines

The Sustainability Disclosure Standards for Enterprise – General Requirements (Trial), jointly formulated by the Ministry of Finance of the People's Republic of China, the Ministry of Foreign Affairs, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Ecology and Environment, the Ministry of Commerce, the People's Bank of China, the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), the National Financial Regulatory Administration, and the China Securities Regulatory Commission, the Guidelines No. 17 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Sustainability Report (Trial) and the Guide No.3 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Preparation of Sustainability Report issued by the Shenzhen Stock Exchange, the European Sustainability Reporting Standards (ESRS) released by the European Commission, and the two IFRS Sustainability Disclosure Standards (ISDS) issued by the International Sustainability Standards Board (ISSB).

The United Nations Sustainable Development Goals (SDGs), the 29th Conference of the Parties of the UNFCCC (COP 29), the Due Diligence Guidance for Responsible Business Conduct of Organization for Economic Co-operation and Development (OECD), etc.



International Initiatives



Global Economic and Macro-Policy Outlook

The National carbon peaking and carbon neutrality goals, global temperature control targets under the Paris Agreement, Science Based Targets initiative (SBTi), the Belt and Road Initiative, trends in digitalization, intelligent transformation, and supply chain restructuring, as well as changes in international trade policies, etc.



Market Trends

Characteristics of diversification, customization, and rapid response, transparency of the value chain, and the rising certification thresholds in international markets for corporate qualifications, product compliance, ESG performance, etc.



Corporate Strategy and Development Needs

Focusing on sustainable growth, observing industry regulations and policy direction, strengthening the company's resilience and risk management capabilities, and promoting long-term high-quality development.

Sustainability Matters

Dimension	Sustainability Matters	
 Environmental	Climate Response Waste Disposal Environmental Compliance Management Water Resources Utilization	Pollutant Discharge Ecosystem and Biodiversity Protection Energy Utilization Circular Economy
 Social	Rural Revitalization Innovation-Driven Development Responsible Sourcing Equal Treatment of SMEs Data Security and Customer Privacy Equal Employment Employee Communication Employee Compensation and Benefits	Social Contributions Ethics of Science and Technology Supply Chain Security Medical Quality and Safety Supporting Industry Development Human Rights Protection Employee Development and Training Occupational Health and Safety
 Governance	Due Diligence Risk Management and Compliance Fair Competition	Stakeholder Engagement Anti-Commercial Bribery and Anti-Corruption Tax Compliance

Step 2-1 Impact Materiality Assessment

We assessed the impact materiality of each matter based on two dimensions: the severity of impact and the likelihood of occurrence.

Criteria 1: Severity of Impact

We conducted stakeholder surveys to assess the impact of sustainability matters across economic, environmental, and social dimensions. We used statistical methods such as weighted averages and variance analysis to quantify the qualitative scores (1-5 scale) of each matter. The overall severity score was calculated by combining the weight distribution to determine the impact materiality of sustainability matters.

Criteria 2: Likelihood of Occurrence

We inferred the probability of the impact happening based on the frequency of similar events in the past and classified and quantified the likelihood of occurrence based on experience, to determine the likelihood of occurrence of sustainability impact.

Impact Materiality Assessment Outcomes

Impact Materiality: Low	Impact Materiality: Medium	Impact Materiality: High
<ul style="list-style-type: none"> • Water Resources Utilization • Rural Revitalization • Ethics of Science and Technology • Equal Treatment of SMEs • Circular Economy • Data Security and Customer Privacy • Due Diligence • Tax Compliance • Ecosystem and Biodiversity Protection 	<ul style="list-style-type: none"> • Occupational Health and Safety • Social Contributions • Employee Compensation and Benefits • Climate Response • Human Rights Protection • Waste Disposal • Equal Employment • Supporting Industry Development • Anti-Commercial Bribery and Anti-Corruption • Fair Competition • Innovation-Driven Development • Stakeholder Engagement 	<ul style="list-style-type: none"> • Environmental Compliance Management • Pollutant Discharge • Product and Service Safety and Quality • Energy Utilization • Responsible Sourcing • Employee Development and Training • Risk Management and Compliance • Supply Chain Security • Employee Communication

Step 2-2 Financial Materiality Assessment



We assessed the financial materiality of each matter based on two criteria: the potential magnitude and the likelihood of occurrence.

Criteria 1: Potential Magnitude

The magnitude of direct and indirect, positive and negative impacts that the opportunities and risks associated with each material sustainability matter may bring to the company's financial performance during the reporting period and in future projections.

Criteria 2: Likelihood of Occurrence

The likelihood of financial effects on the company from the opportunities and risks associated with each sustainability matter in the short, medium, and long-term.

Reference Indicators	
 Costs	Considering factors such as market price of resources, trend forecasts, and the company's historical costs
 Profits	Taking into account costs and revenues, and assessing the impact on profits


Financial Materiality Assessment Outcomes

Impact Materiality: Low	Impact Materiality: Medium	Impact Materiality: High
<ul style="list-style-type: none"> • Employee Development and Training • Stakeholder Engagement • Circular Economy • Due Diligence • Rural Revitalization • Equal Employment • Employee Compensation and Benefits • Employee Communication • Ethics of Science and Technology 	<ul style="list-style-type: none"> • Waste Disposal • Innovation-Driven Development • Responsible Sourcing • Supporting Industry Development • Data Security and Customer Privacy • Tax Compliance • Equal Treatment of SMEs • Occupational Health and Safety • Human Rights Protection • Water Resources Utilization • Ecosystem and Biodiversity Protection 	<ul style="list-style-type: none"> • Environmental Compliance Management • Energy Utilization • Climate Response • Supply Chain Security • Product and Service Safety and Quality • Social Contributions • Anti-Commercial Bribery and Anti-Corruption • Fair Competition • Pollutant Discharge • Risk Management and Compliance

Financial Materiality: "Low" refers to potential impacts in the short, medium, and long term; "Medium" indicates impacts in the short term, with possible effects in the medium and long term; "High" refers to impacts in the short term, with the likelihood of material effects in the medium and long term.

Step 3 Consolidating Impact and Financial Materiality Outcomes






Based on the assessment results of impact and financial materiality, we have developed a materiality matrix and identified 10 key material matters.





Impact and Financial Materiality	Sustainability Matters	Impact and Financial Materiality	Sustainability Matters	Impact and Financial Materiality	Sustainability Matters
Low	<ul style="list-style-type: none"> 15 Equal Treatment of SMEs 8 Circular Economy 25 Due Diligence 4 Ecosystem and Biodiversity Protection 17 Data Security and Customer Privacy 12 Ethics of Science and Technology 30 Tax Compliance 	Medium	<ul style="list-style-type: none"> 22 Employee Development and Training 18 Supporting Industry Development 28 Anti-Commercial Bribery and Anti-Corruption 21 Employee Communication 19 Equal Employment 26 Stakeholder Engagement 9 Rural Revitalization 24 Occupational Health and Safety 20 Human Rights Protection 29 Fair Competition 23 Employee Compensation and Benefits 11 Innovation-Driven Development 7 Water Resources Utilization 	High	<ul style="list-style-type: none"> 5 Environmental Compliance Management 2 Pollutant Discharge 13 Responsible Sourcing 1 Climate Response 27 Risk Management and Compliance 6 Energy Utilization 16 Medical Quality and Safety 14 Supply Chain Security 10 Social Contributions 3 Waste Disposal



Step 4 Reporting and Practice Guidance





The results of the materiality assessment are reviewed and confirmed by the company's Strategic and Sustainable Development Committee. Detailed management measures and specific actions for each identified issue are outlined in the relevant sections of this report.

Material Matters	Impact Scope				Affected Stakeholders	Risks	Opportunities	Impact Duration	Corresponding SDGs	Location in the Report
	Value Chain Upstream	Corporate Operations	Value Chain Downstream	Communities						
Climate Response	✓	✓	✓	✓	<ul style="list-style-type: none"> • Employees • Customers • Suppliers • Investors • Banks • Media Organizations • Government and Regulatory Authorities • Non-Governmental Organizations 	<ul style="list-style-type: none"> • The potential impacts of floods and typhoons on human well-being and health, as well as secondary disasters such as mudslides and landslides. • The risk of extreme high temperatures leading to health issues like heatstroke and dehydration, as well as concerns over food and water security; extreme low temperatures affecting transportation, energy supply, and daily life. • The tightening of climate policies may increase the company's compliance costs and operational pressures. 	<ul style="list-style-type: none"> • Integrating green and low-carbon development principles into the company's strategic development plan to enhance its ability to respond to climate change. • Climate change-induced eye health issues (such as trachoma, cataracts, eye diseases, severe allergic eye diseases, glaucoma, etc.) will increase the company's business volume. 	Short, Medium, and Long Term	 	Climate Response Circular Economy
Environmental Compliance Management	✓	✓	✓	✓	<ul style="list-style-type: none"> • Employees • Customers • Suppliers • Investors • Banks • Media Organizations • Government and Regulatory Authorities • Non-Governmental Organizations 	<ul style="list-style-type: none"> • Unexpected environmental incidents (such as illegal emissions) may lead to penalties from regulatory authorities, attract public attention, and negatively impact the hospital's brand reputation. • Dynamic updates to environmental regulations may increase the company's monitoring, rectification, and compliance costs, leading to higher short-term operational 	<ul style="list-style-type: none"> • Complying with environmental regulations and promoting green operations helps establish the hospital's responsible image and enhances trust among patients and society. • Establishing and improving the environmental management system, refining various environmental management objectives, and enhancing the company's environmental governance capabilities. 	Short, Medium, and Long Term	  	Environmental Compliance Management

Impact Timeframe Definition: **Short term** generally refers to within one year after the end of the reporting period (inclusive); **Medium term** refers to one to five years after the end of the reporting period (inclusive); **Long term** refers to more than five years after the end of the reporting period.









Material Matters	Impact Scope				Affected Stakeholders	Risks	Opportunities	Impact Duration	Corresponding SDGs	Location in the Report
	Value Chain Upstream	Corporate Operations	Value Chain Downstream	Communities						
Medical Quality and Safety	✓	✓	✓	✓	<ul style="list-style-type: none"> • Customers • Suppliers • Media Organizations • Government and Regulatory Authorities 	<ul style="list-style-type: none"> • Deviations in the implementation of surgical protocols, medication guidelines, etc., may lead to fluctuations in treatment effectiveness and increase the risk of medical disputes. • The disparity in the skills of primary care staff, combined with heavy workloads, may increase the risk of misdiagnosis, postoperative complications, and other hazards. 	<ul style="list-style-type: none"> • Establishing a quality management system that spans the entire product and service lifecycle to ensure the provision of safe, reliable, and effective healthcare services to patients. 	Short, Medium, and Long Term		Product and Service Safety and Quality
Energy Utilization	✓	✓			<ul style="list-style-type: none"> • Employees • Customers • Suppliers 	<ul style="list-style-type: none"> • Fluctuations in energy prices, such as electricity and gas, may increase operational costs and impact long-term sustainability. • Some traditional medical equipment has high energy consumption, and prolonged use may increase energy expenditure and have a greater environmental impact. • The construction of clean energy facilities requires upfront capital investment and carries the risk of technology adaptation. 	<ul style="list-style-type: none"> • Actively promoting green office management, continuously improving energy efficiency, expanding the use of renewable energy, and reducing energy consumption 	Medium and Long Term		Energy Utilization

Material Matters	Impact Scope				Affected Stakeholders	Risks	Opportunities	Impact Duration	Corresponding SDGs	Location in the Report
	Value Chain Up-stream	Corporate Operations	Value Chain Down-stream	Communities						
Responsible Sourcing	✓	✓	✓		<ul style="list-style-type: none"> Customers Suppliers Investors 	<ul style="list-style-type: none"> Suppliers failing to meet ESG practices and standards may trigger supply chain disruption risks, impacting business stability. 	<ul style="list-style-type: none"> Establishing strict supplier admission standards, prioritizing partners who meet environmental requirements, fulfill social responsibilities, and adhere to business ethics. 	Medium and Long Term	 	Supply Chain Security
Supply Chain Security	✓	✓	✓			<ul style="list-style-type: none"> Increased costs of supply chain compliance checks may lead to a short-term decrease in procurement efficiency. 	<ul style="list-style-type: none"> Ensuring the safety and reliability of medical supplies through digital platforms and a full-process quality traceability system, while promoting the construction of a green supply chain to reduce resource waste. 			
Risk Management and Compliance	✓	✓	✓	✓	<ul style="list-style-type: none"> Employees Customers Suppliers Investors Banks Media Organizations Government and Regulatory Authorities Non-Governmental Organizations 	<ul style="list-style-type: none"> Inadequate emergency response plans may lead to risk escalation and reputational damage. Internal control weaknesses could result in fraudulent activities, triggering compliance risks. 	<ul style="list-style-type: none"> Continuously optimize the governance system, establishing a risk management framework with clear responsibilities, reasonable allocation of duties, and mutual checks and balances. Improve risk monitoring mechanisms and strengthen risk supervision efforts. Enhance compliance training mechanisms. 	Short, Medium, and Long Term		Risk Management and Compliance

Material Matters	Impact Scope				Affected Stakeholders	Risks	Opportunities	Impact Duration	Corresponding SDGs	Location in the Report
	Value Chain Up-stream	Corporate Operations	Value Chain Down-stream	Communities						
Social Contributions		✓		✓	<ul style="list-style-type: none"> • Employees • Banks • Media Organizations • Government and Regulatory Authorities • Non-Governmental Organizations 	<ul style="list-style-type: none"> • Misalignment between medical aid programs and the actual needs of beneficiary groups may lead to resource waste and undermine social benefits. • If public welfare actions are perceived as "image projects," they may trigger misunderstandings about business motives, damaging brand credibility. 	<ul style="list-style-type: none"> • Aligning specific public welfare activities with national public health strategies to gain policy support. • Publishing sustainability reports can strengthen stakeholder trust and enhance brand reputation. 	Long Term		Social Contributions
Pollutant Discharge	✓	✓	✓	✓	<ul style="list-style-type: none"> • Employees • Customers • Suppliers • Investors • Banks • Media Organizations • Government and Regulatory Authorities • Non-Governmental Organizations 	<ul style="list-style-type: none"> • Upgrading of pollutant emission standards may force the upgrading of technical equipment, increasing short-term capital investment pressure. • Exceeding emission limits may lead to fines, production shutdowns, and damage to brand reputation. 	<ul style="list-style-type: none"> • Ensure pollutant discharges comply with national and regional environmental standards, improve the company's environmental management level, and reduce negative environmental impacts. 	Short, Medium, and Long Term	  	Pollutant Discharge

Stakeholder Engagement

We value the suggestions and concerns of all our stakeholders. Through diversified communication channels, we gather their expectations and feedback on the company and incorporate this information into our management considerations.


Stakeholders	Matters of Concern	Communication Channels
Employees 	Tax Compliance Occupational Health and Safety Medical Quality and Safety	Employee Feedback and Complaints Employee Training and Activities Employee Representative Assembly Employee Satisfaction Survey
Customers/ Patients 	Medical Quality and Safety Data Security and Customer Privacy Tax Compliance	Customer Service and Complaint Handling Satisfaction Survey Official Website and Social Media
Suppliers 	Medical Quality and Safety Data Security and Customer Privacy Tax Compliance	Communication and Site Visits Supplier Review Management Industry Conferences Supplier Meetings and Lectures
Investors 	Medical Quality and Safety Supply Chain Security Risk Management and Compliance	Information Disclosure of Listed Companies Shareholder Meetings and Earnings Call Investor Hotline and Interactive Platforms Investor Reception and Research Public Opinion Monitoring
Banks 	Medical Quality and Safety Supply Chain Security Risk Management and Compliance	Information Disclosure of Listed Companies Project Cooperation Communication and Site Visits
Media Organizations 	Waste Disposal Water Resources Utilization Medical Quality and Safety	Information Disclosure of Listed Companies Social Media and Media Press Communication Public Opinion Monitoring
Government and Regulatory Authorities 	Waste Disposal Water Resources Utilization Medical Quality and Safety	Information Disclosure of Listed Companies Cooperation on Government Project Communication and Site Visits
Non-Governmental Organizations 	Medical Quality and Safety Data Security and Customer Privacy Innovation-Driven Development	Public Welfare Services Communication and Site Visits Public Opinion Monitoring

Sustainability-Related Governance

We, based on the new development stage, regard the improvement of the modern governance system as an important engine for driving high-quality and sustainable development. We have established and improved the corporate governance system, integrating the concept of sustainable development into our governance, continuously enhancing a governance mechanism with clear responsibilities and efficient operations, improving the level of sustainable development governance, and driving us to achieve long-term value.


Governance Structure and Mechanism

We strictly adhere to the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Code of Corporate Governance for Listed Companies, and other relevant laws, regulations, and supervisory rules to establish and continuously improve a corporate governance structure composed of the General Meeting of Shareholders, the Board of Directors, the Board of Supervisors, and the management team. Under the Board of Directors, we have established four specialized committees: The Strategic and Sustainable Development Committee, the Audit Committee, the Nomination Committee, and the Compensation and Appraisal Committee. These committees provide in-depth deliberation, oversight, and review of matters within their respective scopes of responsibility, jointly guiding the implementation of our ESG efforts. They supervise the execution of ESG goals and related initiatives, offering professional advice and reference to support the Board's decision-making, thereby enhancing the effectiveness of our ESG governance and ensuring the realization of our ESG strategy and objectives.



Board Committees	Composition and Responsibilities
Strategic and Sustainable Development Committee	The committee is composed of 3 directors, including 1 independent director and is primarily responsible for researching and providing recommendations on our medium to long-term development strategy, major investment and financing projects, sustainable development goals, and ESG-related matters.
Audit Committee	The committee consists of three independent directors, with an independent director serving as the committee chair. It is mainly responsible for supervising and reviewing the company's internal audit system, internal control systems, and their implementation, reviewing the company's financial information and its disclosure, and overseeing the evaluation of external audit work.
Nomination Committee	The committee consists of three directors, including two independent directors, with an independent director serving as the committee chair. It is mainly responsible for researching the selection criteria and procedures for directors and senior management and making recommendations, selecting qualified candidates for directors and senior management, reviewing them, and providing suggestions.
Compensation and Appraisal Committee	The committee consists of three directors, including two independent directors, with an independent director serving as the committee chair. It is mainly responsible for formulating and reviewing the compensation policies and plans for non-independent directors and senior management, setting the assessment standards for non-independent directors and senior management, and conducting assessments.

We have developed a series of sustainable development policies in alignment with our ESG strategy and business practices. These policies outline our position on various sustainability issues, including the environment, human rights, business ethics, and occupational health and safety. They serve as a guide to ensure that our business operations are conducted in a manner that aligns with sustainable development principles.



In 2024, in accordance with the Company Law of the People's Republic of China, the Guidelines for the Articles of Association of Listed Companies, the Rules Governing the Listing of Stocks on the STAR Market of the Shenzhen Stock Exchange, the Guidelines No. 2 of Shenzhen Stock Exchange for Self-Regulation of Listed Companies – Standardized Operation of ChiNext Listed Companies, and other relevant laws, regulations, and normative documents, we reviewed and revised a series of internal governance documents to ensure the standardized development of governance work and enhance our corporate governance capabilities.

- Articles of Association
- Rules of Procedure for the Board of Directors
- Implementation Rules for the Compensation and Appraisal Committee
- Implementation Rules for the Nomination Committee
- Implementation Rules for the Audit Committee
- Working Rules for Independent Directors
- Working Rules for the Board Secretary

In 2024

<p>We convened a total of</p> <p>4 Board meetings</p>	<p>Held</p> <p>4 Supervisory Board meetings</p>	<p>Organized</p> <p>1 General Meeting of Shareholders</p>	<p>Convened</p> <p>4 Audit Committee meetings</p>
<p>And reviewed</p> <p>26 proposals</p>	<p>And reviewed</p> <p>20 proposals</p>	<p>And reviewed</p> <p>12 proposals</p>	<p>1 Compensation and Appraisal Committee meeting</p> <p>1 Strategic and Sustainable Development Committee meeting</p>

Appointment of Directors and Senior Management

We strictly follow relevant laws and regulations, as well as the Articles of Association and the Implementation Rules for the Nomination Committee, in carrying out the nomination and selection procedures for members of the Board of Directors and senior management. The Nomination Committee, based on the company's governance and operational needs, evaluates candidates through a comprehensive set of criteria, including professional competence, educational background, and work experience. After qualification reviews, the committee submits recommendations for board and senior management candidates to the Board of Directors. Board candidates, upon approval by the Board, are proposed to the General Meeting of Shareholders for election to form the new Board. Senior management candidates are appointed upon approval by the Board of Directors.

Our Board of Directors consists of 7 directors, including 3 independent directors, accounting for 43% of board members. Our board members have extensive experience in operations management, risk control and compliance, finance, and accounting, with diverse professional backgrounds covering fields such as medicine, business management, accounting, economics, and engineering. Our senior management team also spans various disciplines including medicine, economics, accounting, and business management, and they possess substantial experience in enterprise operations, risk control and compliance, and financial management. The diversity and expertise of our Board of Directors and senior management provide an important assurance for enhancing our scientific decision-making and governance.

Name	Occupation	Age	Professional competence				Board Committees				Attendance (Board meetings and Board committee meetings)
			Industry Experience	Operations Management	Risk Control and Compliance	Financial Accounting	Audit Committee	Nomination Committee	Compensation and Appraisal Committee	Strategic and Sustainable Development Committee	
Su Qingcan (M)	Chairman & CEO	56	✓	✓	✓	✓		✓	✓	✓	100%
Chen Fengguo (M)	Director	58	✓	✓	✓	✓					100%
Zhang Guangbin (M)	Director	57	✓	✓	✓						100%
Li Xiaofeng (M)	Director & Vice President	53	✓	✓	✓					✓	100%
Wang Zhiqiang (M)	Independent Director	58		✓	✓	✓	✓		✓		100%
Zheng Wenli (M)	Independent Director	62		✓	✓		✓	✓	✓		100%
Hu Jun (M)	Independent Director	69		✓	✓		✓	✓		✓	100%
Zhang Zhiyong (M)	Vice President	43	✓	✓	✓						/
Zhang Binbin (M)	Vice President	61	✓	✓	✓						/
Chen Luyan (F)	CFO	47	✓	✓	✓	✓					/
Cao Naien (M)	Board Secretary	50	✓	✓	✓	✓					/

We place great emphasis on continuously enhancing the performance capabilities of our directors, supervisors, and senior management. We periodically send them the latest revised or newly released regulatory rules or relevant case studies for study, and proactively organize their participation in various training programs on laws, regulatory rules, and performance-related topics hosted by the stock exchanges and the association of listed companies. In 2024, we organized a total of 13 training sessions for directors, supervisors, and senior management covering topics such as the new Company Law, equity incentives, mergers and acquisitions, and the performance of independent directors.

Compensation of Director and Senior Management

In accordance with the Articles of Association and the Implementation Rules of the Compensation and Appraisal Committee, the compensation policies and schemes for directors and senior management are formulated by the Compensation and Appraisal Committee. The compensation scheme for directors is implemented after being approved by the Board of Directors and submitted to the General Meeting of Shareholders for approval. The compensation scheme for senior management is implemented upon approval by the Board of Directors.

We have established a "Compensation and Allowance Management Policy for Directors, Supervisors, and Senior Management," which stipulates that directors holding other positions within the company, as well as senior management, receive compensation based on their actual roles. Their compensation structure includes fixed salary, bonuses, and other components. Specifically, base salary is determined with reference to job responsibilities, individual competencies, and market salary benchmarks; bonuses and allowances are based on individual performance and the company's overall operational results. Independent directors receive allowances in accordance with relevant regulations. In addition, we link performance-based compensation for directors and senior management to key areas such as compliance operations, risk management, talent development, and occupational health and safety.

We implement an employee stock ownership plan under which incentive shares are granted to our directors and senior management. This long-term incentive mechanism is designed to strengthen the alignment of interests among the board, management, shareholders, and the company, thereby supporting the achievement of our business objectives. As of December 31, 2024, directors and senior management participating in the ESOP indirectly held a total of 16,095,000 shares through the employee stock ownership platform, representing 1.92% of the company's total shares.

Name	Position	Shareholdings at the end of the reporting period (Shares)
Chen Fengguo	Director	7,050,000
Li Xiaofeng	Director & Vice President	1,500,000
Zhang Guangbin	Director	3,930,000
Zhang Binbin	Vice President	1,890,000
Chen Luyan	CFO	1,275,000
Cao Naïen	Board Secretary	450,000
Total		16,095,000

Conflicts of Interest

We strictly regulate and manage related party transactions in accordance with relevant laws, regulations, and regulatory requirements, to prevent conflicts of interest. The company's Articles of Association stipulate that directors, supervisors, and senior management have a duty of loyalty to the company and must not use their positions to exploit business opportunities that rightfully belong to the company, nor engage in or support others in operating businesses that compete with the company's business.

We have established and continuously improved the "Related Party Transaction Management System," which clearly defines matters such as the scope of related parties, the scope of related party transactions, pricing basis, approval authority, and decision-making procedures. This is to regulate related party transactions and ensure their legality and compliance, effectively protecting the legitimate rights and interests of the company and all shareholders. Our directors, supervisors, and senior management have made long-term commitments regarding related party transactions, promising to avoid and minimize such transactions with the company. When unavoidable, these transactions will be conducted in strict accordance with fair, reasonable, and customary business principles, and we will comply with the procedures for abstaining from voting on related party transactions. We also pledge not to use related party transactions to illegally transfer the company's funds or profits, obtain any improper benefits, or impose any unjust obligations on the company. In case of violation of these commitments, the responsible director will bear full responsibility and fully compensate or indemnify the company for any losses. If compensation is not possible, the company reserves the right to reduce the cash dividends payable accordingly.

Investor Rights Protection

We strictly adhere to relevant laws, regulations, and internal policies regarding the convening, holding, and voting procedures of shareholders' meetings, treating all shareholders fairly. We have established the "Implementation Rules for Online Voting at Shareholders' Meetings" and "Implementation Rules for Cumulative Voting," among other systems, to facilitate online voting and cumulative voting systems. These measures provide convenient channels for shareholders, especially minority shareholders, ensuring their legal rights, including the right to be informed, vote, and supervise major matters of the company.

Information Disclosure Management

We have developed and continuously improved the "Information Disclosure Management System," "External Information Reporting and Usage Management System," and "Insider Information Registrant Management System," among others.

These systems clearly define the scope and procedures for information disclosure. We are constantly refining our information disclosure management mechanism to enhance the quality of disclosure.

Ensuring its authenticity, accuracy, completeness, and timeliness. This guarantees that all investors have equal access to the company's information, fully safeguarding the right of shareholders to be informed.

Investor Relations Management

We place great importance on investor relations management and strictly comply with relevant laws, regulations, and regulatory rules. We have developed and continuously improved the "Investor Relations Management System," establishing a robust investor relations management mechanism to safeguard the legitimate rights and interests of investors. We actively engage with investors through various channels, including investor hotlines, faxes, IR emails, investor relations management mini-programs, the SZSE Easy Interaction Platform, investor



surveys, roadshow events, earnings presentations, and collective reception days in the Xiamen area. Through these channels, we listen to investors' opinions and suggestions on the company's development, maintain good relationships with investors, and promote the improvement of our corporate governance.

In 2024, we hosted a total of 4 investor research sessions, receiving over 170 investor visits and interactions. Our response rate to online investor inquiries was 100%, and we handled more than 900 consultation calls from retail shareholders.



Investor On-site Research

Party Building

We adhere to Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era as our guiding principle, give full play to the role of Party organizations as strongholds of strength, continuously strengthen the development of grassroots Party organizations, empower business operations, and promote innovative development through high-quality Party building.

We uphold the core leadership role of the Party and continuously promote the effective integration and organic unity of Party leadership with business operations. We also advance the development of grassroots Party organizations, strengthen their role as strongholds, and enhance the cohesion and combat effectiveness of Party branches by strictly implementing systems such as the "Three Meetings and One Lesson," organizational life meetings, and democratic evaluation of Party members.

We focus on talent development as a strategic priority and are committed to closely integrating Party building with our talent strategy and talent development efforts. By cultivating key personnel, we aim to build a high-quality talent team. In 2024,

- we handled **6** transfers of Party organizational affiliation, involving **119** Party members. Among them, **47** were key personnel, discipline leaders, or middle-level managers, accounting for **39.5%**.
- At the same time, we actively provided ideological guidance and talent development support for new hires and outstanding employees, organizing four training sessions for new employees and welcoming one outstanding employee as a full Party member.

We continuously strengthen discipline education within the Party and improve the joint learning and co-building mechanisms for grassroots Party organizations. In 2024,

- we organized **25** "First Topic" study sessions, **5** sessions on Party discipline, **2** joint learning activities on Party building, and **70** Party class sessions.
- Additionally, we held **85** Party member meetings through the Xiamen "e-Home for Party Building" platform.



We organized
4 training sessions



We organized
25 "First Topic"
study sessions



We held
85 Party member
meetings

Discipline Education on Party Conduct








Thematic Party Lecture

01

Environmental

2024 Key Performance Targets for Environmental Matters

-  Complete the 2024 GHG (Scope 1 and Scope 2) Inventory in accordance with the requirements of ISO 14064-1:2018.
-  Continue implementing energy-saving and emission-reduction actions to improve energy efficiency.
-  Strengthen environmental compliance management, ensuring that 100% of subsidiaries achieve ISO 14001 Environmental Management System certification.
-  Ensure that emissions from exhaust gas, wastewater, and waste pollutants meet regulatory standards, with no significant environmental pollution incidents.
-  Secure the compliant transfer and disposal of medical waste, with no significant environmental pollution incidents.




Climate Response

As extreme climate events such as heatwaves, droughts, and floods caused by climate change become more frequent, global economic and social development, as well as ecological environments, are facing increasingly severe challenges. As a leading domestic ophthalmology hospital group, we actively respond to the national "dual carbon" strategy and adhere to the United Nations Framework Convention on Climate Change and the Paris Agreement. We integrate the concept of green and low-carbon development into our strategic planning, systematically identify climate change-related risks and opportunities, and steadily advance energy-saving and emission-reduction measures. We continuously improve energy usage efficiency and effectively reduce greenhouse gas emission intensity, striving to enhance our climate change adaptation capacity and operational resilience while contributing to global climate goals.

Corporate Strategy

We have set the "1236" strategic development goals based on the external environment and industry development trends.



We are committed to accelerating the improvement of our nationwide ophthalmology medical service network, deepening the high-quality coordinated development of medical education, research, and clinical disciplines, strengthening the construction of clinical specialties, focusing on the introduction and cultivation of high-level ophthalmology medical talents, and accelerating the development of new ophthalmic productivity. We are also actively building the Huaxia Ophthalmology Smart Healthcare System, enhancing our diagnostic and treatment capabilities and service levels, continuously providing patients with cutting-edge diagnostic technologies and high-quality medical services, and driving the company toward high-quality development.

Climate-Related Risks, Opportunities, and Financial Impacts

To efficiently allocate resources and enhance the effectiveness of climate change risk management, we have incorporated the climate change risk management process into our corporate risk management framework. Based on our business characteristics, we refer to scenario models published by the Intergovernmental Panel on Climate Change (IPCC) and the International Energy Agency (IEA) to systematically identify and assess the physical and transition risks we may face in the short, medium, and long term due to climate change. At the same time, we thoroughly analyze potential strategic opportunities and, based on this, develop corresponding risk management strategies and response measures, actively enhancing our ability and resilience in addressing climate change challenges.

Scenario Analysis Explanation

The Very Low GHG Emissions Scenario

IEA Net Zero Emissions by 2050 Scenario (NZE), which assumes that global energy-related carbon dioxide emissions will reach net zero by 2050, providing the world with the opportunity to limit the global temperature rise to within 1.5°C.

Key Assumptions for the Very Low GHG Emissions Scenario

Climate Policy

In this scenario, the policy and regulatory environment is becoming stricter. In Mainland China, policies such as the "Working Guidance for Carbon Dioxide Peaking and Carbon Neutrality in Full and Faithful Implementation of the New Development Philosophy" and the "Action Plan for Carbon Dioxide Peaking Before 2030" are issued to peak carbon dioxide emissions before 2030 and strive to achieve carbon neutrality by 2060.

Macro-economy

In this scenario, by 2050, the global population is anticipated to reach around 9.7 billion, with a trend of slowing growth. The global economy is expected to grow at an average annual rate of 2.6%, but the growth rate will vary across different countries, regions, and time periods.

Energy Utilization

In this scenario, energy efficiency significantly improves, and coal and other high-carbon fossil fuels are progressively phased out:

- By 2025, the sale of new fossil fuel boilers will be halted.
- By 2030, electric vehicles will account for 60% of global car sales, with an annual increase of 1,020 GW in solar and wind energy installations.
- By 2035, the sale of new internal combustion engine vehicles will be halted.
- By 2040, global electricity will achieve net-zero emissions, with all coal- and oil-fired power plants that do not implement emission reduction measures being phased out.
- By 2050, nearly 70% of global electricity generation will be derived from solar photovoltaic and wind energy.

Application of the Very Low GHG Emissions Scenario

In this scenario, the policy and regulatory environment is stringent. Countries around the world collaborate closely to drive the evolution and development of policies, aiming to reduce the costs of clean energy technologies, broaden the diversity of key mineral resources and clean energy technologies, and build a resilient global supply chain system. The transition risks faced by the company reach their highest level, and therefore, a transition risk analysis is necessary under this scenario.

The Very High GHG Emissions Scenario

IPCC Representative Concentration Pathway (RCP) SSP5-8.5 scenario, which assumes that global greenhouse gas emissions will continue to rise by the end of the 21st century. Compared to the period of 1850-1900, the global surface temperature is likely to be higher by 3.3°C to 5.7°C over the period 2081-2100.

Key Assumptions for the Very High GHG Emissions Scenario

Surface Temperature

In regions where the company operates, such as Asia and Europe, the annual average near-surface temperature changes are significant. It is projected that the number of days with temperatures above 35°C will increase substantially in the future, while the number of days with temperatures below 0°C will also rise significantly under the very high GHG emissions scenario.

Sea Level

Relative to 1995-2014, the likely global mean sea level rise by 2050 is 0.20-0.29 meters and 0.63-1.01 meters by 2100 under the very high GHG emissions scenario. In the Asia region where the company operates, the combined effects of thermal expansion of seawater and glacier melting could result in a sea level rise close to or exceeding the global average. Additionally, with the added impact of typhoon storm surges and astronomical tides, the sea level in the coastal areas where the company operates could rise by several meters, posing a serious threat to ports, factories, and transportation infrastructure.

Application of the Very High GHG Emissions Scenario

In this scenario, the policy and regulatory environment is lenient, and with the increase in global temperatures, more frequent extreme weather events, changes in precipitation, and rising sea levels, the physical risks faced by the company are their highest. Therefore, physical risk analysis is conducted under this scenario.

Climate-related Risk Analysis

Under the Very Low GHG Emissions Scenario

Risk Type	Risk Description	Opportunity	Mitigation Measures	Impact ¹ Duration	Financial ² Impact
Policy and Law	Industry Policy Change Risks <ul style="list-style-type: none"> Stricter industry pricing and service quality standards could impose pressure on compliance costs if the company fails to adapt quickly. The further development of the national public health system and the provision of multi-level medical and health services could have an impact on the company's future development if regulatory policies in the healthcare sector change. 	<ul style="list-style-type: none"> National plans and policies related to eye health, along with support for social medical services, will drive the company to continuously deepen its nationwide chain operation model and market layout, thereby achieving market scale expansion. 	<ul style="list-style-type: none"> Closely monitor industry policy developments and leverage the advantages of a large ophthalmic chain group to proactively respond to policy changes. 	Short, Medium, and Long Term	Moderate Impact
Market	Increased Market Competition <ul style="list-style-type: none"> The ophthalmic medical service industry is attracting more social capital, and public hospitals are gradually increasing their focus on ophthalmology, intensifying competition in the ophthalmic healthcare market in China. The wave of industry mergers and acquisitions is driving up market concentration, and price wars may erode profits. 	<ul style="list-style-type: none"> The growing demand for treatments for eye diseases in the elderly and myopia prevention in children and adolescents will drive the company to offer more diversified, differentiated, and high-quality services, enhancing its market competitiveness. 	<ul style="list-style-type: none"> Continuously improve diagnosis and treatment technologies and service capabilities, optimize the national medical service network, deepen the collaboration of medical education and research, and enhance overall industry competitiveness to actively respond to changes in the market competition landscape. 	Short, Medium, and Long Term	Major Impact
Reputation	Medical Risks <ul style="list-style-type: none"> Due to factors such as limitations in medical knowledge and individual differences among patients, if medical accidents or disputes arise, the company may face risks such as complaints, financial compensation, administrative penalties, criminal liability, or legal lawsuits, which could negatively impact the company's reputation and brand image. 	<ul style="list-style-type: none"> Enhancing the company's brand reputation through high-quality services will help increase its influence, attract more consumers, and drive business growth. 	<ul style="list-style-type: none"> Focus on medical safety and quality control management, establish a comprehensive treatment protocol and medical quality control system, and standardize and regulate clinical diagnosis, treatment, and nursing practices. Actively promote the informatization of medical quality management, improve the level of medical quality management, and elevate overall management standards. 	Short, Medium, and Long Term	Major Impact

Under the Very High GHG Emissions Scenario

Risk Type	Risk Description	Mitigation Measures	Impact ¹ Duration	Financial ² Impact
Acute Physical Risks	Floods, Typhoons <ul style="list-style-type: none"> These could have significant impacts on human welfare and health, as well as trigger secondary disasters such as landslides and mudslides. 	<ul style="list-style-type: none"> Develop and continually improve flood and typhoon emergency plans. Organize emergency drills for typhoon and flood prevention, and enhance employees' ability to respond to such events. Strengthen key buildings and equipment, and relocate vulnerable inventory to safe locations to minimize potential damage from typhoons and floods. Invest in equipment with strong climate adaptability and disaster risk resistance. 	Short, Medium, and Long Term	Minor Impact
	Extreme High or Low Temperatures <ul style="list-style-type: none"> Extremely high temperatures could lead to heatstroke, dehydration, and issues related to food and water security, while extremely low temperatures may impact transportation, energy supply, and living conditions. 	<ul style="list-style-type: none"> Arrange employee work schedules to avoid outdoor work during extreme high or low-temperature periods. Install cooling or heating systems in workplaces, conduct regular health checks for employees, and address potential health risks. 	Short, Medium, and Long Term	Moderate Impact
Chronic Physical Risks	Sea Level Rise <ul style="list-style-type: none"> This could lead to large-scale land flooding, threatening the livelihoods of millions of people and the disappearance of critical ecosystems such as mangroves, wetlands, and coral reefs. 	<ul style="list-style-type: none"> Establish close communication with local meteorological authorities to monitor the rate and scale of sea level rise, assess the potential risks to company assets and operations, and relocate facilities if necessary. 	Medium and Long Term	Moderate Impact
	Average Temperature Increase <ul style="list-style-type: none"> This could result in food and water shortages, increased forest fire risks, and disruptions to hydropower generation. 	<ul style="list-style-type: none"> Regularly conduct water-saving training for employees to raise awareness. Promote the use of water-saving technologies and equipment to improve water recycling rates and reduce water waste. 	Short, Medium, and Long Term	Minor Impact

1. The impact duration is categorized into short-term, medium-term, and long-term. Short-term generally refers to within one year (inclusive) after the end of the sustainability information reporting period. Medium-term generally refers to one to five years (inclusive) after the end of the sustainability information reporting period. Long-term generally refers to more than five years after the end of the sustainability information reporting period.

2. The financial impact is classified as minimal, minor, moderate, major, or severe. Minimal impact refers to an effect of less than RMB 1 million on monetary value (e.g., revenue) or less than 1% on net profit. Minor impact refers to an effect between RMB 1 million and RMB 5 million on monetary value (e.g., revenue) or between 1% and 5% on net profit. Moderate impact refers to an effect between RMB 5 million and RMB 10 million on monetary value (e.g., revenue) or between 5% and 10% on net profit. Major impact refers to an effect between RMB 10 million and RMB 50 million on monetary value (e.g., revenue) or between 10% and 15% on net profit. Severe impact refers to an effect exceeding RMB 50 million on monetary value (e.g., revenue) or more than 15% on net profit.



GHG Emissions Management

We conducted the 2024 greenhouse gas inventory in accordance with the ISO 14064-1:2018 standard, using the operational control approach for entities within the consolidated scope where we have operational control.

GHG Inventory Boundaries

The 2024 greenhouse gas inventory covers Scope 1 direct emissions and Scope 2 indirect emissions. The specific boundaries of the inventory are defined as follows:

GHG Category	Definition	Primary GHG Emission Sources
Scope 1	Direct greenhouse gas emissions refer to the emissions generated by the organization itself, including emissions from the combustion of fossil fuels and industrial processes. These are categorized into fixed combustion emissions, mobile combustion emissions, process emissions, and fugitive emissions.	<ul style="list-style-type: none"> • Natural gas stoves • Gasoline-powered company vehicles • Diesel-powered company vehicles
Scope 2	Energy indirect greenhouse gas emissions refer to the emissions generated from the consumption of energy such as electricity and thermal energy by the organization. This includes purchased electricity, purchased steam, and other forms of energy.	<ul style="list-style-type: none"> • Purchased electricity

GHG Type

The types of greenhouse gases include carbon dioxide (CO₂), methane (CH₄), nitrous oxide (N₂O), hydrofluorocarbons (HFCs), perfluorocarbons (PFCs), sulfur hexafluoride (SF₆), and nitrogen trifluoride (NF₃).

Emission Factor

For various emission sources under Scope 1 and Scope 2, we calculate greenhouse gas emissions by selecting appropriate emission factors based on the 2006 IPCC Guidelines for National Greenhouse Gas Inventories, the General Rules for Calculation of the Comprehensive Energy Consumption (GB/T 2589—2020), and the latest electricity emission factors published by the Ministry of Ecology and Environment.


GHG Emissions

In 2024, our greenhouse gas emissions, including Scope 1 and Scope 2, totaled 23,153.84 tCO₂e. Among them, direct GHG emissions (Scope 1) were 1,821.67 tCO₂e, accounting for 8% of the total emissions, while energy indirect GHG emissions (Scope 2) were 21,332.17 tCO₂e, accounting for 92% of the total emissions. The 3,048.57 tCO₂e increase in greenhouse gas emissions in 2024 compared to 2023 is primarily attributable to the expansion of the accounting scope to include hospitals such as Shenzhen Nanshan Huaxia Eye Hospital, Chengdu Aidi ye Hospital, EnshiHuiyi Ophthalmology Hospital, suining Fuxing Ophthalmology Hospital, Weishan Medical University Ophthalmology Hospital, and Anxi Huaxia Ophthalmology Hospital.

GHG Emissions

Category	2023	2024
Scope 1: Direct Emissions (Unit:tCO ₂ e)	1,414.98	1,821.67
Scope 2: Indirect Emissions (Unit:tCO ₂ e)	18,690.29	21,332.17
Total Emissions (Unit:tCO ₂ e)	20,105.27	23,153.84
Carbon Emission Intensity (Unit:tCO ₂ e/hundred million RMB of operating revenue)	500.98	574.96

GHG Emissions



GHG Emission Reduction Measures


We deeply understand our responsibility and mission in addressing climate change and actively respond to the national carbon peaking and carbon neutrality goals. We integrate greenhouse gas emission reduction into our corporate operations management, focusing on enhancing energy efficiency, promoting green and low-carbon operations, practicing green procurement, and fostering a low-carbon culture. These efforts aim to reduce our operational carbon emissions while working with industry partners to drive the green transformation of the healthcare sector, contributing our professional strength to global climate change mitigation.

Enhancing Energy Efficiency

We are committed to achieving carbon reduction goals by enhancing energy efficiency. Through optimizing equipment operation management and upgrading energy-saving facilities, we systematically reduce energy consumption and carbon emissions.

Specific measures to enhance energy efficiency include:

- Prioritize the use of energy-efficient equipment when constructing or renovating office areas, and gradually phase out high-energy-consuming devices.
- Encourage employees to turn off electrical devices such as computers and printers when leaving the office for extended periods, reducing standby energy consumption.
- Set air conditioning temperatures reasonably, no lower than 26°C in summer and no higher than 20°C in winter, while implementing limited-hour control for central air conditioning to optimize operation strategies and reduce energy waste.
- Regularly clean and maintain air conditioning equipment to ensure its efficient operation.




Promoting Green and Low-carbon Operations

We integrate the concept of green and low-carbon development into the entire process of medical service operations. By advocating for green office practices, implementing waste classification management, and other measures, we are promoting the transformation of medical services towards a resource-saving and environmentally-friendly model.

Specific measures to promote green and low-carbon operations include:

- Make full use of natural lighting when constructing or renovating office areas to reduce the use of artificial lighting.
- Use energy-efficient lighting such as LEDs and design lighting areas reasonably to avoid excessive lighting.
- In public areas (including restroom), implement intermittent lighting at night to ensure illumination while reducing energy consumption.
- Strengthen employees' energy-saving awareness by ensuring lights are turned off after work and after overtime to prevent unnecessary lighting such as daylight lamps or continuously lit lamps.
- Promote the use of electronic documents and cloud storage to reduce the use and printing of paper.
- Set up recycling points for used paper, plastic, and other general waste, encouraging employees to participate in resource recycling.
- Cooperate with professional recycling agencies to ensure the safe and compliant disposal of recycled waste.



Practicing Green Procurement

We continuously improve our green procurement policy by establishing green procurement standards and supplier evaluation mechanisms. We prioritize selecting medical products and services with environmental certifications and recyclable materials, advocating for suppliers to jointly assume environmental responsibilities.

Specific measures for practicing green procurement include:

- Focus on the performance of partners in environmental protection, social responsibility, business compliance, etc., and conduct due diligence on suppliers based on the "Supplier Survey," "New Qualified Supplier Evaluation Form," "Supplier On-site ESG Audit Form," and on-site audit results. The due diligence includes aspects such as pollutant discharge compliance, clean production, and energy conservation.
- Encourage suppliers to implement energy-saving and emission reduction measures and jointly promote the development of a green supply chain.
- Organize training on supply chain environmental and social issues, actively promoting the company's sustainable development concepts and policies.



Fostering a Low-Carbon Culture

We promote low-carbon culture development through both institutional construction and educational promotion, incorporating environmental protection requirements into employee behavior standards. Regular energy-saving training and themed activities are held to cultivate awareness of low-carbon practices among all employees, continuously fostering a green development atmosphere within the organization.

Specific measures for cultivating our low-carbon culture include:

- Regularly hold green office training and thematic seminars to educate employees on environmental protection knowledge, green office practices, and energy-saving concepts.
- Use internal company bulletin boards, WeChat official accounts, emails, and other channels to disseminate information and initiatives related to green office practices.
- Organize employee participation in environmental public welfare activities to enhance their environmental awareness and sense of social responsibility.



Energy Utilization


We highly value energy management and strictly comply with the relevant laws and regulations, including the "Energy Law of the People's Republic of China," the "Energy Conservation Law of the People's Republic of China," and the "Renewable Energy Law of the People's Republic of China." We actively promote green office management, establish and strictly enforce electricity cost control measures, and guide our subsidiary hospitals to formulate local policies such as water and electricity management systems and energy-saving regulations. We aim to continuously improve energy efficiency, expand the use of renewable energy, and reduce energy consumption.

In 2024, our energy consumption during operations was primarily electricity, with a total consumption of 39,754,330.42 kWh, accounting for 84% of the total energy consumption.

Energy Structure

Energy Type	2024	2023	Comprehensive Energy Consumption in 2024 (tons of coal equivalent)	Comprehensive Energy Consumption in 2023 (tons of coal equivalent)
Electricity (kWh)	39,754,330.42	32,772,733.13	4,885.81	4,027.77
Natural Gas (L)	568,248.18	424,892.63	610.37	456.39
Diesel (L)	205,173.36	154,299.93	257.10	193.35
Gasoline (m ³)	36,418.71	18,400.00	48.44	24.47
Total			5,801.72	4,701.98

2024 Energy Structure



Water Resources Utilization

As a responsible healthcare provider, we deeply understand the importance of water conservation for both the ecological environment and human health. In our daily operations, we actively promote water-saving practices by optimizing water management in medical services and office areas, promoting the use of water-efficient equipment, and conducting water conservation training for employees, systematically reducing water consumption.

We strictly implement the requirements of the "Environmental Protection Law of the People's Republic of China," the "Water Law of the People's Republic of China," the "Law of the People's Republic of China on Prevention and Control of Water Pollution," and the "14th Five-Year Plan for the Construction of a Water-Saving Society," and other relevant laws, regulations, and policies. We have established an "Environmental Protection Policy" to strengthen water resource management across key areas such as medical services, daily operations, fire protection, landscaping, and equipment cooling. We continuously improve water utilization efficiency through categorized management and refined control measures.



Highlight | Refined Water Resource Management

Zhangzhou Huaxia Ophthalmology Hospital strictly implements water resource management requirements and continuously improves water use efficiency through the following refined management measures:

- Establish a zoning management mechanism to implement classified control over different functional areas, ensuring safe and efficient water use across all zones.
- Assign designated administrators to conduct regular inspections in administrative areas, promptly identifying and addressing abnormal water usage.
- Incorporate water conservation requirements into nursing management in operating rooms and inpatient wards, raise awareness among patients and families during admission, and strengthen daily supervision to ensure proper use of water and timely repair of leaks.
- Enhance equipment maintenance in outpatient clinics, optical centers, and laboratories, assign water management responsibilities, and report leaks for immediate repair.
- Establish a monthly water usage analysis mechanism to regularly monitor water bills and consumption, quickly detect abnormal fluctuations, and optimize management measures to ensure efficient use of water resources.

Ecosystem and Biodiversity Protection

We strictly comply with the "Kunming-Montreal Global Biodiversity Framework," the "Environmental Protection Law of the People's Republic of China," the "Law of the People's Republic of China on the Protection of wildlife," the "Regulations of the People's Republic of China on Wild Plants Protection," and other relevant laws, regulations, and international conventions. We have integrated biodiversity conservation into our sustainable development management system, continuously advancing ecological protection and restoration efforts. We are committed to refraining from operating in nature reserves, ecologically sensitive areas, and ecologically fragile zones. For all new projects, we conduct rigorous ecological risk assessments during site selection to ensure our operations align with the principles of ecological sustainability. Currently, none of our projects are located in ecologically sensitive areas, and we implement targeted ecological protection measures based on environmental impact assessments to minimize disturbances to regional biodiversity.

Throughout the construction of new projects, we strictly enforce ecological protection requirements and optimize pollution control measures during the construction phase, including reducing dust emissions, controlling noise pollution, and properly managing solid waste. In the decoration phase, we consistently use eco-friendly building materials and strictly prohibit the use of paints and coatings listed in the national elimination catalog. Before commencing operations, we engage qualified professional institutions to conduct environmental protection acceptance inspections, systematically evaluating the effectiveness of environmental facilities, operational practices, and management efforts. In addition, we incorporate eco-friendly elements into hospital landscaping designs, such as optimizing vegetation arrangements to enhance the stability of the surrounding ecological environment.



Highlight| Practicing Ecological Protection Concepts in Volunteer Tree Planting

In 2024, the leadership team and party members of Xuchang Huaxia Ophthalmology Hospital actively participated in the "Act Together for Green City" volunteer tree planting event, demonstrating their commitment to ecosystem protection and biodiversity development. During the event, participants worked together to plant trees, contributing to the improvement of the local ecological environment.



Environmental Compliance Management

We strictly comply with the "Environmental Protection Law of the People's Republic of China," the "Environmental Impact Assessment Law of the People's Republic of China," and other relevant laws and regulations. We have established and continuously improved our environmental management system, progressively enhancing our environmental governance standards. Currently, 100% of our subsidiary hospitals have passed the ISO 14001 Environmental Management System certification.



Highlight | Optimizing Environmental Compliance Management Structure

Santai Huaxia Ophthalmology Hospital has established an Environmental Protection Leading Group, with the General Manager serving as the team leader, and the hospital director and deputy directors serving as deputy leaders. The leadership team includes department heads from the Medical Department, Nursing Department, Administrative and Logistics Department, Infection Control Office, Public Health Department, Inpatient Department, Outpatient Department, and other key departments. As the core institution for environmental protection work, the leadership team is responsible for formulating environmental protection plans, supervising the implementation of environmental regulations, promoting the construction and renovation of environmental protection facilities, conducting environmental protection education and publicity, and responding to environmental emergencies. This structure provides organizational support for the orderly implementation of all environmental protection activities in the healthcare institution.



Highlight | Promoting Environmental Protection Culture

Jiangyou Huaxia Ophthalmology Hospital regularly organizes training sessions and lectures on green office practices to educate employees on environmental protection knowledge and the principles of green office. These sessions cover methods and tips for green office practices, aiming to raise employees' environmental awareness and participation. Additionally, Jiangyou Huaxia Ophthalmology Hospital uses internal communication channels, such as company bulletin boards, WeChat official accounts, and emails, to release information and initiatives related to green office practices. The hospital also highlights the importance of green office practices, shares successful cases of green office practices, and fosters a positive atmosphere for green office culture.



Environmental Emergency Management

We strictly comply with the "Emergency Response Law of the People's Republic of China" and other relevant laws and regulations. In response to potential natural disasters (such as floods, droughts, meteorological disasters, earthquakes, geological disasters, marine disasters, biological disasters, and forest and grassland fires), we have developed specific emergency response plans, including the "Emergency Plan for Sudden Environmental Incidents," "Emergency Plan for Sodium Hypochlorite Leakage," "Emergency Treatment Procedures for Sewage Treatment," and "Flood and Typhoon Emergency Response Plan." We have established an emergency command leadership team and formed a professional emergency rescue team. We regularly conduct emergency prevention, disaster relief drills, and emergency response training. Additionally, we widely promote knowledge on environmental pollution prevention and emergency response to sudden environmental incidents, including disaster avoidance, self-rescue, and mutual assistance, to raise awareness of disaster reduction among our employees and enhance our ability to respond to emergencies. In 2024, we carried out 7 environmental emergency drills, continually improving our emergency handling and response capabilities for sudden environmental events.

Emergency Management Process for Sudden Environmental Incidents

In the event of a sudden environmental incident, the hospital's emergency command center should promptly arrange for monitoring personnel to rush to the site. In coordination with the rescue team, an emergency monitoring plan should be developed as quickly as possible based on the actual situation.



Determine the range of pollutant spread based on the rate of pollutant dispersion and the meteorological and regional characteristics of the event location, and set up the corresponding number of monitoring points within this range.



In the early stages of the incident, monitoring should be conducted according to the monitoring capabilities of the event location and the severity of the emergency, following the principle of as much monitoring as possible. As the spread of pollutants and the trends in monitoring results change, the frequency and monitoring locations should be adjusted accordingly.



Once the testing plan is determined, emergency testing personnel should immediately conduct on-site testing and analysis or collect samples, and promptly send the collected samples to the laboratory for analysis. Upon receiving the notification, the testing company's analysts should quickly arrive and be ready, starting the analysis as soon as the samples arrive.



Timely report the on-site monitoring situation and results to the command office, provide recommendations for eliminating pollution hazards, and offer suggestions for major protective measures such as the isolation and de-escalation of contaminated areas, as well as the evacuation and return of personnel.



Highlight | Collaboration on Emergency Rescue

To further enhance environmental emergency management, Yuzhou Huaxia Eye Hospital and Chongqing Huaxia Ophthalmology Hospital signed the "Emergency Mutual Aid Agreement for Sudden Environmental Incidents." In the event of a sudden environmental accident, both parties will fully utilize their emergency rescue capabilities to assist each other in a timely, swift, and accurate manner, aiming to eliminate or reduce environmental pollution to the greatest extent possible.



Highlight | Sodium Hypochlorite Leakage Emergency Drill

In 2024, Xiamen Ophthalmology Center's Wuyuan Branch conducted an emergency drill for sodium hypochlorite leakage. When the residual chlorine alarm triggered, the on-duty personnel immediately rushed to the scene for inspection and promptly reported the situation to higher authorities. Upon receiving the report, the engineering supervisor quickly organized the entire engineering and maintenance team to handle the situation at the wastewater treatment station.

This emergency drill allowed the engineering team to thoroughly understand the entire emergency response procedure, ensuring the company can make the quickest, most effective, and most accurate work arrangements, personnel mobilization, and handling processes in the event of an environmental emergency. The drill enhanced the company's ability to respond to sodium hypochlorite liquid leakage incidents.

Highlight | Flood Control and Disaster Response Drill

In 2024, Chengdu Aidi Eye Hospital conducted an internal flood control and disaster response drill at the hospital, with full participation from all non-duty personnel. The drill focused on four main aspects: initiating emergency response, organizing evacuation and relocation, managing shelter sites, and providing medical assistance and psychological support. It simulated the hospital's response at various stages following a flood and adopted a combination of manpower, technology, and material resources to strengthen the hospital's internal emergency handling capacity. The exercise aimed to maximize the protection of life and property in the face of unavoidable natural disasters.



Pollutant Discharge


We recognize the unique responsibility that comes with being a provider of healthcare services and place great importance on the environmental impact of our operations. We treat pollutant emission management as a critical part of our business operations, strengthening the control of emissions from exhaust gas, wastewater, and waste, while continuously investing in environmental protection facilities. We ensure that all emissions fully comply with national and local environmental standards, striving to minimize our environmental footprint and fulfill our responsibility to protect the ecosystem and safeguard public health.

Wastewater Management

We generate wastewater pollutants during our business operations, primarily including animal and vegetable oils, volatile phenols, cyanides, petroleum compounds, biochemical oxygen demand (BOD), anionic surfactants, and chemical oxygen demand (COD). We strictly comply with the "Environmental Protection Law of the People's Republic of China," the "Water Pollution Prevention and Control Law of the People's Republic of China," and other relevant laws and regulations. We have established a "Wastewater Treatment Management System" and obtained a pollutant discharge permit. Based on the characteristics of different pollutants, we implement a monitoring mechanism that includes daily tracking, weekly inspections, monthly assessments, and quarterly analyses, ensuring the real-time, accurate, and comprehensive management of environmental data.

Medical Wastewater Treatment

We optimize the treatment process of medical wastewater through facilities such as equalization tanks, reaction tanks, oxidation tanks, sedimentation tanks, disinfection tanks, and water pumps, aiming to enhance pollutant removal efficiency. In 2024, we upgraded our wastewater treatment station by introducing an intelligent monitoring system, enabling real-time monitoring of pollutant discharge concentrations and automatic alerts. This system is connected to national, provincial, and municipal environmental supervision platforms to improve data transparency and regulatory compliance. We have assigned dedicated personnel to manage the wastewater treatment station, strengthening daily inspections and equipment maintenance to ensure stable operation. Wastewater treated at our station complies with the Discharge standard of water pollutants for medical organization (GB18466-2005), and follows the pretreatment limits for comprehensive and other medical institutions. After treatment, our medical wastewater meets discharge standards before being directed into the municipal sewage network and sent to the city's sewage treatment plant. Meanwhile, any exhaust gas generated during the wastewater treatment process is purified through the treatment station's air purification system.



Medical Wastewater Treatment Process



Highlight | R&D Innovation — "Collection Device for Wastewater Discharge of Steam Sterilizers"


Traditional wastewater treatment for steam sterilizers required manual discharge, posing safety risks and resulting in low efficiency. In 2024, Chengdu Aidi Eye Hospital obtained a patent for a "Collection Device for Wastewater Discharge of Steam Sterilizers." This device enables automatic wastewater discharge through a drainage component, eliminating the need for manual operation by medical staff. It effectively reduces the risk of burns from high-temperature steam and enhances the safety and convenience of wastewater treatment. The device not only simplifies the wastewater management process but also addresses the challenges of wastewater collection and subsequent treatment, reduces discharge noise, and minimizes the environmental impact on surrounding hospital areas.



Domestic Sewage Treatment

Our domestic sewage mainly includes wastewater from cleaning activities and toilet facilities. The following measures are implemented to ensure that all sewage is treated and discharged in compliance with relevant standards:

- Optimize the operation and management of sedimentation tanks and filtration systems in hospital cafeterias to enhance oil-water separation efficiency, and strengthen daily maintenance to ensure the stable operation of sewage treatment facilities.
- Regularly clean grease traps and septic tanks, strictly control domestic sewage discharge sources, and prohibit the storage or disposal of chemicals, oils, and other pollutants near sewage pipelines to reduce the risk of pipeline blockages and secondary pollution.
- Ensure that all domestic sewage undergoes treatment through a three-stage septic system, achieving discharge standards before release.
- Strengthen cleaning management by actively using environmentally friendly products for sanitation activities, reducing the use of highly polluting chemicals and lowering domestic sewage contamination.



Air Emissions Management

In our business operations, the main sources of air emissions include vehicle exhaust, kitchen fume emissions, and generator room flue gas. We have implemented the following management measures to ensure efficient treatment and safe discharge of air emissions:

- For vehicle exhaust in parking garages: Dedicated ventilation systems are installed. Exhaust ducts in underground garages are routed to avoid windows and pedestrian pathways on upper floors. Exhaust outlets are directed toward green spaces and away from areas with heavy pedestrian and vehicle traffic. Exhaust pipes are oriented according to prevailing wind directions to prevent backflow of emissions.
- For kitchen fume emissions: Fumes are directed to the rooftop through dedicated ducts and discharged after purification by oil fume filters.
- For emissions from backup generator rooms: Dedicated flue gas pipelines are installed, channeling emissions directly to the rooftop via exhaust stacks.



Waste Disposal

As a specialized institution in the healthcare sector, we strictly comply with the "Solid Waste Pollution Prevention and Control Law of the People's Republic of China," the "Regulations on the Management of Medical Waste," the "Measures for Medical Wastes Management of Medical and Health Institutions," and other relevant laws, regulations, and guidelines. We have formulated and implemented internal policies such as the "Medical Waste Classification and Collection Management System," the "Medical Waste Recovery and Transportation System," the "Temporary Storage Management System for Medical Waste," and the "Medical Waste Entrustment System," managing waste in a transparent and responsible manner while regularly disclosing related data.

In our business operations, we strictly follow the principles of "reduction, recycling, and harmless treatment" to manage various types of waste generated from medical activities through classification and control. For general waste, we actively promote resource recycling and reuse to minimize waste generation and reduce resource consumption. For hazardous medical waste, we have established a comprehensive management system covering the entire business chain, implementing a closed-loop process from source classification and dedicated packaging to professional disposal. We also continuously optimize disposal processes to minimize environmental impact.

General Waste

In our business operations, the general waste we generate mainly consists of domestic waste.

We follow local government regulations on waste sorting, ensuring that waste is properly classified and recycled across all floors and departments on a daily basis. Our cleaning staff are responsible for collecting and transporting the waste to designated domestic waste stations for further sorting and processing.


Hazardous Waste

In our business operations, the hazardous waste we generate primarily consists of medical waste, including infectious solid waste and injurious solid waste. We have established a medical waste management structure, under which the head of the Medical Waste Management Leadership Team takes overall responsibility for medical waste management. Team members are responsible for implementing and enforcing the provisions of the "Regulations on the Management of Medical Waste," ensuring that medical waste is effectively managed and disposed of in compliance with regulations, and safeguarding environmental and public health.

We require all departments of our affiliated hospitals to actively establish medical waste transfer points and set up hazardous waste storage rooms in accordance with the "Catalogue of Classifications of Medical Wastes." Different types of medical waste must be stored separately using specialized packaging bags or containers that meet the "Provisions on the Standards and Warning Marks of Special Packages and Containers of Medical Wastes," and must be disposed of in compliance with regulations through certified third-party agencies to prevent the loss or leakage of medical waste. Our hazardous waste management measures include:

- Chemical waste (e.g., discarded chemical reagents and disinfectants): Handled by professional disposal agencies.
- High-risk waste (e.g., pathogen-containing culture media, specimens, strains, and preservation solutions): Subjected to steam sterilization or chemical disinfection at the point of generation, followed by collection and disposal as infectious waste.
- Discarded anesthetics, psychotropic substances, radioactive materials, toxic drugs, and related waste: Managed in strict accordance with applicable laws, regulations, and national standards

Medical Waste Management Framework



Circular Economy

We actively respond to the "14th Five-Year Plan (2021-2025) for National Economic and Social Development of the People's Republic of China," striving to build a resource recycling system that spans the entire medical process. By systematically optimizing resource allocation and utilization efficiency, we integrate the principles of a circular economy into all aspects of our operations and development.

In practice, we focus on promoting the rational use and regeneration of medical consumables, establishing a waste sorting and recycling system to repurpose materials such as packaging waste. We continuously explore more circular economy solutions tailored to the healthcare industry through the following measures:

Using eco-friendly materials

Prioritizing the procurement of environmentally friendly, energy-efficient, and recyclable office furniture, equipment, and consumables.

Choosing durable products

Selecting high-quality, long-lasting office supplies, such as sturdy desks and chairs and durable printers, to reduce waste from frequent replacements.

Recycling paper


Promoting paperless operations by encouraging the use of emails and electronic documents for information sharing and storage. When paper use is necessary, advocating for double-sided printing and copying, and reusing single-sided printed paper as scrap paper or notepads.

Recycling office supplies

Setting up designated recycling bins for the collection and sorting of used paper, ink cartridges, toner cartridges, batteries, and other office supplies, and partnering with professional agencies for processing or reuse.

Encouraging employees to bring their own cups

Reducing the use of disposable paper cups and fostering sustainable office habits.



02

Social

2024 Key Performance Targets for Social Matters

- Strengthen efforts in scientific research and innovation, and promote breakthroughs and development in ophthalmic medical technology, with annual R&D investment no less than 70 million RMB
- Zero incidents of intellectual property infringement throughout the year
- Establish and improve supplier admission and evaluation standards, giving priority to partners that meet environmental protection requirements, fulfill social responsibilities, and adhere to business ethics
- Apply ESG evaluation criteria to assess newly admitted suppliers
- Achieve 100% coverage in hospital service quality inspections
- Zero penalties throughout the year for violations of labor laws or employment discrimination
- Zero information security incidents and violations of customer privacy throughout the year
- Maintain a local employee hiring ratio of no less than 60% for the year
- Achieve 100% employee training coverage, with an average of no less than 40 training hours per person
- Zero extremely serious, major, relatively serious, or general safety accidents throughout the year
- Zero safety incidents causing direct economic losses exceeding 1 million RMB



Rural Revitalization and Social Contributions

Guided by the mission of "Whether rich or poor, we serve each patient with care, and protect healthy and bright eyes for all," we regard the fulfillment of social responsibility as an integral part of our corporate development. In active response to the national rural revitalization strategy, we are committed to leveraging our medical expertise to promote rural development and social equity. In terms of healthcare support, we have continued to carry out free clinics, ophthalmic disease screening, and health education activities in rural and community settings. These efforts aim to provide basic medical services to residents in remote areas and local communities. By integrating medical resources and innovating support models, we strive to narrow the urban-rural healthcare gap and contribute lasting momentum toward rural revitalization and the realization of the "Healthy China" vision.

Rural Healthcare Revitalization

We strictly implement the national 14th Five-Year Plan for Eye Health and actively respond to the rural revitalization strategy, continuously contributing to the development of healthcare services in rural areas and earnestly fulfilling our social responsibilities. We actively participate in public welfare initiatives by dispatching experienced medical professionals to support regions such as Tibet, Ningxia, and Xinjiang, donating medical equipment and supplies, and providing free eye examinations and treatment services to local residents. These efforts have helped improve rural healthcare infrastructure and raise the level of eye health in underdeveloped areas. We also continue to strengthen cooperation with grassroots healthcare institutions by offering medical personnel training and technical support, aiming to cultivate rural ophthalmic talent and enhance the diagnostic and treatment capabilities of primary-level hospitals. Through these efforts, we contribute to narrowing the urban-rural healthcare gap and promoting the sustainable development of rural healthcare services.



Highlight | "Care from Bright Journey of Overseas Chinese" Public Welfare Project

We partnered with the All-China Federation of Returned Overseas Chinese and the Overseas Chinese Charity Foundation of China to jointly launch the "Care from Bright Journey of Overseas Chinese" public welfare project in 2021. This long-term initiative provides additional medical assistance beyond basic healthcare coverage for patients, aiming to prevent poverty caused or worsened by eye diseases.

In 2024, we organized the participation of 16 affiliated hospitals in cities such as Hefei, Huainan, Longyan, Sanming, Xianyou, Changzhou, Pizhou, Wuxi, Jinan, Linyi, and Lishui. Since the project's inception, we have conducted screenings for over 100,000 patients with vision disorders from underprivileged backgrounds and helped more than 5,000 patients with cataracts and pterygium regain their sight.



"Care from Bright Journey of Overseas Chinese" Public Welfare Event – Xianyou Stop

Highlight | "Seeing is Believing – Rural Eye Health Revitalization Project"

Eye health directly affects people's vision and ability to live independently, yet in remote areas, this basic need faces significant challenges. Due to inconvenient transportation and a lack of medical resources, local villagers struggle to receive timely and effective eye care, which causes serious disruptions to daily travel, work, study, and even mental health. In 2024, we completed the first phase of a three-year collaboration with Orbis International (ORBIS) and the Shanghai Xin'ao Brightness Charity Foundation on the "Seeing is Believing – Rural Eye Health Revitalization Project." During the project, we conducted over 800 community mobilization and public screening events, trained more than 150 grassroots healthcare workers, and provided eye health public welfare assistance to over 2,700 disadvantaged individuals. Additionally, we actively promoted the development of eye health service systems in rural areas, gradually forming a sustainable grassroots service model that effectively improves the eye health of rural residents, allowing people in remote areas to truly experience the hope and dignity brought by light.



"Seeing is Believing – Rural Eye Health Revitalization Project" Signing Ceremony Scene

Highlight | "Torchlight Project"

The "Torchlight Project" is co-organized by the China Association of Gerontology and Geriatrics Ophthalmology Branch and the Beijing Star Macular Disease Foundation. The project invites renowned experts as mentors to provide training opportunities for grassroots ophthalmologists in remote and underdeveloped regions, aiming to improve local eye healthcare services. Since its launch in late 2019, the project has been carefully planned and guided by Professor Li Xiaoxin, the President of Xiamen Ophthalmology Center. It has successfully held two sessions and trained 60 grassroots ophthalmologists, making a significant contribution to reducing the incidence and impact of elderly eye diseases in China. In 2024, Professor Li Xiaoxin was awarded the "Outstanding Contribution Award for Rural Revitalization" by the "Torchlight over Grassroots" Public Welfare Fund for his contributions to rural development.



Professor Li Xiaoxin Awarded the "Outstanding Contribution Award for Rural Revitalization" by the "Torchlight over Grassroots" Public Welfare Fund

Highlight | "Bright Journey to Tibet" Charity Project

For many years, we have diligently implemented the national call for deepening the "team-based" medical talent assistance to Tibet. We have carried out more than ten "Bright Journey to Tibet" initiatives, including screening surgeries, charitable donations, and technical support. These public welfare activities focus on training medical talent and provide sustainable, "blood-producing" assistance, continuously bringing light to the people of the Tibetan Plateau. This initiative has greatly contributed to improving the overall medical service capabilities in the Tibet region.

In 2024, our medical team once again traveled to Lhasa, Tibet, where we provided ophthalmic diagnostic and treatment services for local eye patients through outpatient consultations, surgical training, and discussions of difficult cases. We helped local medical staff enhance their skills in diagnosing and treating eye diseases, improving the overall ophthalmic capabilities of doctors in the region, and promoting the localization and normalization of ophthalmic technology development.



Bright Journey to Tibet

Highlight | "Huaxia Bright Journey" Charity Project



As an important force in ophthalmic healthcare in Fujian Province, we actively responded to the national call and proactively joined the grand team of the Fujian-Ningxia Cooperation. Since 2007, we have made multiple trips to Ningxia, in line with the local healthcare development needs. Through public screening, free surgeries, charitable donations, technical support, and other methods, we have contributed to further deepening the Fujian-Ningxia cooperation with our efforts.

In 2024, our Bright Journey medical team went to Longde County, Ningxia, where we conducted eye disease screenings and offered free consultations for local villagers. We helped 30 impoverished cataract patients regain their sight. Additionally, we provided guidance and training to the local ophthalmic team on cataract surgery, ophthalmic anesthesia, nursing, and other aspects, offering "Huaxia experience" to support the development of ophthalmology in Longde.



"Huaxia Bright Journey Project" in Longde County, Ningxia

Healthy Community Development

We actively practice our core values of "Responsibility, Care, Innovation, Win-Win" and consistently prioritize deep interaction and collaborative development with the community. The company has established a "Community Policy" that focuses on creating diversified communication mechanisms and participatory health service models. We are committed to becoming a long-term partner in community health management and working together to build a more inclusive and sustainable community health ecosystem.

In terms of community communication, we regularly organize public welfare activities such as free medical consultations, health lectures, and disease prevention screenings. These activities provide a platform for face-to-face communication between doctors and patients, enabling us to respond promptly to the health needs of community residents. At the same time, we actively incorporate community feedback and integrate residents' health needs into our service optimization system, continuously improving the accessibility and satisfaction of medical services.

In terms of community co-construction, we adhere to the principle of local priority. Through local procurement and employment plans, we provide cooperation opportunities for local businesses during our business development process. We prioritize purchasing products and services from local suppliers whenever possible. When recruiting talent, we give preference to local personnel and offer training and career development opportunities to help them enhance their professional skills and promote local employment growth. We collaborate with local streets, public welfare organizations, and other partners to carry out various community health charity volunteer activities, creating a sustainable community health support network that ensures quality medical resources are distributed more equitably to every community member.

Highlight | "Huaxia Catching Light in China Tour" Charity Project

Corneal diseases, as one of the leading causes of blindness, lack widespread access to effective treatments like corneal transplants. As a result, many patients suffer permanent blindness due to the lack of timely intervention. In light of this, we launched the "Huaxia Catching Light in China Tour" corneal transplant charity project, offering professional treatment and public welfare assistance to impoverished corneal disease patients across the country, helping them regain their sight.



"Huaxia Catching Light in China Tour" Project

In 2024, we partnered with the Red Cross Society of China Xiamen Branch to establish a special assistance channel for corneal transplants. Over the next three years, we plan to provide charitable support to 100 economically disadvantaged or vulnerable individuals suffering from corneal diseases. This initiative includes assisting with medical subsidy applications and facilitating corneal transplant surgeries, helping these patients restore their vision as soon as possible.

Highlight | Xiamen Junior Reporter Eye Health Science Base



At the end of 2023, as the first smart eye health science platform in Fujian Province, our ophthalmic science museum officially began operations. The museum is centered on the core values of systematic, professional, and public welfare-based education. It innovatively integrates five functional areas: image display, science education, interactive experience, eye care lectures, and hospital history exhibits. Through expert presentations, science research studies, career experiences, and intelligent interactions, the museum deeply blends eye health knowledge with elements of history, life, art, and science, creating an enjoyable and educational science learning model.

On February 14, 2025, to further deepen eye health science education for young people and reduce the incidence of myopia, we, in collaboration with the West Strait Morning Post, officially launched the Xiamen Junior Reporter Eye Health Science Base. The base uses expert lectures, career experiences, and intelligent interactions to educate young people on eye health science, cultivate scientific eye care habits, and prevent and control the onset of myopia, thereby promoting the innovative development of ophthalmology in Xiamen.



Launch Ceremony of the Xiamen Junior Reporter Eye Health Science Base

Highlight | Free Medical Consultation Activities

We actively implement the Healthy China strategy by organizing charity free medical consultation activities, including vision screenings, cataract examinations, and eye disease consultations, at the communities of our affiliated hospitals. Through distributing promotional materials and health education, we raise awareness of eye health care knowledge. These activities allow residents to access professional, convenient, and attentive medical services right at their doorstep, enhancing their understanding of eye diseases and eye care, while also improving the overall public health level.



Free Medical Consultation Activity at Jin'an Community, Huli District, Xiamen



"Health Delivery to Celebrate Mid-Autumn Festival"
Charity Free Medical Consultation Activity



"Celebrate the National Day in Bright Vision"
Series of Eye Health Medical Services at Party Day



Free Medical Consultation Activity at Kanghui Community, Huli District, Xiamen



Dongguan Huaxia Ophthalmology Hospital "Public Health Action"
- Eye Health Free Medical Consultation Activity

Medical Support Along the Bright Journey

As a globally responsible leader in healthcare services, we uphold the vision of a shared future for mankind. Since 2014, we have launched an international public welfare strategy by dispatching professional medical teams to countries such as Cambodia, Myanmar, Nepal, and Sri Lanka to carry out "Bright Journey" medical aid missions. By continuously expanding our philanthropic reach and bringing high-quality medical resources to underserved communities, we are systematically advancing international humanitarian cooperation and actively contributing to the building of a "Healthy Silk Road" under the Belt and Road Initiative. We are committed to enhancing the connectivity of global medical resources and fostering a more open and inclusive international healthcare cooperation ecosystem. Through our professional capabilities, we aim to promote global health equity and sustainable development.

Highlight | "Care from Bright Journey of Overseas Chinese" in Cambodia

Due to its tropical location and prolonged exposure to intense ultraviolet rays, coupled with limited healthcare infrastructure, Cambodia faces a cataract incidence rate significantly higher than the global average. Many patients are at risk of vision loss due to a lack of timely treatment. As a pioneer in comprehensive ophthalmology services in China, we have actively responded to the national Belt and Road Initiative by dispatching professional medical teams to Cambodia since 2016 to carry out charitable medical missions. By the end of 2024, our medical teams had screened nearly 10,000 patients across more than 20 provinces and cities in Cambodia and provided free cataract surgeries to over 1,000 patients.

From December 14 to 21, 2024, our medical team participated in the "Care from Bright Journey of Overseas Chinese" event, co-organized by the Overseas Chinese Charity Foundation of China and Cambodia's Ministry of National Defense. During this mission, the team completed 760 consultations and screenings and performed free cataract surgeries for 135 Cambodian patients. Additionally, we donated intraocular lenses, surgical kits, medical consumables, and other supplies. By leveraging our model of "team collaboration and shared expertise," we introduced the well-established "Huaxia Model" to Cambodia, helping to enhance local ophthalmic service capabilities and ensuring more patients receive professional and standardized eye care close to home.



Huaxia Medical Team Providing Treatment for Local Patients in Cambodia



The Ministry of National Defense of Cambodia Presents Certificates of Appreciation to the Overseas Chinese Charity Foundation of China, Huaxia Eye Hospital, and the China Hong Kong & Macau Business Association of Cambodia, and Issues Letters of Gratitude to Medical Team Personnel



The Company Donates Medical Supplies to Preah Ket Mealea Hospital in Cambodia

Innovation-driven Development

We uphold the philosophy of being guided by academics, supported by technology, and centered on patients. By promoting the integrated development of medical care, education, and research, we are deeply committed to advancing discipline development and academic research. We have built a comprehensive academic and research system and established an innovation platform to steadily enhance our capabilities in medical, scientific, and academic innovation. Through this, we create a positive cycle where research outcomes inform and improve clinical techniques, driving continuous improvement in care quality and enabling us to provide patients with more professional and high-quality medical services.

Technology Innovation

We place great importance on and actively encourage scientific research and innovation. Focusing on "academic, scientific research, and platform development" as well as "strategy, talent, and discipline development," we promote the overall collaborative development of the "medical education and research" system, which integrates clinical diagnosis and treatment, medical research, and training education. We continuously strengthen research management, deepen the development of our research talent pool, and provide comprehensive support for research innovation outcomes. This not only enhances our research innovation capabilities but also actively engages in academic exchange and collaboration within the industry. We promote university-enterprise cooperation to contribute to the high-quality development of the ophthalmology sector.

Coordinated Development of the "Medical, Education and Research" System

We continuously deepen the collaborative development of the "medical education and research" system, actively building research and innovation platforms. By leveraging the accumulation of clinical diagnosis and treatment cases, we enhance our research strategy, improve clinical medical research and innovation capabilities, and promote the transformation of research outcomes to elevate the quality of clinical medical services. We have established a Strategic and Academic Committee, the highest academic advisory body within the company, responsible for overseeing academic decision-making, review, and evaluation, providing direction and leadership for the high-quality development of our medical education and research initiatives.

Xiamen Ophthalmology Center, as the technical hub for ophthalmic diagnosis and treatment within the company, has been recognized as a national clinical key specialty (ophthalmology) unit and a National Drug Clinical Trial Institution(GCP). It has established postdoctoral research workstations, academician expert workstations, as well as key laboratories for corneal and conjunctival diseases in Fujian Province, Xiamen City, and key laboratories for eye diseases in Xiamen City. Furthermore, through various clinical research collaboration networks, we conduct epidemiological surveys on ophthalmology and research on major causes of blindness and difficult eye diseases. Our affiliated hospitals lead or participate in numerous studies on common eye diseases such as dry eye, corneal diseases, diabetic retinopathy, and age-related macular degeneration, covering areas such as diagnostic guidelines, clinical applications, and basic clinical translation.

In 2024, the hospitals affiliated with our company received the following honors and qualifications in the field of scientific research innovation:

- Quanzhou Huaxia Eye Hospital was approved as the "Fujian Province 'Science and Innovation China' Doctoral Innovation Station."
- Quanzhou Huaxia Eye Hospital was recognized as a "2023-2024 Fujian Province Doctoral Innovation Station with Good Performance."
- Xiamen Ophthalmology Center's Xie Lixin Academician Workstation was approved as the "2024 Fujian Province Academician and Expert Workstation."
- Xiamen Ophthalmology Center was designated as the "Xiamen City Eye Disease Clinical Medical Research Center."
- Fujian Vision Technology was recognized as a "Innovation Company."
- Qingdao Huaxia Ophthalmology Hospital was approved as the "Qingdao City Shinan District Key Laboratory for Blindness-causing Eye Diseases."
- Zhenjiang Rehabilitation Ophthalmology Hospital was approved as the "Zhenjiang City Level Clinical Key Specialty."
- Chengdu Aidi Eye Hospital was approved as the "Qingyang District Level Clinical Key Specialty."
- Zhengzhou Optometry Ophthalmic Hospital was recognized as a "Zhengzhou City Technology-based Enterprise."



Qingdao Huaxia Ophthalmology Hospital was approved as the "Key Laboratory for Blindness-causing Eye Diseases"

Innovative Medical Research Model

We actively explore innovative medical research models and continuously strengthen the development of our disciplines. By encouraging and supporting ophthalmic clinicians to engage in medical research, we foster collaboration between clinical practice and basic research, leading to continuous breakthroughs and new achievements. We also promote the submission of research project applications, academic publications, and scholarly articles by our affiliated hospitals, driving innovation in both fundamental ophthalmic research and diagnostic and treatment technologies. Since our founding, we have undertaken numerous national and provincial-level research projects, including the "863" and "973" programs, the National Natural Science Foundation of China, the National Science Fund for Distinguished Young Scholars, the China Postdoctoral Science Foundation, foreign expert introduction programs, and various provincial and municipal initiatives.



In 2024, we achieved notable progress in scientific research, including:

- Applied for and carried out over 300 national and provincial-level research projects, including the "973 Program, " "863 Program, " National Key Research and Development Programs, the National Natural Science Foundation of China (NSFC), the China Postdoctoral Science Foundation, Foreign Experts Introduction Projects, and various provincial and municipal research programs.
- Published a total of 1,510 academic papers, including 378 indexed by SCI.
- Granted 192 patents and 175 software copyrights cumulatively.
- Participated in the development or revision of 53 industry standards in total.
- The collaborative project titled "Development of a Child Eye Health Prevention and Treatment System," jointly undertaken by Xiamen Ophthalmology Center, Children's Hospital of Fudan University Xiamen Branch, and The First Affiliated Hospital of Xiamen University, was awarded Third Prize in the Xiamen Science and Technology Progress Awards.



"Development of a Child Eye Health Prevention and Treatment System" Project Wins Third Prize of Xiamen Science and Technology Progress Awards



Applied for and carried out over
300 national and provincial-level
research projects



Granted
192 patents



Published a total of
1,510 academic papers



Participated in the development or revision of
53 industry standards in total

Incentive Mechanism for Scientific Innovation

To encourage our affiliated hospitals and teams to actively engage in clinical research and scientific innovation, and to enhance the research capabilities of our clinical teams, we have established the Huaxia Eye Hospital Research Fund. This fund supports our physicians and full-time researchers in carrying out clinically valuable research projects, with a focus on clinical studies and the translation of research outcomes into practice.

At the same time, we have partnered with the Fujian Provincial Natural Science Foundation to include basic research within the funding scope of the Huaxia Eye Hospital Research Fund. Since its establishment, the fund has supported a total of 46 research projects, including 36 single-center studies and 10 multi-center studies.

In addition, to continuously stimulate the initiative and creativity of our researchers and improve the level of scientific innovation at Huaxia Eye Hospital and its affiliated hospitals, we have established an internal research reward mechanism through the formulation of the "Research Reward Measures." We set up five internal awards: Technology Project Award, Scientific and Technological Achievement Award, Intellectual Property Award, Paper and Monograph Award, and Scientific Cooperation Award. According to the "Research Reward Measures," we provide corresponding rewards to researchers who contribute to or achieve progress and results at various stages of research projects. In 2024, we awarded project application and approval rewards to 47 project teams, intellectual property rewards to 21 R&D personnel, and Paper and Monograph Awards to 58 individuals who published articles.

Construction of Smart Healthcare Platform

We are actively advancing the construction of a smart healthcare system, continuously investing in digital innovation. By integrating internet-based patient services, intelligent clinical services, refined hospital management, and unified research data, we are building a smart healthcare platform. This initiative drives the digital transformation of hospitals, promotes efficient and scientific operational management, enables cloud-based intelligent diagnosis and treatment, reduces regional barriers in ophthalmic services, and provides patients with more personalized and convenient medical care.

Xiamen Ophthalmology Center has established a national consultation platform for complex ophthalmic cases through its telemedicine and remote consultation systems. This platform provides clinical guidance and technical support to the hospitals under our organization and offers a channel for ophthalmic experts across regions to discuss and exchange complex case studies. We are committed to offering professional and personalized services to patients with challenging eye conditions.

In 2024, we continued to advance the development of our smart healthcare platform:

- The "Xiamen Ophthalmology Center 5G Remote Diagnosis and Treatment Smart Healthcare Platform" project, implemented by Xiamen Ophthalmology Center as part of the "5G + Healthcare" application pilot program, successfully passed evaluation and was recognized as a "National Excellent Project for 5G Healthcare Applications."
- The "AI-Powered Internet Hospital Platform for Multimodal Imaging-Based Diabetic Retinopathy Screening" project, also led by Xiamen Ophthalmology Center, has been successfully deployed across more than 30 affiliated hospitals.
- We launched the "Huaxia Digital Great Wall" initiative, leveraging our nationwide network of clinical electronic medical records and health screening systems. This initiative aims to continuously enhance our healthcare big data infrastructure and comprehensively integrate artificial intelligence into scenarios such as eye disease prevention, diagnosis, and follow-up. By improving the accuracy and reach of early eye disease screening and accelerating capabilities in data modeling, evaluation, and statistical analysis, we are committed to significantly enhancing the efficiency and quality of our medical services.
- We upgraded and launched version 3.0 of the Huaxia Eye Hospital Internet Hospital—Ophthalmology SmartCare Platform, introducing personalized services such as "Online Consultation," "Report Inquiry," "Report Interpretation," and "Vision Tracking," to enhance the precision management of ophthalmic diagnosis and treatment.

To date, we have advanced the development of multiple smart healthcare platforms, including the Ophthalmology SmartCare Internet Hospital Platform, the 5G Remote Diagnosis and Treatment Smart Healthcare Platform, and the Multimodal Imaging AI Internet Hospital Platform for Diabetic Retinopathy Screening. We also launched the "Huaxia Smart Great Wall Initiative" and the localized deployment of the DeepSeek model. These efforts continuously optimize our diagnostic and treatment service model, enhance service efficiency and quality, and enable personalized, intelligent, and precision-based healthcare management.

Ethics of Science and Technology

Against the backdrop of rapid advancements in medical technology, we regard ethical principles as a guiding beacon on the path to medical progress, ensuring that technological innovation goes hand in hand with humanistic care. As a responsible enterprise, we deeply understand that innovation in medical science is not only about improving efficiency and accuracy, but also directly concerns patients' health rights and public trust. Therefore, throughout the entire process of technological development and application, we adhere to ethical standards of safety, fairness, transparency, and traceability. These principles apply across cutting-edge fields such as artificial intelligence, big data, and telemedicine, ensuring that innovations comply with laws, regulations, industry norms, and societal expectations. At the same time, we remain vigilant about the ethical challenges posed by emerging technologies, and actively promote responsible medical innovation to ensure that technology truly serves the sustainable development of human health.

Xiamen Ophthalmology Center has established a Clinical Ethics Committee responsible for conducting independent, competent, and timely ethical reviews of all life science and medical research involving human subjects carried out within the center, in accordance with the Charter of the Ethics Committee. The committee also provides regular education and training on bioethics for relevant researchers and medical staff. To ensure the compliance, independence, and fairness of its ethical review processes, Xiamen Ophthalmology Center has formulated a series of internal regulations, including the Conflict of Interest Policy, Review Meeting Guidelines, Expedited Review Procedures, and Project Review Management Policy, which collectively guide and regulate the ethical review work within the center.

In addition, we place great emphasis on protecting patient privacy and data security, and on avoiding potential bias or discrimination in the application of technology, in order to promote fairer and more accessible distribution of medical resources. Xiamen Ophthalmology Center has implemented a Confidentiality Policy and established a comprehensive confidentiality mechanism. This includes measures such as signed confidentiality agreements and controlled access to information, all designed to safeguard the rights and privacy of subjects, applicants, and other stakeholders involved in clinical trials, and to ensure the protection of participants' legal rights.

Intellectual Property Protection

We strictly comply with national laws and regulations such as the Patent Law of the People's Republic of China and the Copyright Law of the People's Republic of China. To strengthen the management and protection of intellectual property (IP), we have developed the Intellectual Property Management Manual, which outlines measures including pre-project search and investigation, R&D process management, IP registration and utilization, routine tracking and maintenance, confidentiality mechanisms, and access control. At present, we have obtained certification under the Intellectual Property Management System Standard GB/T 29490-2013.

In addition, we require all employees to sign legal documents such as the Agreement on the Ownership of Service Inventions and the Confidentiality Agreement upon joining the company. Upon resignation, employees are formally reminded in writing that they must continue to comply with the provisions related to intellectual property ownership and the confidentiality of trade secrets for a specified period after their departure, as outlined in the aforementioned agreements.

In 2024, we were granted 62 new patents and registered 14 new copyrights. By the end of 2024, we held a total of 192 authorized patents and 175 registered software copyrights. No intellectual property dispute cases were reported throughout the year.



We held a total of

192 authorized patents



We held a total of

175 registered software copyrights



Suppliers and Clients

Guided by the philosophy of "shared responsibility and mutual success," we integrate responsible management practices into key operational areas such as our supply chain, products and services, and customer relationships. Our goal is to build a safe, sustainable, and patient-centered value chain. In terms of supply chain management, we have established a rigorous supplier admission and evaluation mechanism, prioritizing partners that comply with environmental standards and social responsibility requirements. Leveraging digital platforms and end-to-end quality traceability systems, we ensure the safety and reliability of medical supplies while promoting green supply chain practices to reduce resource waste. Regarding product and service management, we adhere to international healthcare quality standards and implement a full-lifecycle quality management system. From R&D and design to clinical application, we continuously optimize diagnosis and treatment protocols and service processes to ensure the safety, effectiveness, and accessibility of medical innovations. We also conduct regular service satisfaction surveys and incorporate patient feedback into our continuous improvement mechanisms. In customer service, we have built diverse communication channels between physicians and patients, offering transparent and convenient health consultation services. We have also established privacy protection protocols and complaint-handling mechanisms to safeguard patient rights. We are committed to continuously enhancing our responsible operational management system, strengthening collaboration with stakeholders, and contributing to the sustainable development of the healthcare industry by delivering high-quality medical care and service experiences.

Supply Chain Security

In the medical services sector, supply chain security is directly tied to medical quality and patient safety. We have established a full-process supply chain security management system and formulated the "Supplier Code of Conduct" to actively convey our expectations regarding responsible practices in business ethics, labor rights, workplace safety, product quality, compliant marketing, and environmental protection to suppliers, contractors, and other partners. ESG-related factors have been incorporated into our supplier admission and evaluation system. Through a rigorous qualification review and assessment mechanism, we prioritize long-term partnerships with high-quality suppliers that share a vision for sustainable development, ensuring the safety and reliability of medical products and consumables at the source. During exceptional periods (such as public health emergencies), we ensure continuity of medical services through diversified procurement strategies and strategic reserve mechanisms.

Responsible Sourcing

We have established strict supplier admission standards, giving priority to partners that meet environmental requirements, fulfill social responsibilities, and comply with business ethics. In procurement decision-making, we take into account product quality, safety performance, and the environmental impact across the product life cycle to promote responsible procurement practices. At the same time, we emphasize transparent supply chain management by implementing traceability systems and conducting regular supplier evaluations. We are committed to collaborative innovation with our value chain partners to jointly build a more resilient and responsible medical supply chain ecosystem.

In terms of sourcing procedures, we strictly comply with the "Company Law of the People's Republic of China", the "Bidding Law of the People's Republic of China", the "Pharmaceutical Administration Law of the People's Republic of China", the "Regulations on the Supervision and Administration of Medical Devices", the "Good Supply Practice for Pharmaceutical Products", and other relevant laws and regulations. We have formulated internal policies such as the "Supplier Management System", "Internal Control Manual (Supplier Management)", and "Procurement Management Measures" to regulate the admission review and procurement processes of medical supplies. A full life-cycle management system has been established, covering supplier admission, evaluation, cooperation, and exit. We firmly oppose corruption, fraud, and unfair competition by suppliers and actively promote the digital development of the EAS (Enterprise Application Suite) procurement management system to minimize potential supply chain risks and lay a solid foundation for delivering safe and efficient medical services.

Supplier Admission

We adhere to the principles of fairness, impartiality, and transparency when evaluating supply chain partners, strictly examining product quality, cost, delivery capabilities, after-sales service, and market reputation. We also assess suppliers' performance in environmental protection, social responsibility, and regulatory compliance. Compliance assessments are conducted based on the "Supplier Questionnaire", "New Qualified Supplier Evaluation Form", "Supplier On-site ESG Audit Form", and on-site audit results. Suppliers who pass the admission review are included in our procurement directory. Apart from framework agreements, all suppliers are required to sign both an Integrity Agreement and a Quality Assurance Agreement to ensure compliance with our business ethics and product quality standards.

Currently, the ESG-related criteria considered during supplier admission include:

Governance dimensions	sound corporate governance, protection of minority investors' rights, anti-corruption, fair competition, anti-monopoly, etc.
Social dimensions	workplace safety, protection of employees' legal rights and interests, employee training, provision of a positive working environment, anti-discrimination, anti-harassment, freedom of association, participation in community development and social innovation, provision of employment opportunities, and localized employment.
Environmental dimensions	compliance with environmental regulations, meeting pollutant discharge standards, promotion of cleaner production, energy conservation and consumption reduction, advocacy of green and environmentally friendly practices, and provision of environmental training.

In 2024, we added 8 new suppliers, all of whom were admitted following ESG-related evaluation criteria.

Supplier Evaluation

For admitted suppliers, we adopt a strategy of dynamic management and real-time evaluation, incorporating an elimination mechanism. Each year, we compile and update the supplier procurement directory and conduct a review and cleanup of existing suppliers. A comprehensive evaluation of each supplier's performance during the previous calendar year is completed before January 30 annually. For any issues identified during the annual review, we implement corrective measures, provide guidance on rectification strategies, assist in formulating improvement plans, track and verify the implementation of corrective actions, and regularly review to identify weaknesses and potential risks. This ensures supplier compliance with requirements and serves as an important reference for the procurement plan of the following calendar year.

We have formulated the "Annual Evaluation Form for Qualified Suppliers" and conduct supplier assessments through both document reviews and on-site audits to ensure that our partners meet environmental, social, and governance (ESG) standards. The evaluation covers a wide range of aspects, including supplier qualifications and certifications, timeliness and stability of delivery, product safety and reliability, environmental impact, human rights and occupational health and safety risks, after-sales service and technical support, compliance risks, business ethics risks, and financial health. Based on the evaluation results, suppliers are categorized into four levels: Excellent, Qualified, Needs Improvement, and Unqualified. For suppliers that fail to meet standards in areas such as ESG, regulatory compliance, product quality, or service performance, we provide opportunities for rectification along with improvement suggestions. If a supplier fails to meet the requirements within the specified timeframe, we will terminate cooperation in accordance with established procedures.



In 2024, we further optimized our evaluation system by placing greater emphasis on supplier performance in areas such as responsible management, market performance, social performance, workplace safety, community responsibility, and environmental performance. Through field visits, interviews, and document reviews, we assess suppliers' ESG practices and provide suggestions for improvement to help them enhance their sustainable governance capabilities.

Supplier Communication

We have established an open, transparent, and trust-based communication mechanism with our suppliers. We actively organize training sessions on responsible supply chain practices, promote our sustainability philosophy and policies, and share industry trends to provide relevant support to our suppliers. We have set up a dedicated reporting email (sjzx@huaxiaeye.com) for potential misconduct in the supply chain. Regular communication and engagement are carried out through on-site visits, organized meetings, joint seminars, email correspondence, and on-site audits to discuss matters such as quality assessment, procurement, operations, integrity building, social responsibility, and business ethics.

In 2024, we conducted communication and engagement activities with 40 suppliers, continuously strengthening supplier collaboration and promoting the development of a responsible supply chain. We conveyed the concept of ESG and its relevance to the healthcare industry, emphasized the growing focus on sustainability from global regulators, investors, and society, and engaged in in-depth discussions on key social responsibility topics in the medical sector. These included enhancing the medical ecosystem, improving product accessibility, raising public health awareness, ensuring product quality, advancing social welfare, promoting responsible marketing, and preventing counterfeit and unlicensed products. We encourage suppliers to join us in practicing sustainable development and achieving long-term mutual success.

Equal Treatment of SMEs

As an important player in the healthcare service sector, we recognize the vital role that small and medium-sized enterprises (SMEs) play in driving innovation and ensuring supply chain resilience. We are committed to building a fair and inclusive procurement and cooperation system that offers equal development opportunities for SMEs.

We strictly comply with relevant laws and regulations such as the "Law of the People's Republic of China on the Promotion of Small and Medium-Sized Enterprises" and the "Regulations on Ensuring the Payment of Accounts to Small and Medium-Sized Enterprises". We apply consistent standards across supplier selection, contract signing, and payment settlement to ensure that SMEs receive equal treatment in cooperation and that payments are made on time. Additionally, we proactively disclose relevant payment information through channels such as the National Enterprise Credit Information Publicity System to maintain transparency and protect the trust and rights of our partners. At the same time, we continue to promote deeper collaboration with SMEs by supporting their operational capabilities through technical exchanges and business empowerment, fostering mutually beneficial development.

Product and Service Quality and Safety

Quality and safety are the lifeline of a medical service enterprise. We have established a quality management system that spans the entire life cycle of our products and services, strictly adhering to international medical quality standards and industry best practices to ensure the delivery of safe, reliable, and effective healthcare services to our patients. We are currently certified under the ISO 9001:2015 Quality Management System.

In medical quality and safety management, we implement full-process quality control from R&D and design to clinical application. By establishing stringent supplier admission mechanisms and raw material inspection standards, we ensure the safety and quality of medical equipment, pharmaceuticals, and consumables. We conduct regular product safety assessments and adverse event monitoring to establish a rapid response mechanism that minimizes potential risks. We also continuously optimize our product traceability system to ensure that any quality issues can be identified and addressed in a timely manner.

In patient service management within hospitals, we have developed a patient-centered service standard system. Through the standardization of clinical pathways, optimization of service processes, and professional training of staff, we continuously improve the consistency and standardization of our services. In addition, we have established a multi-level quality monitoring mechanism to ensure continuous improvement in service quality.

Medical Quality and Safety Management

In accordance with national healthcare laws and policies such as the "Law of the People's Republic of China on Basic Medical and Health Care and Health Promotion" and the "Law of the People's Republic of China on Medical Practitioners", we have formulated internal management systems including the "Medical Quality Management System", "Key Points of Medical Quality and Safety Core System", "Medical Staff Practice Admission System", "Medical Quality and Safety Management Evaluation Standards", and "Surgical Management System". These systems support the continuous development and improvement of a full-process medical quality and safety management system covering pre-admission, in-hospital, and post-discharge stages.

In terms of medical supplies management, we strictly comply with laws and regulations such as the "Pharmaceutical Administration Law of the People's Republic of China", the "Good Manufacturing Practice for Pharmaceutical Products", the "Good Supply Practice for Pharmaceutical Products", the "Regulations on the Supervision and Administration of Medical Devices", the "Measures for the Supervision and Administration of the Operation of Medical Devices", the "Good Supply Practice for Medical Devices", and the "Product Quality Law of the People's Republic of China". We ensure the reliability and quality control of medical supplies through supplier qualification reviews, signing of "Quality Assurance Agreements" with suppliers, standardized procurement procedures, and traceability management. In addition, we regularly conduct sampling inspections of pharmaceuticals and consumables, monitor storage conditions, and assess usage safety to ensure that all procured drugs, consumables, and equipment comply with national certification requirements and meet product quality and safety standards.

Management Structure

We have established dedicated committees at various operational levels to oversee the entire medical quality and safety management process. A systematic medical quality management evaluation framework has been developed, covering areas such as quality management system development, biosafety and quality, medical record compliance, patient safety goals, emergency response plans for medical risk prevention, rational clinical drug use, departmental quality and safety, quality improvement in anesthesiology, and prevention and control of hospital-acquired infections.




Risk Management

We have established a comprehensive emergency response and risk management system through a series of internal management policies, including the "Critical Value Reporting System for Clinical Laboratory Tests", the "Surgical Safety Checklist System", the "In-Hospital Emergency Response Process Management", the "Emergency Rescue Procedure for Critical Patients", the "Reporting System for Major Medical Safety (Adverse) Events", the "Emergency Response Procedure for Unexpected Incidents", and the "Preoperative Systemic Evaluation Protocol for Ophthalmic Surgeries". A company-wide emergency management framework has been put in place, with a designated corporate executive appointed as the overall emergency response leader. Emergency teams at each affiliated hospital are composed of hospital presidents, directors of medical affairs, and specialists from internal medicine and anesthesiology departments. The roles and responsibilities of each team member, as well as reporting protocols for emergency and critical cases, are clearly defined to strengthen the management of critically ill patients. Standardized on-site emergency rescue procedures have also been established to minimize medical risks to the greatest extent possible.

To strengthen the management of risks related to major medical malpractice and medical accidents, we comply with regulations including the "Regulations on the Administration of Medical Institutions", the "Regulations on the Handling of Medical Accidents", and the Ministry of Health's "Reporting System for Major Medical Malpractice and Medical Accidents". We have formulated the "Reporting System for Major Medical Malpractice and Medical Accidents", which requires that any incidents related to medical quality, safety, disputes, or major events be reported immediately. Risk identification, analysis, rectification, and continuous follow-up must be carried out in a timely manner. In addition, we convene a monthly group-wide video conference on medical quality and safety management, requiring participation from hospital presidents and all medical administrative staff across our affiliated hospitals. These meetings serve to communicate our quality and safety philosophy, report on each hospital's monthly performance, outline key focus areas for upcoming medical quality work, and promote lawful and compliant medical practices. In 2024, no major medical accidents occurred within the company.

To further enhance the emergency response capabilities of medical personnel in managing medical risks, we regularly organize specialized training programs, including emergency drills for healthcare workers and hospital CPR (Cardiopulmonary Resuscitation) training. In addition, we conduct monthly training sessions for hospital presidents, vice presidents, physicians, medical technicians, and healthcare administrators on topics such as medical quality and safety management, healthcare laws and regulations, hospital infection control, emergency medicine, clinical practice guidelines, and ophthalmology clinical knowledge. Regular assessments are held to continually improve our medical risk management capabilities. In 2024, our affiliated hospitals conducted emergency procedure drills involving 1,369 participants and organized CPR training for 1,426 participants.



Quality Inspection

We conduct regular medical quality inspections to reduce and eliminate risks of non-compliance across hospitals through on-site inspections and online guidance. Key areas of focus include lawful medical practice, standardized diagnosis and treatment, quality and safety, medical records, medical insurance, hospital infection control, medical waste, and wastewater treatment. Each year, we formulate a special inspection action plan for hospitals and oversee its implementation, placing particular emphasis on regulatory compliance in hospital operations and the effectiveness of hospital quality management.

In 2024, we issued self-inspection plans including the "Rectification Plan for Issues Related to Medical Record Quality and Hospital Infection Control" and the "Regulations on the Refined Management and Standardized Use of Anesthetics and Class I Psychotropic Drugs in Affiliated Hospitals of Huaxia Eye Hospital". These initiatives guided affiliated hospitals in maintaining legal medical practices and improving infection control management. Medical quality inspections were carried out in accordance with the "Huaxia Eye Hospital Medical Quality and Safety Management Evaluation Standards". We adopted a combined approach of inspections led by headquarters and cross-audits among hospitals to systematically identify problems in medical services at 60 affiliated hospitals and promptly follow up on rectification efforts, ensuring continuous improvement in medical quality.

Hospital Patient Service Management

Centering on the philosophy of "Patient Always Comes First," we continuously optimize service processes and have built a full-cycle patient-centered service management system. By developing a high-standard service framework and advancing digital platform integration, we achieve efficient coordination across appointment scheduling, diagnosis and treatment, and follow-up stages, thereby enhancing the overall patient experience. We also place strong emphasis on humanistic care, strengthening service awareness training for medical staff to ensure patients receive professional, compassionate, and personalized healthcare services. In patient satisfaction management, we focus on continuous improvement by regularly collecting patient feedback and refining service standards and management mechanisms. This enables every patient to access safe, high-quality, and empathetic medical care.



Customer Service System Won an Award at the 1st Private Healthcare "New Quality Productive Forces" Case Competition

Management Structure

We have established both a Group Service Quality Promotion Committee and Hospital Service Quality Promotion Committees. These bodies are responsible for formulating, reviewing, and optimizing patient service standards, procedures, policies, and evaluation methods. They guide the development of hospital customer service teams and ensure that human resources, performance management systems, and hardware and software infrastructure meet the needs of improved patient services. These committees also promote the shift from "quality service" to "touching service." The Hospital Service Quality Promotion Committee leads the advancement of service quality enhancement initiatives and conducts regular service quality inspections. In accordance with corporate requirements, each affiliated hospital also organizes quarterly evaluations and special inspections focused on patient service quality. This drives the standardization of service processes and quality across the group and delivers a higher standard of consistent, premium healthcare experience to all patients.

Service Standards

We are committed to building a high-standard service system and have so far developed more than 30 standardized manuals, policies, and procedures covering all aspects of patient services. Throughout the service process, we continuously improve the overall patient experience before, during, and after treatment by introducing innovative, high-quality, and convenient service measures.

During hospitalization, our hospitals proactively engage in face-to-face communication with patients and organize service activities such as health education sessions, comfort visits, and holiday-themed interactions based on patient needs. These efforts aim to enhance patient comfort and sense of care during their hospital stay. For patients with special needs, hospitals also provide tailored support services to accommodate them.

After discharge, hospitals maintain ongoing attention to patients' recovery progress by conducting regular follow-ups with post-operative patients and monitoring their healing process. If any abnormalities are detected, timely reminders are issued to encourage follow-up visits. This creates a closed-loop service management approach that truly realizes continuous, patient-centered care.



Postoperative Follow-up Indicator, Target, and Achievement Status for 2024

Indicator	2023	2024	Year-on-Year Growth	Target Value	Achievement Status
Follow-up Call Connection Rate	87.5%	91.6%	4.7%	≥85%	✓

Highlight | "Pocket Hospital"

We have implemented the "Pocket Hospital" convenience platform at the hospital level, enabling patients to make online appointments, access virtual consultations, and complete payments digitally. The platform features an AI-powered virtual assistant that offers 24/7 support and delivers health-related content to meet the personalized needs of patients more efficiently.



Highlight | Excellence in Service — Hospital President Interview Series



In 2024, our Service Quality Promotion Committee organized the "Excellence in Service — Hospital President Interview Series." During these interviews, hospital presidents engaged in in-depth discussions on service philosophies and management practices. They explored key issues such as optimizing service processes and improving patient satisfaction, and proposed a series of constructive recommendations. These insights were transformed into actionable plans, facilitating knowledge sharing and complementarity across our affiliated hospitals.

Service Evaluation

We improve service attitudes and enhance service quality across hospitals by conducting training, supervision, inspections, guidance sessions, specialized service initiatives, tool provision, and performance-based incentives. By integrating service evaluation data and feedback, we continuously refine service quality and enhance the patient care experience. We systematically consolidate service quality data from all affiliated hospitals into the "Hospital Service Quality Inspection and Evaluation Form". This form includes monthly service inspection results, outcomes of special service improvement initiatives, results from cross-hospital evaluations, patient satisfaction survey results (including company-level and hospital-level surveys), and the handling of complaint tickets. These results are linked to the overall hospital performance evaluation, providing a more comprehensive basis for assessing and improving service quality while reinforcing accountability.

In 2024, key performance indicators in customer service improved. The capabilities and stability of the customer service teams were strengthened, the rate of immediate resolution of dissatisfaction increased, the complaint rate declined, and both patient satisfaction and Net Promoter Score (NPS) improved significantly.

Hospital Evaluation System Implementation Score in 2024

Indicator	2023	2024	Target Value	Achievement Status
Implementation Score of the Hospital Evaluation System	94.0%	89.9%	≥80%	✓

Due to the adoption of a new indicator system in 2024, the scores for 2023 and 2024 are not based on the same criteria and therefore cannot be compared.

Highlight | Service Quality Inspections

In 2024, we actively introduced innovative management approaches and added several new service quality assessment dimensions to standardize and enhance service improvement efforts. The Hospital Service Quality Promotion Committees conducted a total of 452 service quality inspections, carried out over 300,000 inpatient care visits, and organized more than 260 patient service activities. These efforts enriched the company's standardized patient service system and strengthened the PDCA cycle within service-specific initiatives, driving quality improvement across all aspects of care delivery.

Highlight | Unannounced Inspection on Patient Service Quality

In 2024, to strengthen the implementation of patient service initiatives, the Customer Service Department organized 15 surprise inspections on patient service quality. During each inspection, members of the hospital's Service Quality Promotion Committee convened to conduct in-depth discussions and analyses of service quality. Issues were promptly identified and root causes examined, followed by the implementation of targeted improvement measures.



Unannounced Inspection on Service Quality at Heze Huaxia

Service Training

We provide diversified and professional training programs for service personnel to enhance their capabilities and build a service team that is professional, reliable, caring, and meticulous. In 2024, we organized a series of training activities for medical service staff, including:

We developed the "Customer Service Department New Employee Orientation Manual" and implemented a three-month training program for new hires. The program includes both theoretical instruction and hands-on training. Upon completion, participants must pass an assessment and undergo a comprehensive evaluation before officially beginning their roles.

New Employee Training

We regularly hold monthly, thematic, and peak-season mobilization meetings focused on patient service to clarify work direction. Throughout the year, we organized 105 in-service training sessions and assessments across different levels, covering a total of 10,137 participants. Learning records were established, and the training content included medical knowledge, communication skills, best practice case sharing, and management methods to enhance team capabilities and facilitate the exchange of successful patient service experiences.

Patient Service Mobilization Meetings

We selected 15 core customer service staff members to participate in the National Health Commission's training program on patient experience. This initiative aimed to elevate management expertise and develop core talent.

National Health Commission Training on Patient Experience

We conducted comprehensive hospital-wide training on service etiquette as well as empowerment sessions for customer service teams, reinforcing professional skills and service awareness across the team.

Service Etiquette Training

Complaint Management

In accordance with the "Regulations on the Handling of Medical Accidents" and related supporting documents, we have formulated the "Regulations on the Prevention and Handling of Medical Disputes." Each affiliated hospital has established a hospital-level Complaint Management Department, with publicly displayed complaint hotlines and procedures. A standardized "Dispute Handling Flowchart" has been developed to regulate the complaint resolution process. All complaints received via suggestion boxes, external platforms such as 12315, the Mayor's Hotline, the Health Commission, and online sources are converted into work orders and handled promptly. In addition to the above channels, patients may also directly provide feedback to on-site guidance staff. In 2024, the completion rate of complaint work orders reached 100 percent, with ongoing improvements in the timeliness of processing. The execution rate of inpatient care visits consistently remained at 100 percent, and both the post-operative follow-up rate and successful contact rate steadily improved.

Work Order Processing Performance in 2024

Indicator	2023	2024	Year-on-Year Growth	Target Value	Achievement Status
Work Order Completion Rate	100%	100%	0	100%	✓

In 2024, we launched the digitalization of our patient service system. This included the implementation of the "Bestide Patient Experience Management System," the deployment of Tencent's AI-powered virtual assistant, and the development of the HCRM Follow-up Management System. Through coordinated system operations, we established an integrated service management dashboard and smart service notification functions, which helped optimize patient service processes, enhance service efficiency, and improve the timeliness of complaint handling. These efforts have effectively embodied our "patient-centered" philosophy in practical service delivery.

Satisfaction Surveys

We encourage patients to actively share feedback on their care experiences and provide valuable suggestions, continuously improving the management of satisfaction surveys and enhancing customer service. To improve the accuracy of service feedback, we introduced a customer experience management system based on personalized touchpoint perception. This system tailors scenario-specific survey questions according to the patient's care journey, covering aspects such as the performance of doctors and nurses in relevant departments, public facilities, and environmental hygiene. Satisfaction questionnaires are distributed via text messages, mini-programs, and official WeChat accounts.

In 2024, we advanced our digital closed-loop system by innovatively building an integrated patient service information platform. We introduced a patient relationship management system, an AI-powered virtual assistant, and a patient CRM follow-up management system. By applying intelligent analysis of the patient journey and theoretical tools to improve patient satisfaction, we evaluated and enhanced service quality based on actual patient feedback.

Customer Satisfaction Survey Results in 2024

Indicator	2023	2024	Year-on-Year Growth	Target Value	Achievement Status
Questionnaire Participation Rate	14.9%	16.9%	13.1%	≥15%	✓
Satisfaction Score	95.9	95.8	-0.1%	≥90	✓

Data Security and Customer Privacy

We attach great importance to information security and the protection of customer privacy. We strictly comply with the "Cybersecurity Law of the People's Republic of China", the "Personal Information Protection Law of the People's Republic of China", and other relevant laws and regulations. While advancing our digitalization initiatives, we continuously improve our information security management systems and privacy protection mechanisms. We optimize internal controls and elevate our information security management capabilities to ensure data safety and safeguard patient privacy. In 2024, no information security breaches or incidents involving the violation of customer privacy occurred.

Information Security Management Framework

To ensure the effective implementation of information security management, we have established a clearly defined organizational structure. This includes the Information Security Leadership Group, the Information Security Management Group, and the Information Security Implementation Team. These units work in coordination across different organizational levels and roles to provide structural support for the company's information security management efforts.

Information Security Leadership Team

- The Information Security Leadership Team serves as the decision-making body, chaired by the company's Vice President. Team members include general managers of each hospital and the head of the corporate IT department, who also acts as the coordinator and main point of contact.
- The team is primarily responsible for formulating the overall information security strategy, reviewing and approving related policies, appointing key security personnel, and making decisions on major incidents and system vulnerabilities. It also oversees coordination, supervision, and review of incident response efforts.

Information Security Management Team

- The Information Security Management Team is led by the head of the corporate IT department and consists of all IT department staff.
- The team organizes information security-related discussions and meetings, formulates strategies and plans for review by the leadership team, and oversees daily management of policy development, risk assessments, and staff training. It also assists the leadership team in promoting, implementing, guiding, and supervising information security activities.

Information Security Implementation Team

- The Information Security Implementation Team consists of all members of the IT department, designated hospital information officers, information staff, and technical personnel from system vendors.
- The team is responsible for implementing security policies at their respective units. Key tasks include managing system account permissions, retaining operational logs, ensuring network protection, performing antivirus tasks, managing data security, maintaining software and hardware environments, providing technical support and inspections, and executing backup and recovery strategies.



Information Security Policy Development

We have formulated the "Information Security Policy", which provides guidance for information security practices at both the company level and across affiliated hospitals. The policy covers management practices, inspection procedures, training and awareness, and incident response. In addition, we have issued the "Overall Guidelines and Security Strategy for Information Security", which defines our overarching security objectives and provides detailed strategies across multiple dimensions, including security governance, organizational structure, system development and operations, network security, physical security, data security, and backup and recovery. We have also developed a series of internal information security regulations, such as the "Project and Information System Construction Management Policy" and the "Information System Change Management Policy", to ensure institutional support for implementing information security management.

Information Security Management Measures

We continuously strengthen information security through both technical and administrative measures, such as internet isolation, data backup verification, user access control, authorization and approval for information access and usage, and enforcement of confidentiality responsibilities, to ensure the safety of system data and information. Currently, some information systems at the company and its affiliated hospitals have passed the Level II and Level III evaluations under the national cybersecurity protection framework.

In 2024, we implemented the following information security inspection activities to ensure the protection of corporate information assets:

- Monthly cybersecurity vulnerability scans were conducted on the information systems of the company and its affiliated hospitals, and any identified vulnerabilities were promptly addressed.
- External information security assessments were carried out on third-party deployed software systems, including penetration testing with formal reports generated.
- Internal control evaluations were conducted on the operation and effectiveness of information systems, and external professional firms were engaged to audit the effectiveness of internal controls.

In addition, we actively encourage all employees to report any identified information security issues or risks to their direct supervisor or the company's information security management department. This enables timely response measures to be taken, helping to mitigate any potential negative impact on the company caused by information security risks.

Patient Privacy Protection

As a healthcare service provider, we regard the protection of patient privacy as both a fundamental professional ethic and a legal obligation. We have formulated the "Code of Business Conduct", which includes explicit statements regarding the use and protection of customer information. We are committed to complying strictly with applicable laws and regulations and have implemented a range of technical and administrative measures to safeguard customer data. Customer information is collected, used, and retained only for legitimate purposes and as required for service provision. Customers are granted the right to consent or refuse the collection or use of their personal data, as well as the right to access, review, copy, modify, or delete their information. Unless explicitly authorized by the customer or required for service delivery, we do not disclose customer information to third parties.

In compliance with the "Personal Information Protection Law", the "Data Security Law", and other relevant regulations, we have developed the "Patient Privacy Protection Policy", which clearly defines the principles, responsible departments, and specific measures for protecting patient privacy. The company's Medical Affairs Department is responsible for formulating privacy protection policies and overseeing their implementation across all affiliated hospitals. According to internal requirements, we implement full life-cycle management of patient privacy, covering data collection, storage, use, sharing, and destruction. Technical encryption, access control, and audit checks are applied throughout, and we sign the "Patient Privacy Protection Informed Consent Form" with patients, and data confidentiality agreements with third parties, to effectively safeguard patient privacy.

Supporting Industry Development

As a key player in the healthcare industry, we are committed to promoting high-quality development across the sector. Through technological innovation, joint standard-setting, and resource sharing, we actively engage in deep collaboration with upstream and downstream partners along the industry chain to build an open and collaborative healthcare ecosystem. We continue to increase investment in research and development, driving advancements in diagnostic and treatment technologies as well as the optimization of service models. Practical experience is translated into industry standards to support the standardized development of the sector. At the same time, we place strong emphasis on medical talent cultivation by facilitating academic exchanges and technical training to nurture and supply skilled professionals for the industry.

Participation in Industry Associations

Chinese Non-government Medical Institutions Association

Executive Director

Strabismus and Pediatric Ophthalmology Specialized Committee of Ophthalmologists Branch, Chinese Medical Doctors Association

Deputy Director of the Committee

Hospital Management Branch of Chinese Non-government Medical Institutions Association

Vice President

Strabismus and Pediatric Ophthalmology Group of the Chinese Medical Association Ophthalmology Branch

Deputy Team Leader

Nursing Branch of Chinese Non-government Medical Institutions Association

Member

Medical Brand Management Union

Director

Continuing Education Branch of Chinese Non-government Medical Institutions Association

Vice President

National Public Welfare Alliance for Eye Health Education

Alliance

Chinese Non-public Medical Institutions Association

Member

Fujian Physicians Association

Director

Formulation of Industry Standards

In 2024, we participated in the development or revision of 15 industry standards, including:

Industry Standards
Guidelines for the standardized diagnosis and treatment of non-specific orbital inflammation (2024)
Expert Workgroup of Guidelines for Application of Artificial Intelligence in OCTA Image Analysis and Ocular Disease Diagnosis (2024)
Chinese expert consensus on the diagnosis and treatment of dry eye (2024)
Expert consensus on preoperative corneal topography and tomography screening for laser vision correction in China (2024)
Guidelines for application of artificial intelligence in retinal image automatic segmentation and disease diagnosis (2024)
Expert consensus for preoperative visual function and imaging examination standards in vitreoretinal surgery (2024)
Standard operating guidelines for ocular ultrasound examination and measurement (2024)
Expert consensus for pars plana vitrectomy treatment of type 2 diabetic retinopathy
Consensus on the application of artificial intelligence in myopia (2024)
National consensus on the management of major chronic fundus diseases in China: a modified Delphi approach
Guidelines for the operation of imaging equipment in orbital diseases (2024)
Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China
Expert consensus on imaging model and application of advancing age-related macular degeneration (2024)
Expert consensus on community screening of diabetic retinopathy
Chinese expert consensus on the diagnosis and treatment of contact lens-associated dry eye (2024)

Academic Exchange and Technical Training

Highlight | Huaxia Optometry Forum and National CME Program "Training Course on New Technologies in Optometry"

To elevate the medical education and research standards of strabismus and pediatric ophthalmology as well as optometry, and to support the development of a new approach to myopia prevention in the modern era, Huaxia Eye Hospital and Xiamen Ophthalmology Center jointly held the 2024 Huaxia Optometry Forum and the national continuing medical education program "New Technologies in Optometry Training Course" in Xiamen during Eye Care Month. Dozens of experts and scholars in the fields of strabismus, pediatric ophthalmology, and optometry from both China and abroad engaged in in-depth discussions on the development of visual health and myopia prevention among children and adolescents. The event attracted 458 in-person attendees and 44,000 online viewers.



Highlight | The 10th Huaxia Eye Hospital International Forum

In 2024, the 10th Huaxia Eye Hospital International Forum and the national continuing medical education program titled "Seminar on New Advances in Ophthalmic Diseases," jointly hosted by Huaxia Eye Hospital and Xiamen Ophthalmology Center, was held in Xiamen. The event attracted 437 in-person participants and over 16,000 online viewers.

The forum featured multiple thematic sessions, where dozens of renowned ophthalmologists delivered insightful lectures. Key topics included corneal diseases, glaucoma, uveitis, myopia prevention and control, strabismus, refractory retinal diseases, keratoconus, intraocular lens implantation, presbyopia treatment, cataracts, and high myopia in children. Experts from across the country engaged in both in-person and online discussions to spark new ideas, explore emerging technologies, validate innovative therapies, and share cutting-edge findings, contributing collectively to the high-quality development of ophthalmology in China.

During the forum, we launched the "Huaxia Digital Great Wall" initiative, which is based on the group's nationwide clinical electronic medical record and health screening system. The initiative aims to further enhance our healthcare big data platform and promote the application of artificial intelligence (AI) in the prevention, diagnosis, and follow-up of eye diseases. It supports nationwide data collection and effective feedback, improves the precision and coverage of early eye disease screening, and accelerates the realization of data modeling, assessment, and analytics in ophthalmology.





Highlight | 2024 Huaxia International Refractive Surgery Forum and National CME Program "Advances in Refractive Surgery Training Course"



In 2024, the Refractive Surgery Subcommittee of the company's Academic Committee, together with Xiamen Ophthalmology Center, co-hosted the 2024 Huaxia International Refractive Surgery Forum and the national continuing medical education program titled "Advances in Refractive Surgery Training Course" in Xiamen, Fujian Province. The forum brought together several leading experts and professors to focus on cutting-edge developments in the field of refractive surgery. Discussions centered on meeting the diverse eye health needs of the public and addressing the current challenges and hot topics in refractive surgery. The event aimed to promote the high-quality clinical translation of academic insights through top-level scholarly exchange. The forum attracted 350 in-person participants and 6,000 online viewers.



Highlight | Fujian Seminar on New Anesthesia Technologies

In 2024, the "Fujian Seminar on New Anesthesia Technologies" was held in Xiamen, jointly organized by the Xiamen Medical Association and Xiamen Ophthalmology Center, with Huaxia Eye Hospital as a co-organizer. This seminar was part of the national continuing medical education program for the year. Focusing on the unique characteristics of ophthalmic surgery, the seminar featured in-depth discussions on anesthesia management, precision anesthesia, innovations in anesthesia technology, and clinical practice. The event also highlighted the latest research findings in the field of anesthesia from both domestic and international perspectives. A total of more than 50 experts from 30 hospitals across China participated in the seminar.





Highlight |

The 10th Huaxia Cataract and Corneal Disease Innovation Forum and National CME Program "Seminar on New Advances in Corneal and Cataract Diseases"

In 2024, the 10th Huaxia Cataract and Corneal Disease Innovation Forum and the national continuing medical education program "Seminar on New Advances in Corneal and Cataract Diseases", jointly hosted by Huaxia Eye Hospital and Xiamen Ophthalmology Center, was held in Quanzhou. More than 50 experts were invited to deliver lectures, and the forum was attended by nearly 1,000 participants both online and onsite. With a strong clinical focus, the forum centered on the latest technologies and treatments for cataract and corneal diseases. During the forum, the "Quanzhou Huaxia Eye Hospital Cataract and Presbyopia Center", the "National Training Center for Corneal Cross-Linking and Corneal Collagen Cross-Linking Surgery", and the "Artificial Cornea Surgery Training Center" were officially inaugurated. These centers aim to expand access to high-quality medical resources and serve as models for advancing the treatment of corneal diseases.



Highlight | The 10th Huaxia Eye Hospital Forum on Strabismus and Pediatric Ophthalmology

In 2024, the 10th Huaxia Eye Hospital Forum on Strabismus and Pediatric Ophthalmology, along with the national continuing medical education program titled "New Technologies in Strabismus and Pediatric Ophthalmology," was jointly organized by the Xiamen Medical Association, Huaxia Eye Hospital, and Xiamen Ophthalmology Center. The forum was conducted in a hybrid format combining online and in-person participation. More than 30 experts and scholars from across the country gathered in Xiamen to discuss hot topics such as complex strabismus, amblyopia, myopia prevention and control, pediatric retinal diseases, dry eye, and glaucoma. They shared the latest advancements in clinical diagnosis and treatment, new technology applications, and scientific research. Nearly 200 ophthalmology professionals attended the forum on site, with 5,000 online views recorded.



Highlight | "Gathering Wisdom, Setting Sail for a Crystal-Clear Future" — 2024 Huaxia Eastern Region ICL Academic Salon

In 2024, the "Gathering Wisdom, Setting Sail for a Crystal-Clear Future" Huaxia Eye Hospital Eastern Region ICL Academic Salon was held in Shanghai. Refractive surgery experts and technical specialists from across the company's Eastern Region gathered for in-depth discussions on academic research, clinical practices, lens calculation methods, and departmental operations related to ICL (Implantable Collamer Lens) procedures. The salon served as a valuable platform for ophthalmology professionals to stay informed about advancements in ICL technology and to share diagnostic and treatment experience, thereby strengthening communication and collaboration in the refractive field across the region.





Highlight | The 10th Huaxia Nursing Forum and Fujian Provincial CME Program "Advances and Safety Management on Ophthalmic Nursing"

In 2024, our company and affiliated Xiamen Ophthalmology Center jointly hosted the 10th Huaxia Nursing Forum and the Fujian Provincial Continuing Medical Education Program titled "New Advances and Safety Management in Ophthalmic Nursing" in Xiamen. The forum focused on two key themes: technological advancements and safety management. In-depth discussions and exchanges were held on the application of new technologies, development trends, and best practices in safety management within the field of ophthalmic nursing. The event recorded a total of more than 18,000 participants.



Highlight | The 10th Chinese Dry Eye Conference

In 2024, the 10th National Conference on Dry Eye, the 8th National Conference on Ocular Surface and Tear Film Diseases, the 8th National Conference on Traditional Chinese Medicine Eye Health, and the 3rd Ophthalmic Drug Innovation Forum were held in Guangzhou. With the theme "Integration Across Disciplines, Building on the Past and Looking to the Future," the conference systematically reviewed ten major advancements in China's field of dry eye and ocular surface diseases, and engaged in discussions on ten key challenges for future development. Several experts from the company were invited to participate and exchanged insights on topics related to clinical research, pharmaceutical development, and technological translation.



Employees

As the core force behind healthcare service delivery, our employees are the most valuable asset of the company. We are committed to building a people-oriented development system, embedding the values of responsibility, care, innovation, and win-win throughout every stage of talent development. We take responsibility as the foundation, establishing a comprehensive career development framework that offers competitive compensation and benefits along with continuous learning and growth opportunities. With care at the core, we have developed a robust health protection system and foster a safe and inclusive working environment. Through innovation, we provide an open and collaborative platform, encouraging employees to break boundaries by introducing various incentive mechanisms for research and innovation. Guided by the goal of mutual success, we promote knowledge sharing and experience exchange, and have established a value-sharing mechanism that aligns personal growth with corporate development.

Equal Employment

We uphold the principle of equal employment and oppose all forms of discrimination. Our "Human Resources Management Policy" stipulates that all employees must be treated fairly and reasonably in recruitment, training, promotion, and compensation decisions. No individual may be treated differently based on race, color, gender, sexual orientation, marital or parental status, pregnancy, parental identity, religion, political belief, nationality, ethnic background, social origin, social status, disability, age, or membership in any group or organization.

Human Rights Protection

We respect international human rights charters such as the "Universal Declaration of Human Rights", the "International Covenant on Civil and Political Rights", and the "International Covenant on Economic, Social and Cultural Rights", as well as internationally recognized standards including the International Labour Organization's "Declaration on Fundamental Principles and Rights at Work" and the United Nations "Guiding Principles on Business and Human Rights" (UNGPs). We strictly comply with domestic laws such as the "Labor Law of the People's Republic of China" and the "Labor Contract Law of the People's Republic of China". We have formulated and issued our "Human Rights Policy", which outlines our commitments and regulatory requirements in areas such as anti-discrimination, anti-harassment, anti-conflict and anti-violence, prohibition of forced labor, and prohibition of child labor.


To address human rights issues, we have established a reporting center to accept complaints and reports regarding violations of national laws and company policies within the organization. Upon receiving any complaints involving human rights issues, we assign dedicated personnel to follow up and promptly initiate an investigation process. We strictly protect the identity of complainants to ensure that no employee is subject to retaliation for reporting such incidents. Verified violations result in appropriate disciplinary actions, necessary remedial measures, and reinforced training and awareness initiatives.

In 2024, no major penalties were imposed on the company due to violations of labor-related laws.

Protection of Female Employees' Rights and Interests

We attach great importance to safeguarding the legitimate rights and interests of female employees. We uphold the principle of equal pay for equal work regardless of gender and prohibit all forms of gender-based discrimination. We have established the "Labor Protection Policy for Female Employees", which guarantees appropriate labor protection measures and statutory leave policies during pregnancy, maternity, and breastfeeding periods. We do not reduce basic salaries or terminate employment contracts due to female employees' physiological conditions.

We have set up nursing rooms in office areas to provide a dedicated space for breastfeeding female employees and ensure reasonable work schedules during the lactation period. In addition, we pay special attention to the specific needs of female staff by organizing celebrations for occasions such as International Nurses Day and International Women's Day, striving to create an equitable and comfortable working environment for all women.



Anti-Violence and Anti-Harassment

We prohibit all forms of violence and acts that disturb public order. We also forbid any speech, conduct, or behavior that infringes upon personal dignity, freedom, or integrity, including but not limited to insults, discrimination, bullying, intimidation, threats, corporal punishment, defamation, sexual harassment, and psychological or physical coercion. Any intrusive, coercive, threatening, insulting, or exploitative actions, whether in the form of gestures, language, or physical contact, are strictly prohibited. Neither the company nor any third-party security personnel employed by the company may use violence, conduct unlawful body searches (including cross-gender searches), or threaten to engage in such acts.

Prohibition of Forced Labor and Child Labor

We strictly prohibit all forms of forced labor and the employment of child labor. During the recruitment process, we verify the age of all prospective employees. We oppose all forms of forced labor, child labor, slavery or servitude, and human trafficking. We commit to not employing any minor under the age of 18 in work that may endanger their health or safety.

We comply with all applicable laws and regulations concerning employee working hours and rest periods. We have established attendance management and leave policies, and we guide and supervise business and production departments in reasonably assigning tasks and regulating working hours based on job characteristics, ensuring that employees enjoy sufficient and reasonable rest time.

Employee Communication

We respect employees' lawful rights to freedom of speech and freedom of association. Through the implementation of a collective consultation system, we provide open, transparent, and reasonable channels for expression and complaint, ensuring that employee voices and concerns are genuinely heard. The company has established an Employee Representative Congress, and all employees are legally entitled to vote, be elected, and participate in decision-making. The effective operation of the labor union and its subordinate committees, including the Labor Dispute Mediation Committee and the Labor Protection Supervision Committee, ensures employees' rights to be informed and to supervise are fully protected.

We promote employee communication through a variety of approaches, including:

- Establishing a reporting center to receive complaints and reports concerning violations of national laws or internal company regulations.
- Launching a Chairman's Mailbox to collect employee suggestions each month, responding in a timely manner and adopting reasonable proposals.
- Regularly holding Employee Representative Congress meetings and conducting employee satisfaction surveys to collect and respond to feedback, with a focus on employee welfare and rights.
- Organizing onboarding discussion sessions to identify and help resolve challenges faced by new employees.



Highlight | Women's Representative Congress

In 2024, Shanghai Heping Ophthalmic Hospital, a subsidiary of the company, convened its first Women's Representative Congress. Representatives were elected through a democratic voting process that was open, fair, and transparent. A permanent Women's Committee was established to serve female employees, communicate their concerns, and safeguard their rights. This committee provides an important platform for women to express their views, participate in hospital governance, and contribute to the hospital's development. The committee focuses on areas such as career development, physical and mental well-being, work-life balance, and rights protection. It works to deliver care, ensure support mechanisms are in place, and help female employees realize their full potential.



Talent Development

We place great importance on the career development of our employees and have established dual career paths for both management and professional roles, ensuring that each individual can pursue a growth path aligned with their interests and capabilities. We focus on internal talent cultivation and promotion, supported by systems such as the reserve cadre training program and internal job competition mechanism. Priority is given to internal advancement, providing motivated and capable employees with broad development opportunities. In addition, we continuously improve our talent pipeline. During our rapid expansion, we create new roles and growth opportunities for existing employees to ensure the parallel development of talent and the company.

In 2024, we promoted a group of outstanding internal management personnel and appointed qualified employees to key positions in newly established hospitals. This enabled effective internal talent mobility and the continuation of Huaxia's corporate culture.

Performance Management

We implement a performance management approach that combines Objectives and Key Results (OKRs) with Key Performance Indicators (KPIs). Our strategy is tiered and covers all employees, with clearly defined and quantifiable performance metrics to effectively monitor and evaluate work efficiency, quality, and outcomes. Performance appraisal results are used as the basis for compensation, promotion, and benefits decisions. In addition, we conduct regular performance reviews and one-on-one performance discussions to provide timely feedback and development support, encouraging employee growth and performance improvement.

Employee Training

We value talent cultivation and follow a dual approach that includes both talent acquisition and internal development. We rely on a comprehensive set of platforms. These include two academies, which are Huaxia Eye Academy and Huaxia Management Academy. We also have two research institutes: The Ophthalmology Research Institute of Huaxia Eye Hospital and the Ophthalmology Research Institute of Xiamen Ophthalmology Center. In addition, we operate three national-level bases: The Standardized Residency Training Base, the Drug Clinical Trial Base, and the Group Clinical Skills Training Base. We also maintain three specialized stations: The Academician Workstation, the Postdoctoral Research Workstation, and the National Distinguished Ophthalmologists Studio. Together with various partner universities, these platforms support specialist training programs and university-industry collaboration to develop highly skilled ophthalmic professionals. We regularly conduct 360-degree assessments, employee satisfaction surveys, and internal talent reviews. Based on these insights, we maintain an up-to-date talent map, periodically review training plans, and define career development pathways for core personnel.

In 2024, we continued to improve our human resources development system. We built a training framework that integrates internal and external resources. This includes the chief surgeon training system, a structured mentorship model, a tiered training and evaluation system for nurses, and standardized programs that combine theoretical learning with practical skills. These efforts further enhanced our employees' professional capabilities and clinical performance. We also expanded the "Tomorrow's Stars of Chinese Ophthalmology" initiative and organized training programs for hospital presidents, general managers, management trainees, licensed physicians, and nursing staff. These programs provided highly targeted learning opportunities for clinical professionals, managerial personnel, and future leaders. As a result, we strengthened our talent pipeline and reinforced human capital support for the company's sustainable growth.

In 2024, we conducted over 7,000 training sessions with over 290,000 training attendees.

Highlight | The 7th National Member Training Conference

From March 1 to 2, 2024, the company held the 7th National Member Training Conference with the theme "Deeply Rooted in Mind, Executed in Action." Department heads and outstanding member representatives from affiliated hospitals were invited to deliver lectures. The course content covered key aspects of departmental coordination, teamwork strategies, interpretation of medical insurance policies, and best practices in digital development. Through this systematic training, participants not only deepened their understanding of their professional roles but also significantly enhanced their patient-centered service awareness. The program laid a solid foundation for the continuous improvement of healthcare service quality.



The 7th National Member Training Conference

Highlight | Huaxia Eye Hospital's Phase III Standardized Management Training for Eye Clinics and Optometry Stores

From March 5 to 6, 2024, the third phase of the standardized management training program for eye clinics and optometry stores was successfully held at the headquarters of Huaxia Eye Hospital. Centered on the theme "Standardized Management, Innovative Development," the training focused on clinical operations including medical quality, patient safety, service satisfaction, and prescription accuracy. Special discussions were organized based on different business types, including clinics and optometry stores at the provincial, municipal, and county levels. The program aimed to help frontline ophthalmologists, optometrists, and regional optometry management teams gain practical experience in the integration of clinical care and education. This effort supported professional development and improved service delivery, contributing to China's national efforts in myopia prevention and control.



Huaxia Eye Hospital's Phase III Standardized Management Training for Eye Clinics and Optometry Stores



Highlight | Phase IV Huaxia Eye Hospital Medical Insurance Management Training

On June 14, 2024, the Phase IV Medical Insurance Management Training Program of Huaxia Eye Hospital was successfully held in Xiamen under the theme "United in Purpose, Empowered for Growth." Several leading experts in the field of medical insurance were invited to deliver authoritative and professional courses to more than seventy insurance practitioners from the company and its affiliated hospitals. Through focused learning, in-depth discussions, and interactive exchanges, participants gained a deeper understanding of the core principles of medical insurance management. The program helped enhance the standardization and efficiency of insurance-related operations and encouraged the exploration of new ideas and methods for future insurance management practices.



Phase IV Huaxia Eye Hospital Medical Insurance Management Training

University–Enterprise Collaboration

We continue to deepen our university–enterprise collaboration strategy and actively explore joint talent development models. The company has established long-term partnerships with a number of universities, creating integrated platforms for industry–education cooperation, including affiliated hospitals, teaching practice bases, and eye health service centers. These platforms support ongoing collaboration in talent cultivation, internships and employment, academic exchange, and scientific research. We offer specialized joint training programs, regularly accept university interns, and recommend outstanding graduates for employment. By fostering academic engagement between experts and partner institutions, we provide strong talent support for the company's sustainable development.

In 2024, we further strengthened our university–enterprise collaboration by expanding our joint talent development system. We signed cooperation agreements with six institutions: Chengdu University of Traditional Chinese Medicine, Guangdong Medical University, Xiamen Medical College, Guiyang Health and Wellness University, Yueyang Vocational and Technical College, and Changsha Medical University. These partnerships led to the establishment of affiliated hospitals, teaching practice bases, faculty clinical training bases, eye health service centers, and innovation bases for industry–academia–research integration. In collaboration with Guangdong Medical University, Chengdu University of Traditional Chinese Medicine, and Tianjin Vocational University, we also co-established "Huaxia Classes" to train more than 130 students specializing in ophthalmology, clinical medicine, optometry, and nursing. Throughout the year, we welcomed 175 interns and recommended 243 graduates for employment, effectively enhancing our medical and nursing teams. In addition, 20 of our experts were appointed to honorary positions at partner universities. We also provided specialized guidance on university–enterprise collaboration to 45 affiliated hospitals, promoting resource sharing and advancing our talent development strategy through mutually beneficial cooperation.



Chengdu University of Traditional Chinese Medicine awarded appointment letters to Huaxia Medical experts



Partnership with Xiamen Medical College

Campus Recruitment

We place high importance on attracting and developing young talent and continue to strengthen our talent pool and optimize workforce structure through campus recruitment. In 2024, the company headquarters and affiliated hospitals participated in 92 campus job fairs, including those at Xiamen University, Wuhan University, Fujian Medical University, Wenzhou Medical University, Anhui Medical University, and Harbin Medical University, among other leading comprehensive and medical institutions. A total of 367 outstanding new graduates were hired, including 51 resident physicians, 123 optometry professionals, and 193 graduates for other roles. The recruits represented a range of academic levels, including doctoral, master's, bachelor's, and associate degrees.



2024 Campus Recruitment Events

Employee Compensation and Benefits

We are committed to providing employees with competitive compensation and benefits. The company guarantees the timely and full payment of salaries, which are set above the local minimum wage standards. A standardized performance evaluation system is in place, with scientifically designed salary grades tailored to the characteristics of different job categories. We also offer performance-based bonuses to encourage high-efficiency performance among individuals and teams.

We provide a wide range of employee benefits and activities, including:

- Contributions to five major social insurances and the housing provident fund, along with various subsidies, holiday bonuses, and statutory leave entitlements
- Regular employee care events such as Chinese New Year dinners, Mid-Autumn Festival games and raffles, and monthly birthday celebrations, offering festive greetings and gifts to employees
- Free access to nap beds during lunch breaks and shuttle bus services for employees who live far from the workplace
- Regular team-building activities organized by departments to enhance cohesion and collaboration
- Educational events such as ophthalmology knowledge lectures, distribution of eye health vouchers, and discounts on surgeries and eyewear for employees and their family members
- Support for mental health through workplace stress relief channels, regular mental health seminars, and access to professional counseling services

Community Fun Sports Meet



Badminton exchange activities between the ophthalmology department of Xiamen Ophthalmology Center and the First Hospital



Fudan Zhongshan Friendly Match



Material and Chemical College Friendly Match

Occupational Health and Safety

We consistently place the health and safety of our employees and patients as a top priority. The company strictly complies with the "Work Safety Law of the People's Republic of China", the "Law of the People's Republic of China on the Prevention and Control of Occupational Diseases", and other applicable laws and regulations. We are committed to establishing an occupational health and safety management system in alignment with ISO 45001 standards to create a safer and healthier working environment for employees and to provide more secure medical services for patients.

We have formulated and implemented a comprehensive set of policies and procedures, including the "Workplace Safety Responsibility Policy", the "Inspection and Management Policy for Gas and Electrical Equipment", the "Fire and Electrical Safety Management Policy", the "Hospital Infection Control Policy", and the "Emergency Response Plan for Medical Infections". These policies clearly define safety responsibilities across all organizational levels, optimize the safety management process, systematically identify and control occupational risks in medical activities, continuously improve working conditions, and reduce occupational hazards to ensure the safety and sustainability of medical services.


Safety Management Responsibilities

We strictly enforce the "Universal Responsibility System for Workplace Safety." Safety responsibility agreements are signed at all levels, from the general manager to frontline employees, to clarify job-specific safety obligations and ensure accountability throughout the organization. Hospital presidents serve as the primary responsible persons for safety management and are fully accountable for all safety-related work. They lead and coordinate the efforts of all management levels to fulfill their safety duties and advance the continuous optimization of the safety management system. We continue to strengthen workplace safety oversight, refine hazard inspection procedures, and improve the coverage and effectiveness of safety training. These efforts aim to reduce potential safety risks and enhance occupational health management practices. In 2024, no major safety incidents occurred, and the occupational disease incidence rate remained at zero.



Emergency Management and Drills


We have formulated emergency response systems such as the "Emergency Plan for Public Health Incidents" to standardize the handling process for emergencies.



In 2024, we conducted around 170 emergency drills, including evacuation drills, anti-riot drills, and fire drills, with a total engagement of 7,300 participants approximately.

Highlight | Emergency Drill for Hospital Violence Incident

In 2024, the ophthalmology department of Xiamen Ophthalmology Center conducted an emergency drill to assess the hospital's response capabilities in handling sudden violent incidents. The drill simulated a scenario in which an individual armed with a knife illegally entered the hospital, posing a threat to medical staff and on-site personnel. Upon detecting the abnormal situation, hospital security staff immediately initiated the emergency response plan, implemented protective measures, and reported the incident to the surveillance command center. The command center promptly dispatched the emergency response team, established a restricted zone, and guided personnel evacuation. Relevant departments were mobilized to coordinate containment actions. All response teams operated strictly according to the emergency plan, effectively controlling the situation. The "assailant" was successfully subdued and handed over to the police for further handling.



Emergency Drill for Hospital Violence Incident at Xiamen Ophthalmology Center

Highlight | Emergency Drill for Confined Space Safety Incident

In 2024, Aidi Eye Hospital organized an emergency drill for confined space operation safety to strengthen safety management in such environments and to prevent risks such as poisoning or asphyxiation during operations. The drill simulated an emergency in which a worker fainted while replacing a sewage pump and pipeline at the hospital's wastewater treatment station. Upon witnessing the incident, the on-site supervisor immediately reported the situation. Safety management personnel promptly activated the emergency response plan, and staff from medical, nursing, and emergency departments were dispatched to the site to perform emergency rescue. Follow-up medical treatment procedures were also arranged.

Fire Safety Management

Hospitals are public spaces with a high concentration of people, making fire safety a critical component of the company's overall safety management. The company strictly complies with the "Fire Protection Law of the People's Republic of China" and has established a comprehensive fire safety management system to ensure a safe and stable medical environment.

We have developed and continuously refined a range of internal fire safety policies and procedures, including the "Fire Safety Management Policy", the "Fire Safety Inspection and Patrol Policy", the "Fire Safety Education and Training Policy", the "Fire Equipment Maintenance Policy", and the "Firefighting and Emergency Evacuation Plan and Drill Policy". A hierarchical fire prevention responsibility system is in place, with each department signing a "Fire Prevention Responsibility Agreement" that clearly defines responsible persons and ensures accountability. Fire safety signs are displayed throughout hospital facilities, voluntary fire brigades have been established, and firefighting equipment is properly installed to enhance emergency response capabilities. A patrol and inspection system has been implemented to strictly monitor the use of fire and electricity. Firefighting equipment is maintained in good condition through standardized upkeep procedures. Fire safety awareness is further strengthened through regular staff training and emergency drills. Employees are trained to meet the "Three Abilities" standard: being able to operate fire extinguishing equipment, report a fire by phone, and organize safe evacuation. These efforts continuously improve fire safety awareness and emergency response capabilities across the organization.

Highlight | Fire Emergency Drill in Inpatient Ward

In 2024, the ophthalmology ward of Xiamen Ophthalmology Center conducted a fire emergency drill to simulate an electrical outlet short circuit and fire outbreak in a patient room. The exercise served as a comprehensive test of the hospital's emergency response to fire incidents. When the duty nurse detected the simulated "fire", she immediately reported it and activated the fire alarm system. Upon receiving the alert, the fire control room dispatched patrol personnel to verify the situation. The hospital's mini fire station arrived at the scene within three minutes with firefighting equipment and began extinguishing the flames. Simultaneously, the engineering team shut off the main valve for medical gases to prevent further risk. Medical staff followed the emergency response plan to safely evacuate patients and family members to a designated safe area and provided special assistance to those with limited mobility. Medical teams performed emergency treatment, while psychological counselors assisted in calming evacuees. As the simulated fire expanded, the fire response team coordinated evacuation efforts and worked with the local fire department to complete the fire suppression operation.



Fire Emergency Drill in Inpatient Ward at Xiamen Ophthalmology Center

Safety Training and Education

We place strong emphasis on promoting safety awareness and continuously carry out multi-level, systematic occupational health and safety training programs. These initiatives are designed to strengthen employees' safety skills and risk prevention capabilities, while improving the overall standard of safety management. Through regular safety lectures, hands-on training sessions, and emergency drills, we enhance employees' understanding of safety protocols, help prevent workplace accidents, and reduce operational safety risks. In 2024, the company conducted about 240 safety training sessions, with a total attendance of 9,800 participants approximately.

Occupational Health Management

We implement a variety of occupational health management measures to support the goal of helping employees "work happily and live healthily." Key measures include:



Work-rest balance

We have established a scientifically designed work schedule and rest system to encourage employees to balance work and rest, ensuring sufficient time for recovery even during peak work periods.

Regular physical examinations are provided to help employees detect potential health risks in a timely manner.

Health check-ups



Health consultations

Professional consultation services are available, offering guidance on disease prevention and occupational illness protection. Psychological counseling services are also provided to address work-related stress and suboptimal mental health.

A comprehensive incident investigation and response system is in place to handle occupational injuries and diseases in a timely, standardized, and effective manner.

Work injury management



Recreational and wellness activities

The company organizes a variety of wellness and cultural activities on an occasional basis, such as sports games, fitness walks, and outdoor team-building exercises. These activities promote a healthy lifestyle and enrich employees' recreational lives.



"Huaxia Cup" 3x3 basketball game

Badminton Team



Track & Field Team

Mountain-climbing Team



Track & Field Team



03

Governance

2024 Key Performance Targets for Governance Matters

-  Continuously improved sustainability policies aligned with business and operational needs
-  Zero incidents of conflict of interest
-  Zero incidents of commercial bribery, corruption, or embezzlement
-  Zero incidents of money laundering or insider trading
-  Zero major lawsuits or administrative penalties due to unfair competition
-  Zero incidents of tax violations
-  Regular disclosure of the Sustainability Report to ensure transparency and accountability



Risk Management and Compliance

We have established and continuously improved our internal control and risk management system to identify, assess, and monitor various risks that may arise in our operations. We continuously enhance our internal control systems and process construction, improve inspection and supervision mechanisms, and strengthen risk control across all areas of business management and operational processes. These measures are aimed at effectively preventing risks and ensuring our sustained, stable, and healthy development.

We have established a clear and reasonable risk management structure with distinct responsibilities and mutual checks and balances. This structure involves the Board of Directors, the Audit Committee, the General Manager, the Internal Audit and Control Department, and the Legal and Compliance Department, all working together to form our risk defense line. To effectively implement risk management responsibilities and ensure compliance with operations, we use any violations or non-compliance incidents in various departments and hospitals as one of the evaluation criteria, linking this to the performance and compensation of the relevant management personnel.

Board of Directors

The Board of Directors is the highest decision-making body for risk management. It is responsible for determining the overall objectives of risk management, reviewing risk management reports submitted by management, as well as the company-level risk register, and supervising the cultivation of the company's risk management culture.

Audit Committee

The Audit Committee serves as the supervisory department for risk management. It guides and supervises various functional departments and business units in conducting risk management and assessment activities, and generates an annual risk assessment report.

CEO

Responsible for the effectiveness of risk management, CEO is accountable to the Board of Directors and serve as the primary person in charge of risk management. CEO is tasked with either directly overseeing or delegating to the leader in charge of risk management the day-to-day operations, including drafting the risk management organizational structure, identifying significant risk issues and corresponding contingency plans, approving company's risk register, and coordinating risk management activities within functional departments.

Audit Department

Our risk management functional department is responsible for daily risk management tasks, including regular risk analysis, compiling and updating risk registers, proposing system and process optimization suggestions based on risk response measures, assisting the CEO in handling risk issues, and fostering a risk management culture.

Policy and Legal Department

Our policy and legal department is responsible for identifying and evaluating legal risks related to operations, providing legality reviews for major company matters, continuously monitoring the latest legal trends and understanding their impact on the operations, and promptly reporting any significant legal incidents to the board of directors.

We have developed the "Internal Control Manual" and established a comprehensive risk control matrix. This matrix clearly identifies the key risk points and control procedures in each area of our business operations and management processes, standardizing our business operations and management while strengthening risk control.

By the end of 2024, we initiated the revision of the "Internal Control Manual" based on the actual needs of our operational management and business activities. We optimized internal control processes in areas such as business management, R&D expense management, fundraising management, and stock incentive/employee stock ownership management. Additionally, we further improved processes related to procurement management and charitable donation management, with the goal of continuously strengthening internal control and enhancing our risk management and compliance levels.



Risk Identification and Assessment

We focus on internal control objectives and comprehensively, systematically, and continuously collect internal and external information related to risks, identifying risks associated with our operations. Based on our business activities and the requirements of internal control and risk management, we prepare and regularly update a risk register. Specifically, the company-level risk register is assessed and updated at least once a year. The business process-level risk register is compiled or updated in a timely manner after reviewing key business processes, with a particular focus on new or frequently occurring risks in business processes or areas.

We filter, refine, compare, classify, and combine all risk-related information collected, establishing a risk database. By using both qualitative and quantitative methods, we analyze the impact of various risks and categorize them according to their level of impact.

Based on the results of the risk assessment and our risk tolerance, we weigh the risks against the potential rewards. We then develop risk response strategies such as risk avoidance, reduction, sharing, and acceptance, ensuring their effective implementation to achieve proper control over risks.

Risk Category	Risk Description and Impact	Likelihood of Occurrence	Impact Severity	Risk Level	Mitigation Measures
Management Risks Arising from Rapid Expansion	We have achieved rapid and effective growth through our chain-based business model, with our overall scale and business performance continuing to expand. As our network of affiliated hospitals grows, the scope and complexity of our operations and management have also increased. If our management teams lack sufficient experience in new market operations or have limited understanding of local regulatory frameworks, we may face challenges in maintaining effective oversight, which could pose risks to our future development.	Medium	Medium	Medium	Through continuous exploration and practice, we have built a comprehensive operational management system covering clinical services, nursing, finance, human resources, procurement, and marketing. We have made initial progress in achieving standardization, institutionalization, and digitalization of management. New hospitals are able to replicate our mature management model and leverage our shared corporate resources, which helps to shorten the market development cycle. Going forward, we will continue to refine our standardized and modular chain management system, optimize our business and service processes, and enhance our ability to replicate management practices to effectively mitigate related risks.
Risk of Talent Shortage or Attrition	Ophthalmology professionals remain in short supply across the country. If we experience significant talent attrition or fail to attract sufficient qualified medical professionals, our regional competitiveness may be weakened, which could negatively affect our long-term development.	Medium	Medium	Medium	We maintain a strong reserve of talent and have established a sound talent development system. Our team includes well-known ophthalmology experts and experienced clinicians, enabling us to continuously train and supply professionals for new hospitals. Looking ahead, we will continue to strengthen our capabilities in talent acquisition, development, and retention. By enhancing our internal talent pipeline, we aim to meet the growing demand for medical personnel driven by the expansion of our healthcare service network.

Risk Reporting Mechanism

We have established an early warning mechanism for significant risks that may affect our business operations and have developed corresponding contingency plans. In the event of an emergency or unforeseen risk, we will promptly take effective measures to minimize potential losses and impacts, and continue to monitor the situation to ensure effective control or restore the original state.

We have established the "Major Issues Internal Reporting System," which defines the reporting obligations and procedures for each department or hospital when they become aware, or should be aware, of major issues. Relevant personnel must report these issues to the appropriate departments as per the regulations to ensure that we can take timely actions to address the risks and prevent or minimize them. Major issues include significant legal or regulatory violations, substantial losses, major debts or liabilities, and other critical risk events. The Audit and Internal Control Department regularly reports to the Board of Directors and the Audit Committee on existing risks and the implementation of risk control measures, and is responsible for following up on and summarizing any risk corrective actions.

Risk Supervision Mechanism

We have established and continuously improved our risk supervision mechanism by formulating institutional documents such as the Group Inspection System and the Standards for Inspection Audits. Through initiatives such as inspection audits, internal control reviews, and internal control evaluations, we have strengthened our oversight efforts to promptly identify risks in the operations of our functional departments and hospitals, as well as issues in internal control and risk management. We also ensure that timely corrective actions are taken to address these issues, thereby enhancing the risk prevention capabilities of all departments and affiliated hospitals.

In 2024, our risk supervision and internal control inspection efforts included the following:

- Conducted internal control system reviews and implementation assessments, as well as financial audits, across more than **30** hospitals.
- Performed routine audits on key matters such as the deposit and use of raised funds, related-party transactions, and venture investments, as well as large-sum financial transactions involving the company and its controlling shareholders or affiliates.
- Carried out exit audits for six departing hospital general managers and procurement heads to evaluate their economic and managerial responsibilities during their tenure.
- Completed **21** engineering inspections and acceptance checks, providing rectification suggestions and ensuring their implementation.
- Organized internal control effectiveness evaluations covering areas such as corporate governance, social responsibility, medical and nursing management, capital management, procurement, asset and inventory management, and hospital renovations. Special attention was given to high-risk areas such as medical risk and public relations. An external auditing firm was also engaged to conduct an independent audit of internal control effectiveness.

Business Practices

We aim to achieve "Patient Satisfaction, Employee Contentment, Peer Endorsement, Societal Recognition, and Government Trust." In the course of business development, we uphold the highest standards of business ethics, advocate for fair and free competition, and are committed to fostering an honest, equitable, open, and harmonious business environment. We have formulated a Business Code of Conduct that clearly states our firm stance on anti-corruption and bribery, conflict of interest, insider trading, unfair competition, anti-monopoly, anti-money laundering, information security and privacy protection, as well as whistleblower complaints and protection. This Code serves as the fundamental principles and behavioral guidelines for all employees in the course of business activities, ensuring that fair and honest conduct is practiced throughout the organization and our reputation is well safeguarded.

We encourage our partners to jointly uphold the responsible business practices advocated in our Business Code of Conduct. Through the formulation of the Supplier Code of Conduct, we set clear behavioral standards for suppliers, contractors, and other partners in areas such as anti-unfair competition, anti-corruption and bribery, conflict of interest, protection of property rights, safeguarding human rights, environmental protection, and compliant marketing. We are committed to working with our partners to uphold an honest, fair, stable, and harmonious market order.

Anti-Commercial Bribery and Anti-Corruption

We firmly oppose all forms of corruption and bribery. We require our employees to uphold the principles of integrity and self-discipline, and to refrain from accepting or offering bribes, facilitating bribery, or using their positions to provide or receive rewards or other benefits that could unfairly influence the company's business. In 2024, no incidents of commercial bribery, corruption, or other violations of business ethics occurred.

Employee Business Ethics Management

We require all employees to sign the Anti-Bribery Agreement upon joining the company, which informs them of prohibited bribery practices and the disciplinary actions that will be taken in the event of any violations. These actions include termination of employment and compensation for any resulting losses.

We have established and continuously refined the Disciplinary Action Policy, which clearly stipulates that if an employee is found to have engaged in bribery, all illicit gains will be recovered, full compensation for losses will be required, and the employee will be dismissed without exception. In cases involving criminal offenses, the matter will be reported to judicial authorities in accordance with the law. When an employee is suspected of disciplinary or regulatory violations, the Human Resources Department initiates a fact-finding investigation upon receiving the report. If necessary, the Audit and Internal Control Department will assist with the investigation. Once the violation is confirmed, the Human Resources Department, along with the relevant departments including that of the sanctioned employee, will jointly propose a disciplinary recommendation, which will be processed in accordance with internal approval procedures. We also provide an appeal mechanism for the sanctioned employee, who may file an appeal with the Human Resources Department. The department will then verify the appeal and respond accordingly.

Supplier Business Ethics Management

We strengthen supplier integrity management and advocacy to enhance supplier risk prevention. Together with our suppliers, we work to maintain a standardized, harmonious, and transparent business environment based on honesty and integrity.

To regulate business procurement and ensure transparency, fairness, integrity, and ethical conduct in the procurement process, we incorporate suppliers' performance in anti-corruption, anti-unfair competition, and other business compliance areas into the supplier evaluation criteria during the supplier onboarding process. We require all suppliers to sign an "Integrity Agreement," clearly outlining the behavioral expectations they must adhere to when conducting business with us. This includes prohibiting any form of corruption, bribery, or unfair competition, such as using improper means to undermine or exclude other suppliers. If a supplier violates the terms of the "Integrity Agreement," we reserve the right to terminate the partnership, including but not limited to contract termination and penalty claims. Additionally, we promote anti-corruption and anti-bribery awareness among our suppliers by communicating and advocating these requirements during supplier conferences.

Integrity Risk Supervision

Our Audit and Internal Control Department serves as the supervisory body for integrity-related matters. It is responsible for regularly inspecting and auditing potential integrity risks and violations across all departments and hospitals, covering various areas of operations and business processes. By conducting annual inspections such as audit reviews and internal control evaluations, the department identifies potential integrity risks and issues in a timely manner, urges corrective actions, and continuously strengthens supervision to effectively prevent integrity-related risks.

In 2024, our Audit and Internal Control Department incorporated integrity-related supervision into regular inspection audits, including financial report audits and routine audits of significant matters across hospitals. Key areas of focus included:

- Conducting audit inspections targeting critical business functions such as procurement and advertising, as well as key positions including general managers, hospital directors, and procurement department heads, to identify potential corruption and bribery issues.
- Evaluating the implementation and effectiveness of anti-fraud control procedures, with assurance services commissioned from external professional institutions.


Integrity Culture Building

We continuously promote a culture of integrity by providing integrity education and advocacy to directors, senior management, and employees, aiming to raise awareness and reinforce ethical standards. Our integrity education and training initiatives in 2024 included:

- Collaborating with the Party Branch of Xiamen Ophthalmology Center, our Party Committee organized integrity warning education and Party discipline learning sessions to institutionalize integrity education and guide medical staff in cultivating medical ethics and practicing benevolence.
- Our Audit and Internal Control Department utilized the company's official website and internal platforms to disseminate anti-corruption and anti-bribery guidelines, and provided integrity-related education to relevant personnel through regular inspection audits and reviews at various hospitals.
- Functional departments and hospitals independently conducted their own training sessions focused on integrity and ethical conduct.
- Departments such as Procurement reinforced education on anti-corruption, anti-bribery, and risk prevention through regular departmental meetings.

Fair Competition

We adhere to the principles of integrity, freedom, and fair competition in all our business activities, strictly complying with anti-unfair competition laws and regulations in both national and local jurisdictions where we operate. We have established a Business Code of Conduct that promotes healthy competition and explicitly prohibits any improper, illegal, or unethical means—such as infringing trade secrets or spreading false information—to gain business opportunities or undermine the legitimate rights of competitors, thereby disrupting economic order. In 2024, there were no incidents of lawsuits or penalties resulting from unfair competition practices.




Tax Compliance

We strictly comply with the Enterprise Income Tax Law of the People's Republic of China and relevant tax laws and regulations in the countries or regions where we operate. We fulfill our tax obligations in an honest and lawful manner, upholding tax compliance and transparency as core principles. We have established a Tax Policy that clearly states our position on tax matters, strictly prohibiting practices such as profit shifting to low-tax or tax-advantaged jurisdictions for the purpose of improper tax avoidance. This policy serves as a guiding framework for our tax management practices.

We follow the procedures outlined in our Internal Control Manual to identify and manage potential tax risks arising during business operations. We continuously monitor the release and updates of tax-related laws and regulations in the regions where we operate, and promptly adjust the handling of tax-related matters to effectively prevent tax risks. At the corporate headquarters, we have established a dedicated tax management position and a policy team responsible for overseeing overall tax risk management and headquarters tax affairs, as well as providing tax guidance and consultation to our affiliated hospitals.


Each year, we engage external institutions to audit our internal control evaluation and annual corporate income tax filing to ensure the effectiveness of our tax management and compliance with relevant tax laws. We have also established a regular communication mechanism with local tax authorities and relevant institutions in the regions where we operate, maintaining close and effective communication to collect and relay information in a timely manner, thereby ensuring tax compliance.

In 2024, we conducted tax compliance training through online platforms to enhance awareness and improve the practical capabilities of relevant personnel. Throughout the year, we paid a total of 258.37 million RMB in taxes and reported no tax violations.



Complaint Mechanism and Whistleblower Protection

To uphold integrity in business operations and ensure sustainable development, we have established a comprehensive whistleblowing mechanism and whistleblower protection system. We have formulated a Whistleblowing Policy that provides employees, partners, and the public with safe and accessible reporting channels, including anonymous hotlines, email addresses, and on-site service windows. The policy outlines the procedures for receiving and responding to reports, a reward mechanism for valid disclosures, and measures to protect whistleblowers. We encourage all stakeholders—including employees, suppliers, and customers—to monitor our business activities, with the aim of fostering a transparent and fair governance environment and laying a solid foundation for our long-term, steady growth.




Complaint Channels

We provide multiple channels for whistleblowers to submit complaints or reports, including phone, email, letters, in-person reports, online surveys, and QR code-based reporting, allowing for both anonymous and named submissions. We communicate these reporting channels to employees through pop-up messages on our internal network. Additionally, we promote these channels during inspection and audit processes. For our suppliers, we clearly outline the whistleblowing channels in the "Integrity Agreement" they sign with us.



Complaint Channels

 Complaint hotline: 0592-2109380

 Complaint email: sjzx@huaxiaeye.com

 Company official website anti-corruption reporting section:
<https://www.huaxiaeye.com/Readme/index.html>

 Mailing address: Audit Department, 16th Floor, Building 2, No. 999, Wutongxi Road, Huli District, Xiamen City

Complaint Handling Procedure

The Audit and Internal Control Department has established a Whistleblower Center responsible for handling complaints and reports within the company. The Whistleblower Center will conduct an initial review of the received complaints and reports according to the established procedures. If further investigation is necessary, the matter will be handled in accordance with company policies, and the results will be promptly communicated to the whistleblower. If there are objections to the outcome, the concerned parties may provide feedback or suggestions. The Audit and Internal Control Department will, based on the circumstances, conduct additional investigations or reprocess the matter. For significant whistleblowing cases, the results of the investigation will be reported to the Audit Committee and the Board of Directors.

Whistleblowing Rewards

We have established a whistleblowing reward mechanism. For complaints that, upon investigation, are found to be true and result in appropriate penalties for those who violate laws or regulations, as well as help the company or hospitals recover or reduce losses, the whistleblower will be rewarded in accordance with the "Whistleblowing Policy."

Whistleblower Protection

We place great importance on protecting the rights of whistleblowers and have implemented specific protection policies. Any form of retaliation is strictly prohibited. We support whistleblowers in making anonymous reports and strictly adhere to confidentiality measures. When verifying information from whistleblowers, we ensure the confidentiality of their identity, workplace, and the content of the complaint. All whistleblowing materials are managed as confidential documents and are strictly prohibited from being shared with the reported unit or individual. Any personnel found violating confidentiality or engaging in retaliation will be dealt with severely according to relevant regulations, and if a crime is involved, the matter will be referred to the judicial authorities for legal action.

Data Overview

Environmental	Metrics	Unit	2023	2024
	GHG Emissions ¹			
	Scope 1 – Direct GHG emissions	tCO ₂ e	1,414.98	1,821.67
	Scope 2 – Indirect GHG emissions from purchased energy		18,690.29	21,332.17
	Total GHG emissions (Scope 1+ Scope 2)		20,105.27	23,153.84
	Emission intensity	tCO ₂ e / hundred-mil- lion RMB of operating revenue	500.98	574.96
	Energy Consumption			
	Electricity consumption ²	kWh	32,772,733.13	39,754,330.42
	Natural gas consumption	m ³	18,400	36,418.71
	Gasoline consumption ³	Litre	424,892.63	568,248.18
	Diesel consumption ⁴		154,299.93	205,173.36
Steam consumption	Ton	0	0	
Comprehensive energy consumption	Tonnes of coal equivalent	4,701.98	5,801.72	
Comprehensive energy consumption intensity	Tonnes of coal equivalent / hundred million RMB of operating revenue	117.16	144.07	
Water Resources				
Water withdrawal	m ³	338,517.48	390,954.73	
Waste				
Hazardous waste generated	Ton	/	197.36	
Including: quantity of infectious solid waste generated		/	184.22	
Including: quantity of sharps solid waste generated		/	13.14	
Transfer and disposal volume of hazardous waste		186.19	197.09	
Including: quantity of infectious solid waste transferred and disposed		172.96	184.07	
Including: quantity of sharps solid waste transferred and disposed		13.23	13.04	
General Waste Generation		2,135.30	1,156.54	
Environmental Compliance Management				
Annual Number of Environmental Emergency Drills	Times	/	7	

1: The increase in the company's greenhouse gas emissions compared to 2023 was primarily due to the acquisition of several hospitals during the reporting period, including Shenzhen Nanshan, Chengdu Aidi, Enshi Huiyi, Suining Fuxing, Weishan Yida, and Anxi Huaxia.

2: The increase in the company's electricity consumption compared to 2023 was primarily due to the acquisition of several hospitals during the reporting period, including Shenzhen Nanshan, Chengdu Aidi, Enshi Huiyi, Suining Fuxing, Weishan Yida, and Anxi Huaxia.

3: The increase in the company's gasoline consumption compared to 2023 was primarily due to the growth in business volume during the reporting period.

4: The increase in the company's diesel consumption compared to 2023 was primarily due to the growth in business volume during the reporting period.

Employment

Metrics	Unit	2023	2024
Employee Composition			
Total employees	Person	7,613	7,883
Including: Full-time employee		/	7,112
Non-employee workers ⁵		/	771
Part-time employee		730	213
Employee Composition by Gender			
Male	Person	2,149	2,084
Female		5,464	5,799
Employee Composition by Age			
Under 30	Person	2,779	2,687
Between 31-40		2,638	2,836
Between 41-50		1,237	1,384
Over 51		959	976
Employee Composition by Education			
Higher education ⁶	Person	5,933	6,344
Non-higher education		1,680	1,539
Employee Composition by Nationality			
Mainland China	Person	/	7,881
Others		/	2
Employee Composition by Function			
Administrative employee	Person	1,383	1,785
Medical services employee		2,301	2,264
Nursing & services employee		3,470	3,437
Maintenance employee		459	397
Female administrative employee		968	1,298
Female medical services employee		1,571	1,524

5: Note 1: Non-employee workers include individuals who have signed training agreements, labor service contracts, labor service agreements, or reemployment contracts after retirement.

6: Note 2: Higher education includes associate degree education, undergraduate education, and graduate education.

Employment	Metrics	Unit	2023	2024
	Female nursing & services employee	Person	2,794	2,829
	Female maintenance employee		131	148
	Employment of Local Employees			
	Number of employees from the province	Person	/	6,845
	Proportion of employees from the province	%	/	86.83
	Number of female employees from the province	Person	/	5,073
	Proportion of female employees from the province	%	/	87.48
	Management Composition by Gender			
	Grassroots cadres	Person	220	218
	Female grassroots cadres		136	158
	Proportion of female grassroots cadres	%	61.63	72.48
	Management ⁷	Person	1,428	1,452
	Male management		607	580
	Female management		821	872
	Female management (Middle and upper, including senior management)	%	57.49	60.06
	Senior management personnel	Person	6	6
	Female senior management personnel		1	1
	Proportion of female senior management personnel	%	16.67	16.67
	Number of local senior management	Person	4	4
	Proportion of local senior management	%	66.67	66.67
	Number of female local senior management	Person	1	1
	Proportion of female local senior management	%	100.00	100.00
	Labor Contract Signing			
	Labor contract signing rate	%	100.00	100.00
	Employment of Disabled Individuals			
	Number of disabled employees hired	Person	31	52
	Proportion of disabled employees hired	%	0.43	0.66

7: Note 3: Management refers to middle and senior-level personnel within the company.

Metrics		Unit	2023	2024
Employment	Employee Training			
	Total number of employees trained	Person	/	7,883
	Employee training coverage rate	%	100.00	100.00
	Total number of employee training sessions	Times	/	7,247
	Total training participants	Participant	/	296,760
	Total employee training hours	Hour	296,653	327,412
	Average training hours per employee		/	42.14
	Employee Performance			
	Number of administrative employees undergoing regular performance and career development assessments	Person	/	1,345
	Number of medical services employees undergoing regular performance and career development assessments		/	48
	Number of nursing & services employees undergoing regular performance and career development assessments		/	709
	Number of maintenance employees undergoing regular performance and career development assessments		/	0
	Number of operations employees undergoing regular performance and career development assessments		/	0
	Number of female employees undergoing regular performance and career development assessments		/	1,093
	Number of male employees undergoing regular performance and career development assessments		/	1,009
	Number of employees undergoing regular performance and career development assessments		/	2,102
	Proportion of employees undergoing regular performance and career development assessments	%	/	27.06
	Freedom of Association and Collective Bargaining			
	Total number of employees in trade union	Person	/	1,865
	Proportion of employees covered by collective agreements	%	/	24.01
	Employee Welfare and Benefits			
	Total paid parental leave (as primary caregiver)	Day	/	843
	Employment management non-compliance incidents			
Total monetary loss incurred due to penalties for violations of labor-related laws and regulations	Ten-thousand RMB	/	0	

	Metrics	Unit	2023	2024
Employment	Security Practice			
	Number of security personnel trained in human rights policies or procedures	Person	/	90
	Number of security personnel employed by the company		/	90
	Proportion of security personnel trained in human rights policies or procedures			100.00
Market	Information Security and Customer Privacy Infringement Incidents			
	Number of information security incidents	Item	0	0
	Number of customer privacy infringement incidents		/	0
	Intellectual Property			
	Number of new patent applications	Item	40	61
	Number of new patents granted		39	62
	Number of new software copyright registrations		/	14
	Number of patents held as of the end of 2024		124	192
	Number of registered software copyrights held as of the end of 2024		161	175
	Number of intellectual property infringement incidents against others	Item	0	0
	Product Quality			
	Qualification rate of outpatient prescriptions	%	96	96
	Qualification rate of inpatient medical orders		98	98
	Utilization rate of antimicrobial drugs in inpatients		10	4
	Prophylactic antimicrobial use rate in Class I incision surgeries		7	8
	Complaint Acceptance and Resolution			
	Total number of complaint cases received	Case	/	1,464
	Complaint resolution rate	%	/	100
	Customer Satisfaction			
	Customer satisfaction rate	%	/	95.70

Metrics		Unit	2023	2024
Market	Supplier Management			
	Number of non-affiliated suppliers	Unit	101	108
	Including: Number of suppliers located in the same province as the company		/	12
	Number of key suppliers		/	66
	Number of new suppliers admitted in the year		3	8
	Total number of suppliers that passed desktop assessments		/	108
	Total number of suppliers that passed on-site audits		/	3
	Number of suppliers audited in the year		76	108
	Total number of key suppliers assessed		/	66
	Number of suppliers assessed with significant actual or potential negative impacts		/	0
	Number of suppliers with significant actual or potential negative impacts that were terminated		/	0
	Number of suppliers that completed improvements after assessment		/	0
	Number of potential suppliers eliminated in 2024 due to non-compliance with social responsibility requirements		/	0
	Supplier Training			
Number of suppliers participating in ESG training	Unit	15	40	
Total number of participants in supplier ESG training	Participant	75	132	
Total training hours of supplier ESG training	Hour	8	20	
Proportion of male employees among suppliers participating in ESG training	%	55	60	
Proportion of female employees among suppliers participating in ESG training		45	40	
Proportion of senior management among suppliers participating in ESG training		10	70	
Proportion of middle management among suppliers participating in ESG training		70	20	
Proportion of general employees among suppliers participating in ESG training		20	10	
Supplier Risk Assessment				
Number of suppliers at risk of violating freedom of association and collective bargaining rights	Unit	0	0	
Number of suppliers at significant risk of child labor incidents		0	0	
Number of suppliers at significant risk of forced or compulsory labor incidents		0	0	

Occupational Health and Safety	Metrics	Unit	2023	2024
	Safety Training			
	Total participants in occupational health and safety training	Participant	6,674	9,882
	Number of safety training sessions	Times	238	243
	Number of safety emergency drills		154	173
	Number of attendees for safety emergency drills	Participant	5,476	7,354
	Work Safety Accident			
	Extra-major accident	Case	0	0
	Major accident		0	0
	Serious accident		0	0
	General accident		0	0
	Number of work-related injury incidents		0	0
	Occupational Health			
	Occupational injuries	Person	0	0
	Occupational fatalities		0	0
Occupational fatality rate	%	0	0	
Social Contributions	Community Investment			
	Implementation of public welfare assistance	Case	4,208,041	128,054
	External donations			
	Total social contributions	Ten-thousand RMB	171,572.61	177,085.74
	Including: Total tax payment		26,330.83	25,836.94
	Employee compensation		117,754.05	131,180.35
	Dividends paid to shareholders		16,096.10	12,477.05
	Interests paid to creditors		51.61	40.90
	Social donations		11,340.02	7,550.50

Governance	Metrics	Unit	2023	2024
	Business Ethics Violations			
	Conflict of interest incidents	Item	0	0
	Lawsuits resulting from commercial bribery and corruption		0	0
	Money laundering or insider trading incidents		/	0
	Lawsuits or administrative penalties resulting from unfair competition incidents		0	0
	Tax-related Violations			
	Number of tax-related violation incidents	Item	0	0

The Guidelines No. 17 of Shenzhen Stock Exchange for the Self-Regulation of Listed Companies - Sustainability Report (Trial) Index

Topic	Clause	Location
Chapter III Environmental Disclosure		
Climate Response	Article 21-28	Climate Response
Pollutant Discharge	Article 30	Pollutant Discharge
Waste Disposal	Article 31	Waste Disposal
Ecosystem and Biodiversity Protection	Article 32	Ecosystem and Biodiversity Protection
Environmental Compliance Management	Article 33	Environmental Compliance Management
Energy Utilization	Article 35	Energy Utilization
Water Resources Utilization	Article 36	Water Resource Utilization
Circular Economy	Article 37	Circular Economy
Chapter IV Social Disclosure		
Rural Revitalization	Article 39	Rural Healthcare Revitalization
Social Contributions	Article 40	Healthy Community Development
Innovation	Article 42	Innovation-driven Development
Ethics of Science and Technology	Article 43	Ethics of Science and Technology
Supply Chain Security	Article 45	Supply Chain Security
Equal Treatment of SMEs	Article 46	Equal Treatment of SMEs
Product and Service Safety and Quality	Article 47	Product and Service Safety and Quality
Data Security and Customer Privacy	Article 48	Data Security and Customer Privacy
Employees	Article 50	Employees
Chapter V Disclosure of Corporate Sustainability-Related Governance Information		
Due Diligence	Article 52	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts Supply Chain Security
Stakeholder Engagement	Article 53	Stakeholder Engagement
Anti-Commercial Bribery and Anti-Corruption	Article 55	Anti-Commercial Bribery and Anti-Corruption
Fair Competition	Article 56	Fair Competition

SASB Index

SASB Topics	Metrics	Location
Energy Management	HC-DY-130a.1: (1) Total energy consumed, (2) percentage grid electricity and (3) percentage renewable	Energy Utilization Data Overview
Waste Management	HC-DY-150a.1: Total amount of medical waste: percentage (a) incinerated, (b) recycled or treated and (c) landfilled	Pollutant Discharge Data Overview
	HC-DY-150a.2: Total amount of: (1) hazardous and (2) non-hazardous pharmaceutical waste, percentage (a) incinerated, (b) recycled or treated and (c) landfilled	Waste Disposal Data Overview
Patient Privacy & Electronic Health Records	HC-DY-230a.2: Description of policies and practices to secure customers' personal health data records and other personal data	Data Security and Customer Privacy
	HC-DY-230a.3: (1) Number of data breaches, (2) percentage involving (a) personal data only and (b) personal health data, (3) number of customers affected in each category, (a) personal data only and (b) personal health data	Data Security and Customer Privacy Data Overview
	HC-DY-230a.4: Total amount of monetary losses as a result of legal proceedings associated with data security and privacy	Data Security and Customer Privacy
Access for Low-Income Patients	HC-DY-240a.1: Discussion of strategy to manage the mix of patient insurance status	Not covered in this report

SASB Topics	Metrics	Location
Quality of Care & Patient Satisfaction	HC-DY-250a.2: Number of serious reportable events	Not covered in this report
	HC-DY-250a.3: Hospital-acquired condition rates per hospital	
Management of Controlled Substances	HC-DY-260a.1: Description of policies and practices to manage the number of prescriptions issued for controlled substances	Data Overview
Pricing & Billing Transparency	HC-DY-270a.1: Description of policies or initiatives to ensure that patients are adequately informed about price before undergoing a procedure	Product and Service Quality and Safety
	HC-DY-270a.2: Discussion of how pricing information for services is made publicly available	Product and Service Quality and Safety
	HC-DY-270a.3: Number of the entity's 25 most common services for which pricing information is publicly available, percentage of total services performed (by volume) that these represent	We did not collect relevant data during this reporting period
Workforce Health & Safety	HC-DY-320a.1: Total recordable incident rate (TRIR) for (a) direct employees and (b) contract employees	Data Overview
Employee Recruitment, Development & Retention	HC-DY-330a.1: (1) Voluntary and (2) involuntary turnover rate for: (a) physicians, (b) non physician health care practitioners, and (c) all other employees	Data Overview
	HC-DY-330a.2: Description of talent recruitment and retention efforts for health care practitioners	Talent Development
Climate Change Impacts on Human Health & Infrastructure	HC-DY-450a.1: Description of policies and practices to address: (1) the physical risks because of an increased frequency and intensity of extreme weather events, (2) changes in the morbidity and mortality rates of illnesses and diseases associated with climate change and (3) emergency preparedness and response	Climate-Related Risks, Opportunities, and Financial Impacts
Fraud & Unnecessary Procedures	HC-DY-510a.1: Total amount of monetary losses as a result of legal proceedings associated with medical fraud	Not covered in this report

ESRS Index

European sustainability reporting standards (ESRS)		Location/omission
ESRS 2 General Disclosures		
BP-1	General basis for the preparation of sustainability statements	About This Report
BP-2	Disclosures in relation to specific circumstances	Not covered in this report
GOV-1	The role of the administrative, management and supervisory bodies	Governance Structure and Mechanism
GOV-2	Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodies	Governance Structure and Mechanism Risk Management and Compliance
GOV-3	Integration of sustainability-related performance in incentive schemes	Governance Structure and Mechanism
GOV-4	Statement on due diligence	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts Supply Chain Security
GOV-5	Risk management and internal controls over sustainability reporting	Risk Management and Compliance Climate-Related Risks, Opportunities, and Financial Impacts
SBM-1	Strategy, business model and value chain	About Us Corporate Strategy Supply Chain Security Product and Service Quality and Safety
SBM-2	Interests and views of stakeholders	Stakeholder Engagement
SBM-3	Material impacts, risks and opportunities and their interaction with strategy and business model	Management of Material Matters Risk Management and Compliance Climate-Related Risks, Opportunities, and Financial Impacts
IRO-1	Description of the processes to identify and assess material impacts, risks and opportunities	Management of Material Matters Risk Management and Compliance
IRO-2	Disclosure requirements in ESRS covered by the undertaking's sustainability statement	About Us Management of Material Matters Index
ESRS E1 Climate change		
E1-1	Transition plan for climate change mitigation	Climate Response
E1-2	Policies related to climate change mitigation and adaptation	Climate Response
E1-3	Actions and resources in relation to climate change policies	Climate Response Circular Economy
E1-4	Targets related to climate change mitigation and adaptation	Corporate Strategy

European sustainability reporting standards (ESRS)		Location/omission
E1-5	Energy consumption and mix	Energy Utilization Data Overview
E1-6	Gross Scopes 1, 2, 3 and Total GHG emissions	GHG Emissions Management Data Overview
E1-7	GHG removals and GHG mitigation projects financed through carbon credits	Not covered in this report
E1-8	Internal carbon pricing	Not covered in this report
E1-9	Anticipated financial effects from material physical and transition risks and potential climate-related opportunities	Climate-Related Risks, Opportunities, and Financial Impacts Management of Material Matters
ESRS E2 Pollution		
E2-1	Policies related to pollution	Pollutant Discharge
E2-2	Actions and resources related to pollution	Pollutant Discharge
E2-3	Targets related to pollution	Environmental
E2-4	Pollution of air, water and soil	Pollutant Discharge Waste Disposal
E2-5	Substances of concern and substances of very high concern	Pollutant Discharge Waste Disposal Circular Economy
E2-6	Anticipated financial effects from pollution-related impacts, risks and opportunities	Not covered in this report
ESRS E3 Water and marine resources		
E3-1	Policies related to water and marine resources	Water Resources Utilization
E3-2	Actions and resources related to water and marine resources	Water Resources Utilization
E3-3	Targets related to water and marine resources	Environmental
E3-4	Water consumption	Data Overview
E3-5	Anticipated financial effects from water and marine resources-related impacts, risks and opportunities	Not covered in this report
ESRS E4 Biodiversity and ecosystems		
E4-1	Transition plan and consideration of biodiversity and ecosystems in strategy and business model	Not covered in this report
E4-2	Policies related to biodiversity and ecosystems	Ecosystem and Biodiversity Protection
E4-3	Actions and resources related to biodiversity and ecosystems	Ecosystem and Biodiversity Protection
E4-4	Targets related to biodiversity and ecosystems	Environmental
E4-5	Impact metrics related to biodiversity and ecosystems change	Not covered in this report
E4-6	Anticipated financial effects from biodiversity and ecosystem-related risks and opportunities	Not covered in this report

European sustainability reporting standards (ESRS)		Location/omission
ESRS E5 Resource use and circular economy		
E5-1	Policies related to resource use and circular economy	Circular Economy
E5-2	Actions and resources related to resource use and circular economy	Circular Economy
E5-3	Targets related to resource use and circular economy	Not covered in this report
E5-4	Resource inflows	Circular Economy
E5-5	Resource outflows	Circular Economy
E5-6	Anticipated financial effects from resource use and circular economy-related impacts, risks and opportunities	Not covered in this report
ESRS S1 Own workforce		
S1-1	Policies related to own workforce	Employees
S1-2	Processes for engaging with own workforce and workers' representatives about impacts	Employee Communication
S1-3	Processes to remediate negative impacts and channels for own workforce to raise concerns	Human Rights Protection Employee Communication
S1-4	Taking action on material impacts on own workforce, and approaches to managing material risks and pursuing material opportunities related to own workforce, and effectiveness of those actions	Employees
S1-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	Employees
S1-6	Characteristics of the undertaking's employees	Equal Employment Data Overview
S1-7	Characteristics of non-employees in the undertaking's own workforce	Equal Employment Data Overview
S1-8	Collective bargaining coverage and social dialogue	Employee Communication
S1-9	Diversity metrics	Equal Employment Data Overview
S1-10	Adequate Wages	Employee Compensation and Benefits
S1-11	Social protection	Employee Compensation and Benefits
S1-12	Persons with disabilities	Data Overview
S1-13	Training and skills development metrics	Talent Development
S1-14	Health and safety metrics	Data Overview

European sustainability reporting standards (ESRS)		Location/omission
ESRS S1 Own workforce		
S1-15	Work-life balance metrics	Data Overview
S1-16	Remuneration metrics (pay gap and total remuneration)	Data Overview
S1-17	Incidents, complaints and severe human rights impacts	Human Rights Protection
ESRS S2 Workers in the value chain		
S2-1	Policies related to value chain workers	Supply Chain Security
S2-2	Processes for engaging with value chain workers about impacts	Supply Chain Security
S2-3	Processes to remediate negative impacts and channels for value chain workers to raise concerns	Supply Chain Security Stakeholder Engagement
S2-4	Taking action on material impacts on value chain workers, and approaches to managing material risks and pursuing material opportunities related to value chain workers, and effectiveness of those action	Supply Chain Security
S2-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	Suppliers and Clients
ESRS S3 Affected communities		
S3-1	Policies related to affected communities	Healthy Community Development
S3-2	Processes for engaging with affected communities about impacts	Healthy Community Development
S3-3	Processes to remediate negative impacts and channels for affected communities to raise concerns	Healthy Community Development Stakeholder Engagement
S3-4	Taking action on material impacts on affected communities, and approaches to managing material risks and pursuing material opportunities related to affected communities, and effectiveness of those actions	Healthy Community Development
S3-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	Healthy Community Development

European sustainability reporting standards (ESRS)		Location/omission
ESRS S4 Consumers and end-users		
S4-1	Policies related to consumers and end-users	Supply Chain Security Product and Service Quality and Safety Data Security and Customer Privacy
S4-2	Processes for engaging with consumers and end-users about impacts	Product and Service Quality and Safety Data Security and Customer Privacy Stakeholder Engagement
S4-3	Processes to remediate negative impacts and channels for consumers and end-users to raise concerns	Product and Service Quality and Safety Data Security and Customer Privacy
S4-4	Taking action on material impacts on consumers and end-users, and approaches to managing material risks and pursuing material opportunities related to consumers and end-users, and effectiveness of those actions	Product and Service Quality and Safety Data Security and Customer Privacy
S4-5	Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	Suppliers and Client
ESRS G1 Business Conduct		
G1-1	Business conduct policies and corporate culture	Business Practices
G1-2	Management of relationships with suppliers	Supply Chain Security Equal Treatment of SMEs
G1-3	Prevention and detection of corruption and bribery	Anti-Commercial Bribery and Anti-Corruption Complaint Mechanism and Whistleblower Protection
G1-4	Incidents of corruption or bribery	Anti-Commercial Bribery and Anti-Corruption Data Overview
G1-5	Political influence and lobbying activities	Not covered in this report
G1-6	Payment practices	Equal Treatment of SMEs

ISDS Index

IFRS S1

Core Elements	Disclosure Recommendations	Disclosure Placement
Governance	a)The governance body(s) (which can include aboard, committee or equivalent body charged with governance) or individual(s) responsible for oversight of sustainability-related risks and opportunities.	Governance Structure and Mechanism Risk Management and Compliance
	b)Management's role in the governance processes, controls and procedures used to monitor, manage and oversee sustainability-related risks and opportunities.	Governance Structure and Mechanism Risk Management and Compliance
Strategy	a)The sustainability-related risks and opportunities that could reasonably be expected to affect the entity's prospects within the time horizons—short, medium or long term.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	b)The current and anticipated effects of sustainability-related risks and opportunities on the entity's business model and value chain, and where in the entity's business model and value chain sustainability-related risks and opportunities are concentrated	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	c)How the entity has responded to, and plans to respond to, sustainability-related risks and opportunities in its strategy and decision-making, and the progress against plans the entity has disclosed in previous reporting periods, including quantitative and qualitative information, and trade-offs between sustainability-related risks and opportunities that the entity considered.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	d)The quantitative and qualitative effects of sustainability-related risks and opportunities on the entity's financial position, financial performance and cash flows for the reporting period, and the sustainability-related risks and opportunities identified for which there is a significant risk of a material adjustment within the next annual reporting period to the carrying amounts of assets and liabilities reported in the related financial statements, and how the entity expects its financial position, financial performance and cash flows to change over the short, medium and long term, given its strategy to manage sustainability-related risks and opportunities.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	e)The resilience of the entity's strategy and its business model to those sustainability-related risks	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts

Core Elements	Disclosure Recommendations	Disclosure Placement
Risk Management	a)The processes and related policies the entity uses to identify, assess, prioritize and monitor sustainability-related risks, including information about: the inputs and parameters the entity uses, whether and how the entity uses scenario analysis to inform its identification of sustainability-related risks, whether and how the entity prioritizes sustainability-related risks, how the entity assesses the nature, likelihood and magnitude of the effects of those risks.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts Risk Management and Compliance
	b)The processes the entity uses to identify, assess, prioritize and monitor sustainability-related opportunities, including: whether and how the entity uses scenario analysis to inform its identification of sustainability-related opportunities.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	c)The extent to which, and how, the processes the entity uses to identify, assess, prioritize and monitor sustainability-related risks and opportunities are integrated into and inform the entity's overall risk management process.	Climate-Related Risks, Opportunities, and Financial Impacts Risk Management and Compliance
Metrics and targets	a)Metrics required by an applicable IFRS Sustainability Disclosure Standard.	Environmental Social Governance
	b)Metrics the entity uses to measure and monitor sustainability-related risks or opportunities and its performance in relation to that sustainability-related risk or opportunity.	Environmental Social Governance
	c)Any targets the entity has set it is required to meet by law or regulation.	Environmental Social Governance

IFRS S2

Core Elements	Disclosure Recommendations	Disclosure Placement
Governance	a)The governance body(s) (which can include a board, committee or equivalent body charged with governance) or individual(s) responsible for oversight of climate-related risks and opportunities.	Governance Structure and Mechanism Risk Management and Compliance
	b)Management's role in the governance processes, controls and procedures used to monitor, manage and oversee climate-related risks and opportunities.	Governance Structure and Mechanism Risk Management and Compliance
Strategy	a)The climate-related risks and opportunities that could reasonably be expected to affect the entity's prospects within time horizons—short, medium or long term, whether the entity considers the risk to be a climate-related physical risk or climate-related transition risk.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	b)The current and anticipated effects of climate-related risks and opportunities on the entity's business model and value chain, and where in the entity's business model and value chain climate-related risks and opportunities are concentrated.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	c)Information about how the entity has responded to, and plans to respond to, climate-related risks and opportunities in its strategy and decision-making, including how the entity sets targets, how the entity is resourcing and quantitative and qualitative information about the disclosed progress of plans.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	d)The quantitative and qualitative effects of those climate-related risks and opportunities on the entity's financial position, financial performance and cash flows for the reporting period, the climate-related risks and opportunities identified in paragraph 16(a) for which there is a significant risk of a material adjustment within the next annual reporting period to the carrying amounts of assets and liabilities reported in the related financial statements, and how the entity expects its financial position, financial performance and cash flows to change over the short, medium and long term, given its strategy to manage climate-related risks and opportunities.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	e)The entity's assessment of its climate resilience, including the entity's assessment for its strategy and business model, the significant areas of uncertainty considered in the entity's assessment of its climate resilience and the entity's capacity to adjust or adapt its strategy and business model to climate change over the short, medium and long term. The entity shall use climate-related scenario analysis to assess its climate resilience and disclose how and when the climate-related scenario analysis was carried out, including information about the inputs the entity used, the key assumptions the entity made in the analysis and the reporting period in which the climate-related scenario analysis was carried out.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts

Core Elements	Disclosure Recommendations	Disclosure Placement
Risk Management	a)The processes and related policies the entity uses to identify, assess, prioritize and monitor climate-related risks, including information about: the inputs and parameters the entity uses, whether and how the entity uses climate-related scenario analysis to inform its identification of climate-related risks, whether and how the entity prioritizes climate-related risks, how the entity assesses the nature, likelihood and magnitude of the effects of those risks.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts Risk Management and Compliance
	b)The processes the entity uses to identify, assess, prioritize and monitor climate-related opportunities, including information about whether and how the entity uses climate-related scenario analysis to inform its identification of climate-related opportunities.	Management of Material Matters Climate-Related Risks, Opportunities, and Financial Impacts
	c)The extent to which, and how, the processes for identifying, assessing, prioritizing and monitoring climate-related risks and opportunities are integrated into and inform the entity's overall risk management process.	Climate-Related Risks, Opportunities, and Financial Impacts Risk Management and Compliance
Metrics and targets	a)The cross-industry metric categories of greenhouse gas emissions, internal carbon prices, the percentage of executive management remuneration recognized in the current period that is linked to climate-related considerations, capital deployment towards climate-related risks and opportunities, the amount and percentage of assets or business activities vulnerable to climate-related risks and opportunities.	GHG Emissions Management
	b)Industry-based metrics that are associated with one or more particular business models, activities or other common features that characterize participation in an industry	GHG Emissions Management
	c)The quantitative and qualitative climate-related targets the entity has set or it is required to meet by law or regulation, progress towards reaching the target, information about its performance, and each greenhouse gas emissions target.	GHG Emissions Management

Independent Limited Assurance Report



RSM CHINA CPA LLP
Suite 1001-1 to 1001-26, 10th floor, No. 22
Fuchengmenwai St, Xicheng, Beijing, China
POST CODE: 100037
TEL: 010-6600 1391
FAX: 010-6600 1392
Email:bj@rsmchina.com.cn
<https://www.rsm.global/china/>

Independent Limited Assurance Report

RSMZZ[2025]NO.361Z0288

To the Board of Directors of Huaxia Eye Hospital Group Co., Ltd.

We were engaged by Huaxia Eye Hospital Group Co., Ltd. (“the Company”) to undertake a limited assurance engagement of the key indicators (“the Indicators”) for the period from January 1, 2024 to December 31, 2024 included in its 2024 Sustainability Report (“the Report”).



Assured Indicators

<ul style="list-style-type: none"> ● GHG — Scope 1: Direct GHG emissions (tCO₂e) — Scope 2: Indirect GHG emissions from purchased energy (tCO₂e) — Total GHG emissions (tCO₂e) — Emission intensity (tCO₂e / hundred-million RMB of operating revenue) 	<ul style="list-style-type: none"> ● Energy Consumption — Electricity consumption (kWh) — Natural gas consumption (m³) — Gasoline consumption (Litre) — Diesel consumption (Litre) — Steam consumption (Ton) — Comprehensive energy consumption intensity (Tonnes of coal equivalent/ hundred million RMB of operating revenue)
--	--

<ul style="list-style-type: none"> ● Water Resources <ul style="list-style-type: none"> — Water withdrawal (m³) 	<ul style="list-style-type: none"> ● Hazardous Waste <ul style="list-style-type: none"> — Quantity of Infectious Solid Waste Generated (Ton) — Quantity of Infectious Solid Waste Transferred and Disposed (Ton) — Quantity of Sharps Solid Waste Generated (Ton) — Quantity of Sharps Solid Waste Transferred and Disposed (Ton)
<ul style="list-style-type: none"> ● Environmental Compliance Management <ul style="list-style-type: none"> — Annual Number of Environmental Emergency Drills (Times) 	<ul style="list-style-type: none"> ● Total employees (Person) <ul style="list-style-type: none"> — Total employees (Person)
<ul style="list-style-type: none"> ● Employee Composition by Gender <ul style="list-style-type: none"> — Male (Person) — Female (Person) 	<ul style="list-style-type: none"> ● Employee Composition by Age <ul style="list-style-type: none"> — Under 30 (Person) — Between 31-40 (Person) — Between 41-50 (Person) — Over 51 (Person)

<ul style="list-style-type: none"> ● Employee Composition by Education <ul style="list-style-type: none"> — Higher education (Person) — Non-higher education (Person) 	<ul style="list-style-type: none"> ● Employee Composition by Function <ul style="list-style-type: none"> — Administrative employee (Person) — Medical services employee (Person) — Nursing & services employee (Person) — Maintenance employee (Person) — Female administrative employee (Person) — Female medical services employee (Person) — Female nursing & services employee (Person) — Female maintenance employee (Person)
<ul style="list-style-type: none"> ● Management Composition by Gender <ul style="list-style-type: none"> — Management (Person) — Male management (Person) — Female management (Person) — Proportion of female management (%) 	<ul style="list-style-type: none"> ● Employment of Disabled Individuals <ul style="list-style-type: none"> — Number of disabled employees hired (Person) — Proportion of disabled employees hired (%)
<ul style="list-style-type: none"> ● Work Safety Accident <ul style="list-style-type: none"> — Extra-major accident (Case) — Major accident (Case) — Serious accident (Case) — General accident (Case) — Number of work-related injury incidents (Case) 	<ul style="list-style-type: none"> ● Safety Training <ul style="list-style-type: none"> — Number of safety training sessions (Times)

<ul style="list-style-type: none"> ● Safety Emergency Drills — Number of safety emergency drills (Times) 	<ul style="list-style-type: none"> ● Occupational Health — Occupational injuries (Person) — Occupational fatalities (Person) — Occupational fatality rate (%)
<ul style="list-style-type: none"> ● Patent — Number of new patent applications (Item) — Number of new patents granted (Item) 	<ul style="list-style-type: none"> ● Non-Affiliated Suppliers — Number of non-affiliated suppliers (Unit)
<ul style="list-style-type: none"> ● Labor Contract Signing — Labor contract signing rate (%) 	

The Company's Responsibility

The Company was responsible for selecting the criteria, and preparing and fairly presenting information presented in the Report in accordance with that criteria. This responsibility includes establishing and maintaining internal controls, adequate records and making estimates that are reasonable in the circumstances.

RSM's Responsibility

We are responsible for performing a limited assurance engagement on the Indicators in accordance with *International Standard on Sustainability Assurance 5000 - General Requirements for Sustainability Assurance Engagements* (ISSA 5000), and issuing a limited assurance conclusion.

Procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement.

Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

Our Independence and Quality Control

We have complied with *International Code of Ethics for Professional Accountants* (including *International Independence Standards*) issued by the International Ethics Standards Board for Accountants (IESBA) regarding sustainability assurance engagements. We have maintained independence and fulfilled all other professional ethics requirements. In conducting this engagement, we have adhered to the fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior.

In accordance with *International Standard on Quality Control*, we maintain a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Procedures Performed

In accordance with the requirements of ISSA 5000 and applying professional judgment, we performed the following procedures:

i. Risk Assessment

- Conducted interviews with the Company's management, sustainability reporting team, and relevant data governance departments to gain an understanding of the reporting preparation process.
- Evaluated the applicability of relevant criteria to the Company's operations.
- Identified and assessed risks of material misstatement in the Indicators.
- Gained an understanding of the Company's internal control systems for collecting, reporting, and monitoring sustainability information.

ii. Data Verification

- Evaluated the design of key structures, systems, processes, and controls established by the Company for compiling the Indicators.
- Performed sample testing on data collection and reporting processes for the Indicators.
- Recalculated the Indicators and reconciled them with reported disclosures.
- Conducted sample testing to verify the consistency between source data and system records.
- Performed analytical procedures on significant fluctuations to assess their reasonableness.

iii. Disclosure Compliance Evaluation

- Evaluated whether the Indicators complies with requirements of applicable criteria.
- Assessed consistency between qualitative statements and quantitative data in the report.
- Examined whether the presentation of the Indicators contains potentially misleading expressions.

iv. Other procedures

Other procedures we deemed necessary.

Limited Assurance Conclusion

Based on the procedures performed, as described above, nothing has come to our attention that causes us to believe that the Indicators in the Report are not prepared, in all material respects, in accordance with the Company's reporting criteria described in the Report.

Inherent Limitation

Due to the selective nature of testing and sampling techniques, as well as the inherent limitations of internal controls, misstatements, fraud, or non-compliance may occur and not be detected.

Furthermore, we draw users' attention to the fact that, there is currently no globally accepted framework for evaluation and measurement. This may result in inconsistent measurement methodologies, potentially affecting the comparability of information across different entities.

Comparative Information

i. Assurance Status of Comparative Information

The comparative information for 2023 included in the Report has undergone limited assurance procedures by our firm, and we issued an unqualified limited assurance conclusion in our report dated April 12, 2024. This assurance engagement was conducted in accordance with *International Standard on Assurance Engagements 3000 (Revised): Assurance Engagements Other Than Audits or Reviews of Historical Financial Information* (ISAE 3000).

ii. Explanation of Changes in Historical Year Assurance Scope

Indicator	2023 Assurance Scope	2024 Assurance Scope	Reason for Change
Emission Intensity	Not included	Newly added	Improved data availability
Steam Consumption	Not included	Newly added	Improved data availability
Comprehensive Energy Consumption Intensity	Not included	Newly added	Improved data availability

Indicator	2023 Assurance Scope	2024 Assurance Scope	Reason for Change
Quantity of Infectious Solid Waste Generated	Not included	Newly added	Improved data availability
Quantity of Infectious Solid Waste Transferred and Disposed	Not included	Newly added	Improved data availability
Quantity of Sharps Solid Waste Generated	Not included	Newly added	Improved data availability
Quantity of Sharps Solid Waste Transferred and Disposed	Not included	Newly added	Improved data availability
Annual Number of Environmental Emergency Drills	Not included	Newly added	Improved data availability
Female nursing & services employee	Not included	Newly added	Improved data availability
Female maintenance employee	Not included	Newly added	Improved data availability
Number of safety training sessions	Not included	Newly added	Improved data availability

The above adjustments do not affect the limited assurance conclusion on the Report.

Impact of Reporting Boundary Changes on Comparative Information

During the 2024 reporting period, the Company completed the acquisition of Shenzhen Nanshan Huaxia Eye Hospital (finalized in April 2024), Chengdu Aidi Eye Hospital Co., Ltd. (finalized in May 2024), Enshi Huiyi Ophthalmology Hospital Co., Ltd. (finalized in May 2024), Suining Fuxing Ophthalmology Hospital Co., Ltd. (finalized in May 2024), Weishan Medical University Ophthalmology Hospital Co., Ltd. (finalized in May 2024), and Anxi Huaxia Ophthalmology Hospital Co., Ltd. (finalized in October 2024), resulting in an expansion of the reporting boundary.

Limitation of Use

This report is intended solely for the Company's use in preparing its 2024 Sustainability Report in accordance with applicable criteria, and shall not be used for any other purposes. We accept no liability to any third party other than the intended users.

【This page serves as the officially stamped page of the Independent Limited Assurance Report (RSMZZ[2025]NO.361Z0288).】



大)



999 Wutong West Road, Huli District, Xiamen



400-611-2222



<http://www.huaxiaeye.com>